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Introduction 
The prevalence of cardiovascular diseases (CVDs) is very high in many 
countries who adapted the western life style.1 In the western world, the lifetime 
risk of cardiovascular diseases at age forty is estimated to be one in two for 
men and one in three for women.2 In the Netherlands, more that a million 
people suffer from CVDs.3 This represents 8 percent of the Dutch adult 
population. In addition to this - and this is also true for most other Western 
European countries - CVDs are the most important cause of death in the 
Netherlands: 35% of all deaths each year can be attributed to CVD.1 4 This 
means that reducing the prevalence of CVD has a large potential to improve 
public health. Because of their high prevalence, cardiovascular diseases lead to 
high costs. In the Netherlands, the 2003 medical costs for cardiovascular 
diseases were G5.3 billion,4 corresponding to almost 10% of the total Dutch 
health care costs. Improving risk factors for cardiovascular diseases might thus 
also reduce the burden that cardiovascular diseases impose on the health care 
budget. 
Many interventions, both preventative and curative, are available for CVDs. 
However, insufficient resources are available to implement all effective 
interventions because of fixed healthcare budgets, so choices have to be made. 
The aim of this thesis is to gain more insight into the costs and the cost-
effectiveness of the prevention of CVDs. The aim is twofold, namely, to gain 
more insight into the quality of cost-effectiveness analyses in this field that have 
been performed so far, and to calculate the cost-effectiveness of Hartslag 
Limburg (Limburg Heartbeat), a programme for preventing CVDs. 
In this chapter, the concept of CVDs and their epidemiology will be discussed. 
Then we provide background information about economic evaluations and 
describe the Hartslag Limburg programme. We conclude the chapter with an 
outline of the thesis. 
Types of cardiovascular diseases 
According to the International Classification of Diseases, 1(fh edition (ICD-10), 
CVDs can be divided into several subgroups.5 The subgroups ischaemic heart 
diseases, cerebrovascular diseases, and other heart diseases account for 
almost 85% of all the cardiovascular mortality in the Netherlands. 
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Ischaemic heart diseases are caused by stenosis of the coronary arteries.6 
Clinical presentations include angina pectoris, acute myocardial infarction and 
its complications, repeated myocardial infarction, and other ischaemic heart 
diseases.5 7 Ischaemic heart diseases caused 32.7% of all cardiovascular 
deaths in the Netherlands in the year 2002.8 The most frequently occurring 
ischaemic heart disease is acute myocardial infarction, which causes 70% of all 
ischaemic heart disease deaths.8 
A quarter of the cardiovascular deaths can be attributed to cerebrovascular 
diseases.9 Cerebrovascular disease implies a disturbance of brain function due 
to insufficient blood supply.10 In most cerebrovascular diseases - almost 80% -
insufficient blood supply is due to a closed blood vessel.10 
Just like cerebrovascular diseases, the remaining category 'other heart 
diseases' accounts for a quarter of all cardiovascular deaths.9 Heart failure 
causes 50% of the deaths within this category.9 Heart failure is caused by 
insufficient pumping capacity of the heart, which is accompanied by complaints 
such as fatigue and shortness of breath.11 
Trends in cardiovascular health 
In the Netherlands, trends in mortality due to CVDs are well documented. 
Fortunately, the mortality rate for CVDs has decreased in recent decades. The 
standardized mortality rate due to ischaemic heart diseases, cerebrovascular 
diseases, and other heart diseases decreased from 395 per 100,000 in the year 
1980 to 253 per 100,000 in the year 2000 for men, and from 338 to 225 per 
100,000 for women during the same period.9 This represents decreases of 33 to 
36 percent. 
Much less detailed data are available for trends in the incidence and prevalence 
of CVDs. Information about the incidence and the prevalence of CVD is not 
available for all subgroups of CVD, but only for specific disease types. 
Information is available about changes in the incidence and prevalence of the 
most frequently occurring subtype of ischaemic heart disease, namely, acute 
myocardial infarction. During the period 1985-2000, the incidence of the acute 
myocardial infarction decreased from 4.5 to 3.5 per 1000 for men and from 3.2 
to 2.3 per 1000 for women.12 13 The prevalence of the acute myocardial 
infarction rose during this period. The prevalence increased from 14 per 1000 
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men and 8 per 1000 women in the year 1985 to 22 per 1000 men and 13 per 
1000 women in the year 2000.12 
Although the mortality rate for cerebrovascular diseases has decreased in 
recent years, their incidence rates have remained constant (about 4 per 1000 
for both men and women).1213 The prevalence rate of cerebrovascular diseases 
increased by 30 percent: from 15 per 1000 in 1985 to 20 per 1000 in the year 
2000.13 
The prevalence of heart failure has increased by 40 percent during the last 20 
years.1314 The incidence of heart failure in men decreased slightly, from 2.7 per 
1000 in 1985 to 2.4 per 1000 in the year 2000.12 13 For women, the incidence 
rate of heart failure during this period decreased from 3.5 per 1000 to 2 per 
1000. 
Although no strong evidence exists, previous research suggests that the 
decrease in CVD mortality can at least partly be explained by preventive 
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measures. 
The priority for the prevention of CVDs will continue to be high. In the 
Netherlands, the proportion of elderly people will increase excessively in the 
coming decades. The ageing population will cause the absolute cardiovascular 1fi 19 20 mortality rate to increase to 40 percent within the next 20 years. 
Risk factors for cardiovascular diseases 
As is well known, behavioural factors (poor diet, low exercise rate, and 
smoking) lead to unfavourable profiles of biological risk factors for CVD, such as 
high blood pressure and high levels of cholesterol.1321 The biological risk factors 
increase the risk of CVDs in a multiplicative way.21 The behavioural risk factors 
also exert direct negative effects on cardiovascular health. This is especially 
true for smoking. Figure 1 visualises the relationship between risk factors, 
CVDs, and mortality. 
Although we focus on the effects of risk factors on CVDs, it should be 
mentioned that the risk factors also exert negative effects on other diseases. 
Smoking, for example, is an important risk factor for lung cancer. 
In this section, we first describe the influence of behavioural risk factors on 
biomedical risk factors. Then we discuss the direct consequences of high blood 
pressure, high cholesterol levels, and smoking on CVDs. We conclude with 
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giving an indication about the potential health benefit gained by reducing risk 
factors for CVDs. 
The influence of behavioural risk factors on biomedical risk factors 
Poor diet, especially if it includes much saturated fat, leads to a high body mass 
index (BMI). The saturated fat consumption and the high BMI lead to increases 
in both blood pressure and cholesterol level (Figure 1). 
Low exercise rates may also result in high BMI and high levels of blood 
pressure. Furthermore, exercise rate is related to high-density lipoprotein (HDL) 
cholesterol. The lower the rate of exercise, the lower the levels of this 
favourable cholesterol type will be (Figure 1). 
Smoking exerts a negative effect of cardiovascular health because it increases 
the blood pressure (Figure 1). Smoking also exerts some direct effects on 
cardiovascular health. These are discussed in the following section. 
Biomedical risk factors and cardiovascular diseases 
The underlying process of most cardiovascular diseases is atherosclerosis of 
the arteries. Plaque formation in the arterial walls leads to stenosis and 
decreased blood supply. This process is mostly due to subintimal cholesterol 
accumulation. Instability of these plaques may lead to ruptyre of the covering 
cap, with eruption of cholesterol and subsequent thrombus formation. 
Complete occlusion of the coronary arteries for example, leads to acute 
myocardial infarction. Atherosclerosis is a multifactorial disorder and many risk 
factors play a role. Some of these are reversible either by changing life style or 
by medical treatment. Most common reversible risk factors are hypertension, 
hypercholesterolemia, nicotine, and overweight and sedentary life style. 
The potential health benefit of reducing risk factors for 
cardiovascular diseases 
Changing the risk profile of the population has a high potential for improving 
health. About 30 percent of the CVD mortality in the Netherlands can be 
ascribed to high blood pressure and 45 percent to smoking.22 23 Furthermore, 
research has shown that the prevalence of myocardial infarction would 
decrease by 17 percent for men en 4 percent for women if BMIs of 30 or more 
were prevented.13 Even relatively small reductions in risk factors may lead to 
considerable CVD health gain. For example, a cholesterol reduction of 1 
percent causes a decrease in CVD mortality of 2 to 3 percent, and a reduction 
of diastolic blood pressure by 5 to 6 mmHg has been shown to effect a 
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reduction in the CVD risk of 14 percent.24 25 A combined reduction of several 
CVD risk factors, as is striven for within Hartslag Limburg, will lead to more 
favourable effects than the reduction of only one of the risk factors due to the 
multiplicative effects that the risk factors exert on CVD.2126 
Figure 1. Risk factors for cardiovascular diseases 
BMI, Body mass Index; BP, blood pressure; CVD, cardiovascular disease; Choi, cholesterol; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein. 
Types of interventions for changing behaviour 
Several types of intervention have been carried out in order to increase healthy 
behaviour; for example: individual behavioural counselling, group counselling, 
quit-smoking contests, community programmes and - in the case of smoking -
nicotine replacement therapy. In this thesis, we focus on individual counselling 
strategies and community programmes. 
Counselling programmes are generally directed towards people with increased 
risks of CVDs or towards people with an established cardiovascular event. A 
health counsellor educates people about healthy behaviour and helps change 
unhealthy behaviour to more healthy behaviour. 
Community programmes can be very diverse and aim to change the exercise 
pattern, dietary habits, smoking, or a combination of these factors within the 
whole community. Mass media campaigns are often part of a community 
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programme to prevent CVDs. Furthermore, activities can be organized in which 
people can actively participate to change their behaviour. Examples are 
exercise groups, cooking courses, and quit-smoking contests. Sometimes, even 
screening for cardiovascular risk factors followed by advice from healthcare 
personnel is included. 
Economic evaluation of preventive interventions 
The basic idea of economic evaluation is to compare the costs of different 
treatment alternatives with their various consequences, in order to determine 
whether a treatment offers 'good value for money*. The consequences are 
preferably measured in terms of years of life saved (yols) or quality adjusted life 
years (qaly), as to facilitate comparison between the cost-effectiveness of 
interventions from different medical disciplines. As already mentioned in the first 
section of this chapter, not all interventions that effectively improve health can 
be provided; this is due to budgetary constraints. Choices have to be made 
about the interventions to be implemented. In order to assist policy-makers in 
managing this implementation problem, economic evaluation studies are being 
carried out more and more often. 
Because of the increased interest in evidence-based medicine, the interest in 
cost-effectiveness analyses over the whole field of healthcare - including those 
of preventive interventions - have increased in recent years. In spite of this, few 
studies have been published in this field to date.26 27 28 There are two important 
reasons for this. The main reason is that guidelines for economic evaluation 
were initially designed for medical interventions, such as those for drug therapy 
and surgery.29 30 The application of these techniques to the field of health 
promotion is not straightforward and leads to certain difficulties that must be 
overcome.26 31 
The application of the economic evaluation guidelines to the field of health 
promotion is problematic on several levels. The guidelines can neither be used 
directly for determining the outcome nor for calculating the costs. Furthermore, 
some general techniques of economic evaluation lead to difficulties when they 
are used in health promotion. 
Determining the outcome 
Health economists prefer outcome measures such as years of lives saved or 
quality-adjusted life years.30 Because preventive interventions will only result in 
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changes in the incidence of diseases in the distant future, intermediate end-
terms (such as changes in intention to change behaviour, behavioural changes 
or biological parameters) are frequently used as a starting point to calculate yols 
or qalys. 
The first challenge in economic evaluation research is to achieve reliable 
intermediate measures of effects. This is more difficult than in the field of 
medicine because applying the RCT, which is regarded as the gold standard in 
effect research, is difficult and sometimes even impossible in public health 
research. 2731 
When intermediate outcomes are available, models have to be used to 
extrapolate intermediate end terms into the number of yols. 26 27 Constructing 
such a model requires detailed information about risk factors, relative risks, and 
the incidence and prevalence of the disease. Only when sufficient data are 
available can such a model be built. Constructing such a model is not always 
necessary in the field of medicine. And if necessary, it is often more difficult to 
construct a reliable model in the field of health promotion than in the field of 
medicine. The reason for this is that in the field of health promotion intermediate 
outcome measures like intention to change behaviour and behavioural change 
are frequently used instead of biological parameters. For constructing the 
model, this means that, besides information about the influence of biological 
parameters on diseases, information is necessary about the effects of 
behavioural change on biological parameters and in some cases even about the 
intention to change behaviour on behavioural change. Clearly, this results in 
less reliable estimations of the yols. In the present health promotion study, 
changes in biological parameters were measured to obtain most reliable effects. 
However, it should be kept in mind that all models are based on assumptions to 
some extent. They will thus never be able to fully represent the reality. 
Cost calculation 
The calculation of the intervention costs takes much more planning and effort 
than is the case for medical interventions. This is especially true for large-scale, 
multifactor, community interventions because intervention costs can be very 
complex. A prospective and detailed follow-up is needed to ensure that all 
relevant costs are incorporated while irrelevant costs are excluded. Until now, 
the most usual way to calculate the costs of a community programme has been 
to use the actual expenditures derived from the financial records as an 
estimation of the programme costs. 
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General economic evaluation techniques 
Another aspect of the guidelines for economic evaluation that brings about 
some difficulties when they are applied to health promotion is the concept of 
discounting. Discounting is intended to adjust for any difference in timing of 
costs and benefits.29 30 However, because the benefits of health promotion 
usually will only be observed in the distant future, discounting the future benefits 
is argued to be unfavourable for health promotion programmes when they are 
compared to medical interventions.2731 
Current situation 
Community programmes 
Although not in all,32 33 most community programmes for preventing CVDs 
reported favourable effects on lifestyle, biological risk factors and cardiovascular 
mortality. 3435363733394041 
Some cost-effectiveness evaluations of community programmes for CVDs have 
been performed because of these positive results,42 43 44 45 46 47 48 49 50 51 
The reported cost-effectiveness ratio within the studies reviewed ranged from 
€24 to €6700.46 60 
Guidelines for economic evaluations, however, have been neglected in many 
studies. 
Individual counselling 
The evidence of the effectiveness (in terms of changes in lifestyle or biological 
risk factors) of individual counselling sessions in secondary care is 
contradictory. Although some studies report favourable and long-term effects,52 
or even favourable cost-effectiveness ratios,53 54 others report only small or 
short-term effects, 55 56 57 58or even no effects at all. The same is true for 
counselling in primary care. The effectiveness has been proven in some 
studies,59 60 61 62 63 64 and cost-effectiveness was reported,65 66 67 but some 
studies were not cost-effective in spite of being effective,68 and some studies 
found no effects at all.6970 
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Hartslag Limburg 
Hartslag Limburg (Dutch for Heartbeat Limburg) is a large-scale project 
consisting of a community programme and a high-risk programme. It's purpose 
was to reduce the prevalence and incidence of CVD in the southern part of 
Limburg in the Netherlands.71 The programme was carried out in this specific 
region because of its relatively high prevalence of risk factors and CVD 
morbidity and mortality.7172 
The community programme 
The Hartslag Limburg community programme aims at health promotion among 
all inhabitants of the intervention region of Maastricht and four adjacent 
municipalities (n = 180,000). It can thus be regarded as a primary preventive 
intervention. The programme is based on a unique design through 
implementation by a network of organizations. While the Regional Public Health 
Institute of Maastricht coordinated the programme, many other agencies, 
including health promotion agencies, the local hospital, general practitioners 
(GPs), welfare services, and local authorities, joined the project. The many 
participating organizations made it possible to implement a multiple intervention 
strategy and to reach inhabitants of the region in a variety of ways. 
Special attention was paid to inhabitants of four low socio-economic status 
(LSES) neighbourhoods (n = 20,000), in which 50% of the interventions took 
place. 
The community-based health promotion campaign within Hartslag Limburg was 
realized through nine local health committees: one in each of the five 
municipalities and one in each of the four LSES areas. Each committee consists 
of employees of the Regional Public Health Institute and of welfare services, 
civil servants, and individuals from the target populations themselves. The 
committees approach individuals and groups within the target populations by 
means of health promotion projects and activities. 
The participation of community members in the local health committees is 
essential to facilitate the recruitment and participation of inhabitants. This is 
especially true for the LSES regions because people with a LSES are difficult to 
reach for general health-promoting activities. 
The participation of civil servants is important to make policy changes happen, 
and health promotion activities are partially financed by city councils. 
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The high-risk programme 
The high-risk programme was carried out among GPs' patients who were at 
increased cardiovascular risk (secondary prevention) and among patients 
having recently suffered from a cardiovascular event, who visited the outpatient 
cardiology clinic of University Hospital Maastricht (tertiary prevention). Both 
trials were evaluated separately. 
The intended intervention of the high-risk programme consisted of two parts, 
namely, individual health counselling and optimisation of individual 
cardiovascular drug treatment. Nurses or dieticians who had special counselling 
education provided the health counselling. The counselling focussed on quitting 
smoking, improving the dietary pattern, and increasing the exercise rate. The 
patients and the counsellor decided together which lifestyle factors would be 
included in the counselling. 
Optimization of individual drug treatment was also intended to be an important 
aspect of the intervention. On the basis of a computerized absolute 
cardiovascular risk-factor profile, individual treatment was to be improved by 
adjusting the medication to recent guidelines. 
Outline of the thesis 
The first aim of this thesis was to gain insight into the quality of economic 
evaluation studies in the field of prevention of CVDs. To obtain more information 
about this subject, Chapter 2 reviews the quality of cost-effectiveness studies 
concerning the treatment of tobacco dependence as an example. 
Because the results were disappointing in that the guidelines for economic 
evaluation were not very well adhered to, a second study was performed. It 
recalculates the cost-effectiveness ratios of the original studies reviewed in 
Chapter 1 in order to gain insight into the magnitude of the error that may arise 
due to guideline nonadherence (Chapter 3). 
The subject of the following chapters is the Hartslag Limburg programme. 
Chapter 4 investigates the hypothesis, that focusing a community programme 
on people with a LSES status is more efficient than focusing on groups with 
high socioeconomic status or on the general population. Chapter 5 presents the 
effects in terms of the quality of life of the participants in the high-risk 
programme of Hartslag Limburg. Chapter 6 describes the evaluation of a health 
promotion intervention carried out within Hartslag Limburg, which was 
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established in a public-private partnership. In Chapter 7, the costs of the 
Hartslag Limburg community project are calculated in a detailed way. The 
method also allows the costs to be generalized to other regions. Chapter 8 is 
closely related to Chapter 7 as it describes the cost-effectiveness of the 
Hartslag Limburg community programme. Finally, Chapter 9 draws conclusions 
and presents a general discussion of the research carried out within this thesis. 
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Abstract 
Good decisions on which health interventions to invest can be facilitated by high 
quality evaluations of its cost-effectiveness. Although there are several reviews 
on the evaluations of the cost-effectiveness of smoking cessation programs, the 
reviews did not give information about the quality of the studies. The present 
study tries to fill this gap by thoroughly evaluating the quality of economic 
evaluations of interventions to reduce tobacco consumption. First, the general 
characteristics of all the studies reviewed are described, and then the quality of 
epidemiological characteristics and of the economic evaluation is analysed, 
using a criteria list proposed by Drummond et al. (1997). It is found that the 
quality of many aspects of many of the studies leaves much to be desired. 
However, the studies do consistently conclude that stop-smoking interventions 
are cost-effective, and this conclusion is robust when sensitivity analyses are 
performed. The cost-effectiveness ratios estimated by the studies for smoking 
cessation interventions are much lower than most other health care treatments. 
The study concludes that the broad conclusion that treatments to reduce the 
number of smokers are cost-effective at least in relative terms, is likely to be 
true, despite the concerns expressed about the quality of the economic 
evaluations. The implication for policymakers is that smoking cessation 
interventions are worthwhile. 
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Introduction 
Smoking is one of the biggest health threats facing society today. At present 
trends, an estimated 500 million of the five billion people alive in 2000 will die as 
a result of tobacco consumption.1 Reducing tobacco consumption has 
enormous potential to improve public health. 
During the last two decades, there has been much progress in identifying 
effective interventions in many areas of health care, including in reducing 
tobacco use. There are now a variety of proven, effective interventions and 
treatments to reduce tobacco use including, but not limited to, smoking 
cessation interventions.23 
Limited health care budgets imply that choices have to be made about which 
interventions to implement. Good decisions are facilitated by information about 
the cost-effectiveness of interventions. This information comes from careful 
economic evaluations. A number of cost-effectiveness studies have been 
carried out in the field of treatments for tobacco dependence, and there are 
several reviews of the results.4"7 
In general, authors of these reviews conclude that interventions to make people 
stop smoking are cost-effective. However, although the quality of studies is of 
paramount importance to reach reliable conclusions,8 thorough evaluations the 
quality of the individual studies reviewed were not carried out. The main 
objective of the reviews was to identify the principle findings of the studies 
evaluated. Sensitivity analysis was used to decide on the reliability of the cost-
effectiveness estimates of the interventions. Brown and Garber (1998, 2000) 
tried to increase reliability of their conclusion by limiting the studies for review 
when possible, to those that (1) presented outcome in terms of years of life 
saved, (2) performed the analysis from a societal perspective, (3) discounted 
costs and effects in a consistent way, and (4) gave a description of the age and 
gender of the study population.45 Although their main goal was to review a large 
and diverse set of different interventions and populations, many of the studies 
did not meet their inclusion criteria. This short overview of existing reviews 
concludes that the quality of studies on the cost-effectiveness of smoking 
cessation interventions has not been of primary concern up to now. 
Careful evaluation in other fields of health care, however, indicates that the 
majority of studies is not of sufficient quality.9 Because an accurate evaluation 
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on quality has not yet been performed in the fietd of smoking cessation, a 
knowledge gap exists on this subject. The present study tries to fill this gap by 
thoroughly evaluating the quality of economic evaluations of interventions to 
reduce tobacco consumption. First, the general characteristics of all the studies 
reviewed are described, and then the quality of epidemiological characteristics 
and of the economic evaluation is analysed, using a criteria list proposed by 
Drummond et al. (1997).8 The results of the analysis, both from a scientific 
perspective and the perspective of practical information, are discussed in the 
last section of this paper. 
Methods 
Literature search 
An extensive search of the literature was performed from the year 1966 until the 
year 2000, using the following databases; Medline, Embase, Dare, NHS EED, 
HTA, Cochrane, Psychlit, EconLit. The Istahc journal was searched also. 
Data bases which included a thesaurus function were searched as follows: 
• (Costs and cost analysis) and smoking cessation 
• Cost and smoking cessation 
Data bases without a thesaurus function were searched using the following 
searches: 
• (Cost* or economic*) in title or abstract and (smoking and cessation) in title 
or abstract 
• (Cost* or economic*) and smok* 
• (Cost* in ti or economic* in ti) and smok* in ti 
The Istahc journal was searched with the following terms: 
• Economic in ti 
• Smoking in ti 
• Costs in ti 
• Cost in ti 
• Cost effectiveness in ti 
• Cost-effectiveness in ti 
Additional literature was selected using citation tracking. Only English language 
articles were included. Letters, editorials and reviews were excluded from our 
review. 
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Assessing the quality of the studies 
The guidelines of economic evaluation proposed by Drummond et al (1997) 
were used to assess the quality of the individual studies.8 These guidelines 
incorporate the following aspects: general, measurement of effect, 
measurement of costs, and issues such as discounting and sensitivity analysis. 
All interventions mentioned in the reviewed studies are reviewed for all aspects 
covered in the guidelines. 
The study of Parrott et al. (1998)7 is treated slightly different than other studies. 
The study includes cost-effectiveness analysis of a number of interventions. 
However, because the community interventions and related cost-effectiveness 
analyses were not clearly described, they are excluded from the present review. 
Results 
After excluding letters, editorials and reviews, 22 full economic evaluations were 
identified. All studies identified were cost-effectiveness studies. In 14 studies 
cost-effectiveness was defined as costs per life years saved.710"23 One study 
also included cost utility in its outcome, and presented costs per quality 
adjusted life years (qaly).23 The remaining seven studies define cost-
effectiveness in terms of costs per quitter.24"30 Twelve of the identified studies 
were carried out in the United States.11 1214"16 20 22"25 27 29 30 Six studies were 
performed in the United Kingdom.710131819 21 The three remaining studies were 
done in the Netherlands,28 Finland,26 and Spain.17 
General characteristics 
The general characteristics of the studies do not necessarily influence their 
quality, but definitely affect the way in which results can be interpreted. 
Important general characteristics are described in the following sections. 
Attention is paid to the viewpoint of the analysis, the interventions performed 
and alternative interventions, and to the study population. 
Viewpoint of the analysis 
Studies can be performed from different points of view, and these differences 
greatly affect the interpretation of the results. Therefore, a study's viewpoint 
should be mentioned explicitly in economic evaluation studies. This, however, is 
the case in only 11 of the 22 studies.7 1213 15 17 20 21 23 27 28 30 
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Drummond et al.'s economic guidelines recommend that economic evaluations 
take a societal perspective to prevent decisions being based solely on costs 
and effects for a specific organization or population. But only four of the studies 
explicitly mention having performed cost-effectiveness analysis from a societal 
perspective.7 12 17 28 An organisational perspective is also used, 15 20 28 30 as well 
as the perspective of the NHS,13 21 the medical payer,26 the health authority,7 
and the participants.28  
Interventions performed 
Literature on the cost-effectiveness of smoking cessation covers a wide range 
of interventions (table 1). Interventions include self-help programs, 7 24 25 28-30 
counselling,7 12 14 15 17 18 25 28 quit-smoking contests,7 24 26 nicotine replacement 
therapy,7101617 21"23 community health education programs,7 13 19 20 counselling 
combined with behavioural therapy27 and other combinations of interventions. 
Interventions are compared with placebo therapy,10 16 21 27 counselling,7 14 23 
physicians' advice,17 18 22 a school education program,19 and usual care. 
24-26 28-30 y ^ m o s t f r eqU e n t comparison is between counselling and usual care. 
Three studies compare self-help and usual care. 
Unfortunately, the studied interventions and alternative interventions to which 
they are compared are too heterogeneous to allow cost-effectiveness ratios of 
different studies to be compared. 
7 11-15 19 
Study population 
Not only do the studies compare a wide variety of interventions, the study 
populations differ in characteristics as well. For example smoking habits among 
study populations of different studies are not equal. Furthermore, some 
interventions were available for all smokers,7 11"13 15 17"20 24"31 while in other 
studies interventions were provided to heavy smokers only.102122 
In addition to this, in contrast to preventing healthy people from stopping 
smoking, some studies were designed to promote non-smoking among patient 
populations.14151820 
The age and sex distribution of the study population is also relevant to 
determining whether the results of a specific study can be generalized. Eleven 
studies explicitly mentioned the age- and sex distribution of the population 
receiving the intervention.12 16 17 19 20 22 25 27 28 Five of these studies calculated 
age- and sex-specific cost-effectiveness ratio,12 16 17 22 23 while the other 
remaining six studies simply reported age and sex characteristics of the 
population. 
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Table 1: General characteristics of cost-effectiveness studies performed in the 
field of smoking cessation 
first main coun per- intervention alternative study results ($) 
author outcome try spective inter- population 
measure vention 
costs per not all 
1 quitter US stated Counselling, usual care smokers 235 - 399 
self-help, 22-144 
contest 129-236 
costs per not all 
2 quitter US stated Counselling, usual care smokers 150 
self-help 150 
costs per Fin- not ail 
3 quitter land stated Contest, tv usual care smokers 24 
NRT, 
costs per not behavioural all 
4 quitter US stated therapy placebo smokers 567-1699 
costs per Counselling, all 
5 quitter NL Society self-help usual care smokers 648 -1297 
organi-
sation Counselling, 200-411 
self-help 37-66 
Partici-
pants Counselling 686-1412 
self-help 89-160 
costs per not all 
6 quitter US stated Self-help usual care smokers 90 - 352 
costs per organi- Counselling, pregnant 
7 quitter US sation self-help usual care women 51-118 
costs per all UK 
8 yols UK society Brief advice usual care smokers 300 
brief advice all UK 
+ self-help briefadvice smokers 567 
brief advice 
+ self-help briefadvice all UK 
+ NRT + self-help smokers 5950 
brief advice briefadvice 
+ self-help + self-help all UK 
+ NRT + NRT smokers 1515 
+ specialist 
help 
health 
autho- all UK 
rity brief advice usual care smokers 247 
brief advice 
+ self-help 
brief advice 
+ self-help 
+ NRT 
briefadvice 
briefadvice 
+ self-help 
all UK 
smokers 
all UK 
smokers 
513 
935 
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Table 1: continued 
first 
author 
main 
outcome 
measure 
coun 
try 
per-
spective 
intervention alternative 
inter-
vention 
study 
population 
brief advice 
+ self-help 
+ NRT 
+ specialist 
help 
briefadvice 
+ self-help 
+ NRT 
all UK 
smokers 
heavy 
costs per not smokers 
9 yols UK stated counselling placebo (h)** 
costs per not variety of all 
10 yols US stated interventions usual care smokers nil 
costs per 
all 
smokers 
11 yols US society counselling usual care <h) 
community all 
costs per health smokers 
12 yols UK NHS education usual care (h) 
costs per not Ml-survi-
13 yols US stated counselling usual care vors 
costs per organisa hospital 
14 yols US tion counselling usual care patients 
all 
costs per not smokers 
15 yols US stated NRT* placebo (h) 
all 
costs per medical 
all 
smokers 
16 yols Sp society NRT advice (h) 
costs per not medical hospital 
17 yols UK stated counselling advice patients 
community 
costs per not health all 
18 yols UK stated education usual care smokers 
community 
costs per organisa health school 
19 yols US tion education program children 
costs per counselling, heavy 
20 yols UK NHS NRT placebo smokers 
heavy 
costs per not Counsel- smokers 
21 yols us stated NRT ling (h) 
results ($) 
171 
1430 
1094 - 6828 
705 - 2058 
cost saving 
80- 19000 
1691 -7444 
4113-9473 
2608 - 8058 
480 - 600 
431 - 930 
445-1269 
407 - 733 
965 - 4391 
12 qaly US payer NRT ling (h) 
* NRT = nicotine replacement therapy, ** (h) = hypothetical cohort 
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1 Altman, 1987 
2 Bertera, 1990 
3 Korhorien, 1992 
4 Miller, 1996 
5 Mudde, 1996] 
6 Nelson, 1989 
7 Windsor, 1988 
8 Parrot, 1998 
9 Akehurst, 1994 
10 Croghan, 1997 
11 Cummings, 1989 
12 Haycox, 1994 
13 Krumholz, 1993 
14 Meenan, 1998 
15 Oster, 1986 
16 Plans-Rubio, 1998 
17 Prathiba, 1998 
18 Ratcliffe, 1997] 
19 Secker-Wal-ker, 1997 
20 Stapleton, 1999] 
21 Wasley, 1997 
22 Fiscella, 1996 
The mean age of the population in these studies varied from 38 years of age to 
48 years of age. The percentage of male participants ranged from 0 percent in a 
self-help group for pregnant women to 73 percent in a combined intervention 
using nicotine replacement therapy and behavioural therapy, performed among 
active duty service members. 
Eleven studies did not explicitly mention the age and sex distribution of the 
research sample.7 10 11 13-15 18 21 26 29 30 Three of these studies are cost-
effectiveness analyses of previous performed effectiveness analyses.101415 The 
population for the study performed by Haycox (1994) consisted of the entire 
population of South-West of England.13 Parrot et al. (1998) estimated cost 
effectiveness of the entire population of the United Kingdom7 
Effectiveness of programs 
There are two relevant questions concerning effectiveness of programs. The 
first question concerns the way how consequences are identified and 
measured. The second question is whether effectiveness was established 
before or during the period of economic evaluation. Economic evaluation is 
useful only when effectiveness has been proven. These aspects are addressed 
below. 
Identification and measurement of consequences 
Consequences can be divided into short-term consequences and long-term 
consequences. Long-term health effects are preferred above short-term 
consequences, because the aim of preventive interventions is to improve health 
during future life years. Long-term health effects can be expressed either in life 
years saved or in quality adjusted life years. 
Identifying consequences in terms of quality adjusted life years is the most 
preferred option. It includes long-term effects and takes into account aspects of 
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quality of life. Changes in quality of life are difficult to measure for two reasons. 
First, no consensus exists about methods to measure quality of life. Second 
quality of life changes take place in the future, which means that modelling is 
necessary. Because of these difficulties, only one study explicitly attempted to 
use quality adjusted life years as measure of effect.23 
The next best measure of effect is life years saved. Using information about 
prevalence of smoking-related deaths and modelling techniques, an estimate of 
the years of life saved can be made based on the number of quitters. If costs 
per years of life saved are available, it allows policy makers to compare non-
smoking interventions not only with each other, but also with other health care 
interventions with respect to their life-saving effects. Fifteen studies used years 
of life saved as outcome measure.710"23 
The least favourable outcome measure in economic perspective is the number 
of quitters, because of its short-term scope. This measure of effect in itself 
provides no information about changes in health, and studies using costs per 
quitter as outcome measure cannot be compared to anything other than other 
smoking cessation interventions. Yet, seven studies provide effects only in 
terms of number of quitters.24"30 
In short, the majority of economic evaluations reviewed are cost-effectiveness 
studies. Several studies provided outcome in the less preferred costs per 
number of quitters and only 1 study estimated the most favoured outcome, 
namely cost-utility. 
Was effectiveness established? 
When performing a cost-effectiveness analysis, it is important that reliable 
estimates of effectiveness are made. As is mentioned in the previous section, a 
large number of studies calculated effects in terms of life years saved. To 
estimates long term-effects, modelling techniques are used. No tools are 
available to check the quality or validity of models that are being used to 
extrapolate the number of quitters to years of life saved. For this reason, the 
quality of the models will not be discussed. When reviewing studies on 
effectiveness, analysis is restricted to establishing effectiveness of non-smoking 
programs in terms of number of quitters. 
Attention is paid to the source of the information about the effectiveness 
(empirical data, secondary data), to the kind of effectiveness evaluation 
performed (randomised or observational), to study period, and to the way 
relapse and unaided cessation are dealt with. Table 2 summarises these 
results. 
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Thirteen studies empirically established the effectiveness of non-smoking 
interventions.111518-2124"30 In other studies effectiveness estimates were based 
on secondary literature.7 10 12-14 16 17 22 23 Most of the studies using secondary 
data, performed a review of studies closely related to the intervention under 
study.7 12 16 22 23 Two studies based effectiveness data on one study only.10 14 
One study did not clearly explain the source of the effectiveness data .13 
Most studies used observational designs to establish effectiveness.11 14 17-20 24-29 
Effectiveness was based on randomised controlled trials in 6 cases only.101215 
16 2130 | n f o u r a r | - j c | e s design used is not clear or both designs are used.71322 
23 
Table 2: characteristics of the underlying effectiveness data 
first author source design study period taken 
effect-data effect study (in months) account 
of relapse 
Altman, 1987 empirical observational <3 yes* 
Bertera, 1990 empirical observational 18 n/a 
Korhonen, 1992 empirical observational 6 no 
Miller, 1996 empirical observational 6 no 
Mudde, 1996 empirical observational 6 no 
Nelson, 1989 empirical observational <3 no 
Windsor, 1988 empirical RCT 9 no 
Akehurst, 1994 secondary, 1 study RCT 12 yes* 
Croghan, 1997 empirical observational 12 yes 
Cummings, 1989 secondary, review RCT >12 yes 
Haycox, 1994 ? ? m ? no 
Krumholz, 1993 empirical observational 12 n/a 
Meenan, 1998 empirical RCT 12 n/a 
Oster, 1986 secondary, review RCT >12 yes 
Plans-Rubio, 1998 empirical ? a 12 n/a 
Prathiba, 1998 empirical observational 12 n/a 
Ratcliffe, 1997 empirical observational 12 n/a 
Seeker-Walker, 1997 empirical observational 12 n/a 
Stapleton, 1999 secondary, review RCT 12 yes 
Wasley, 1997 secondary, 1 study ? 12 yes 
Fiscella, 1996 secondary, review ? 12 yes 
* in sensitivity analysis 
Other important features to take into account when interpreting effectiveness 
data are study period and relapse. Relapse is common among smokers 
attempting to quit. Follow-up should thus be long enough to be able to exclude 
excessive relapse. When the follow-up period is relatively short (less than 12 
months) data will be more reliable when corrected for future relapse. 
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All but one study defining cost-effectiveness as costs per yols had a follow-up 
period for at least 1 year.10 11 23 7 12 14-19 21 22 Haycox (1994) was not clear about 
study duration,13 
Among the studies using number of quitters as final outcome, only one study 
reported a study-duration of 12 months.25 Six- or nine-month follow-up of 
patients was used in the studies of Korhonen et ai. (1990), Miller et al. (1996), 
Mudde et al. (1996) and Windsor et al. (1986)26"28 30 Two studies assessed 
smoking status one to three months after the program had been ended.2 4 29 
Only one of the studies defining cost-effectiveness as costs per quitter 
examined effects of relapse in the sensitivity analysis.24 
In summary, this means that there were only five published cost-effectiveness 
studies that performed a randomised controlled trial and took account of 
relapse.1012151621 
Economic quality of studies 
When performing cost-analysis, health care costs as well as non health care 
cost (both direct and indirect) might be of interest. 
Direct health care costs include costs for prevention, diagnosis, therapy and 
care related to the disease or risk factor of interest. Overhead costs - like 
equipment, space, and telephone etceteras - are part of direct health care 
costs. Indirect health care costs include general medical costs that are 
generated during the life years gained by smoking cessation.32 
The most important direct cost outside the health care sector is the value of the 
time of the patient and the family. Indirect non health-care costs mainly consist 
of the costs associated with loss of work due to sick leave and lower 
32 
productivity costs. 
There are several ways in which costs can be identified, measured and valued. 
Drummond et al. (1997) recommend about how to handle in all three stages to 
assure the quality of economic evaluation. Their advice is described below. It 
should be noted, however, when trying to make judgements about quality of the 
economic evaluation, that these three aspects are closely related. 
Identification of costs 
As mentioned before, according to guidelines of Drummond et al. (1997), for a 
study to be internally valid, costs included in the analysis have to be in 
concordance with the viewpoint of the analysis that the study uses.8 Intervention 
costs, changes in health care costs due to changes in smoking related disease, 
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changes in costs due tot changes in lifetime health care costs, costs due to 
productivity changes and participants' costs can be regarded as relevant cost 
components, depending on the perspective. 
Economic evaluations are performed to facilitate future decision-making. 
Therefore, economic evaluations should exclude costs that are irrelevant for 
future performance. For intervention costs, this means that costs of intervention 
development should not be included into the cost analysis. The same is true for 
research costs. Implementation costs might have to be made in future, but only 
once. It is therefore preferable not to incorporate these costs into the cost-
effectiveness analysis; they offer more useful information when mentioned 
separately. When estimating intervention costs it is also important to consider 
contributions from third parties. The total costs of the intervention should be 
reported, independent of the way the costs are financed. 
When calculating intervention costs, the important costs to consider are 
performance and overhead (e.g. electric power, cleaning and administration). 
Overhead costs can be identified either explicitly or implicitly. Costs can be 
estimated using an input oriented approach, which means that all cost 
components are identified separately. Summing up the costs components of the 
intervention that are identified provides an estimate of the total intervention 
costs. A number of studies, especially those evaluating counselling or NRT, 
make use of service units in stead of an input oriented approach when 
estimating costs. Service units are aggregated cost a unit, such as hospital 
visits or visits to a general practitioner. Although not explicitly mentioned, these 
costs include overhead costs. 
The question of whether cost identification is done in concordance with the 
perspective mentioned in the study is discussed below. When there is no 
perspective mentioned in the study, a description of the identified cost 
categories is given. 
Societal perspective 
The studies performed by Mudde et al. (1996), Cummings et al. (1989), and 
Plans-Rubio (1998) and Parrot et al. (1998) were the only studies that explicitly 
mention that the study was performed from the preferred societal perspective.7 
12 17 28 n o w e v e r j careful evaluation of the studies showed that none of the 
studies included all cost categories relevant for a societal perspective. Mudde et 
al (1996) failed to include decreases in health care consumption of smoking 
related diseases due to the intervention.28 Also not mentioned in the study were 
health care costs during additional life years, and declines in productivity losses 
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due to absence from work of smokers. In addition, intervention costs were not 
measured in an adequate way, as they contained development costs and 
implementation costs. Chapter 7 of this thesis elaborates on this. The other 
studies mentioning a societal perspective did not perform the analysis 
completely from a societal view either. In the study of Plans-Rubio (1998), only 
the direct health care costs were assessed.17 Cummings et al. (1989) faultlessly 
identified program costs, and they further identified future health care costs 
related to smoking and health care costs in additional years of life.12 Productivity 
changes were excluded. Parrot et al. (1998) identified program costs and 
patient costs correctly, but they did not include future health care costs and 
productivity changes.7 
Perspective of the organisation 
When the analysis is performed from the perspective of the organisation, 
program costs should be assessed. All five studies performing the study from a 
organisational perspective indeed did include program costs only.15 20 27 28 30 
However program costs were not defined correctly. Development and 
implementation costs were included in intervention costs in one study28 Another 
study incorporated development and research costs into the analysis, while 
ignoring overhead costs.20 The other three studies that performed cost-
effectiveness analysis from the perspective of the organisation did not take 
account of overhead costs.152730 
When the organisation is a medical one, which is the case in the study of 
Meenan et al. (1998), future medical costs related to the organisation should 
have been measured also.15 This was neglected. 
Perspective of the National Health Service 
Some studies have been performed from the viewpoint of the National Health 
Service (NHS). Direct and indirect health care costs are relevant costs to 
consider. One study considered both cost-aspects. 13 Unfortunately, overhead 
costs were not incorporated into the analysis. The other study reported program 
costs only.21 
Perspective of the medical payer 
The perspective of the medical payer was used by one study. In line with the 
perspective used, non-medical costs were not included.23 Consistent with the 
above-mentioned aim of economic evaluations, intervention costs were taken to 
include performance costs and overhead costs only. 
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Perspective of the health authority 
Parrot et al. (1998) used this perspective. Only program costs were included. 
These program costs were correctly identified. 
Perspective of the program participants 
One study calculated cost-effectiveness from the viewpoint of the participants.28 
In this study telephone costs for participants were identified, as were charges 
for the program, time required for participants, transportation costs, and savings 
caused by not smoking or reduced smoking. These costs appear to cover the 
costs made by the program consumers. 
Perspective not mentioned 
Seven of the 11 studies that did not explicitly reported the perspective of the 
studies identified intervention costs only.11 18 19 22 25 26 29 Three of these studies 
included relevant, and excluded irrelevant components.11 18 22 Calculation of 
intervention costs in the other four studies was unsatisfactory. Altman et al. 
(1987) identified program costs and patient costs.24 Program costs were not 
appropriate to the decision making process: research costs and implementation 
costs were included into the analysis. Akehurst and Piercy (1994) rightly 
identified intervention costs, and they also used smoking related disease costs 
in their analysis.10 Intervention costs (unfortunately lacking overhead costs) and 
changes in costs due to changes in lifetime health care costs, were identified by 
Krumholz et al. (1993).14 Finally, Oster et al. (1986) used adequate program 
costs in the analysis together with future smoking related and non-smoking 
related disease costs.16 
In short, when focussing on the internal validity of cost-estimation it is observed 
that costs included do better represent the perspective used, when a narrow 
perspective is adopted. However, intervention costs did often not include the 
recommended cost components. 
Therefore, it can be concluded that there is only one study that identifies costs 
according to perspective stated, 23 and that identifies intervention costs in an 
accurate way. 
Measurement and valuation of costs 
In the reviewed studies there was a tendency to make use of service units (e.g. 
provider visits) when possible. An input oriented approach was used more often 
when interventions were complex or could not be defined as services. 
Counselling and nicotine replacement therapy are interventions that can easily 
be defined into multidimensional units. As a result, they were often identified, 
measured and valued this way in the studies. Nicotine replacement therapy is 
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measured in terms of doses and duration of nicotine replacement intervention.16 
17 21-23 711 V a | u a t i o n i s b a s e d o n r e t a H p r i c e s i n f o u r c a s e s . 7 16 17 22 23 Stapleton 
(1999) valued costs of nicotine patches in terms of manufacturers' wholesale 
21 
prices. 
Physician counselling was often measured in number of minutes of physician 
time needed, and valuation occurs based on charges for physician visit.10121721 
23 When counselling was not provided by physicians, but by nurses or other 
qualified persons, input data are used to estimate costs.14 1825 23 The amount of 
time input was registered, and valuation was based either on actual wages 1823 
or on an estimation of the average wage rate.14 30 Although it was assumed that 
general practitioners provided the counselling, Parrot et al. (1998) used the 
method of cost measurement and cost valuation as described above.7 Because 
of failures in the identification phase, only personnel costs but no overhead 
costs are measured and valued in three of the four input oriented counselling 
based studies.14 25 30 Prathiba (1998) included overhead costs, but the methods 
for measuring and valuating these costs are not clear.18 
If interventions become more complex, measurement and valuation of costs 
become less straightforward. A variety of quit smoking interventions other than 
counselling and nicotine replacement therapy were economically evaluated. 
Altman (1987) evaluated three interventions: a self-help kit, a contest and a 
smoking-cessation class.24 The only cost-aspect for which measurement was 
explicitly mentioned was participants' time input It is valued at $10, but the 
reason for assigning this value was not explained. Measurement and valuation 
of other aspects is not clear. Reading between the lines, it seems that actual 
costs made during the program were used, including staff and staff benefits, 
overhead, rents, supplies and materials, travel and data-analysis. 
More or less the same procedure seems to have been followed by Mudde et al. 
(1996).28 Costs of the program are primarily based on financial records. Hourly 
wages of trainers are based on the national average wage, time input of 
participants was valued based on figures in literature, and transportation costs 
are measured and valued separately. 
Costs of the community health educational program by Seeker-Walker et al. 
(1997) were estimated from project records only.20 
In another community health education project all aspects of the campaign were 
measured separately.19 Time input is measured and valued as a proportion of 
individual gross salary. Overhead was assumed to involve the same proportion. 
Media costs were divided into buying and advertising time. These units are 
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valued using recorded data. Costs of self-help booklets were also measured 
and valued using recorded data. 
In the study by Croghan et al. (1997) quit smoking therapies provided by the 
Mayo clinic to all of their clients were evaluated.11 Costs of this large variety of 
interventions were determined by total operating costs of the Mayo clinic over 
over year. These costs were projected over the total study period. 
Miller et al. (1996) combined behavioural modification with nicotine replacement 
therapy and provided educational material to subjects.27 Costs of behavioural 
modification is estimated by measuring time input of trainers, valuing time input 
as the average wage. Nicotine replacement therapy was measured in duration 
and dosage of therapy. It was valued by using the costs at which the company 
acquired the products. The costs of educational materials were estimated as the 
actual costs per pamphlet, multiplied by the number of pamphlets. 
Recruitment strategy for a quit-smoking contest was the main intervention in the 
study by Nelson et al. (1989).29 Costs were measured as time input of the 
persons involved, and were valued at average wage. Volunteer time was not 
valued. Costs for promotional and educational materials were taken from project 
records. 
Two studies are very inaccurate in measuring and valuing costs of the 
intervention program. Haycox used a hypothetical community intervention.13 
Determination of intervention costs was not explained at all. Korhonen gave 
only rough estimates of costs made by the organisation. Costs incurred by other 
partners were not valued at all.26 
Reductions in costs due to decrease in smoking related disease together with 
an increase in costs due to increase in routine medical costs in additional life 
years were referred to by 4 studies.12 13 16 23 Three studies decided not to 
measure these costs because literature suggest that the benefits that arise from 
reductions in smoking related diseases are of the same magnitude as the 
increase in health care costs during the additional life years.12 1623 Haycox et al. 
(1994) used current figures about smoking related health care and health care 
costs together with modelling to estimate effects on total health care costs.13 
The result was a net cost saving in health care expenditure. Only one study 
included a reduction in costs due to fewer smoking related diseases.17 Costs 
were determined by gaining advice from an expert panel. Finally, one study 
examined the effects of an increase in lifetime medical care costs in sensitivity 
analysis.14 Costs were based on published data. 
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General quality aspects 
Incremental analysis 
For a meaningful comparison of alternatives, additional costs and effects of one 
program over another program need to be explored.8 All reviewed studies were 
full economic evaluations, which means that a comparison between alternatives 
is made when estimating cost-effectiveness. A cost-effectiveness ratio is most 
informative when relevant alternatives are compared. Appropriate alternatives 
of a new program are prevailing interventions or best care. Studies are 
reviewed with respect to the incremental analysis in this section. Information 
about incremental analysis is summarised in table 3 also. 
Half of the studies performed a precise incremental analysis that was well 
described in the article.7 12 14"18 20"23 Most of these studies analysed the 
additional cost-effectiveness of nicotine replacement plus counselling versus 
the relevant alternative of counselling alone.16 17 21 23 Three studies assessed 
incremental cost-effectiveness of counselling compared to routine physicians' 
advice,14 1518 which is also an adequate comparison. One study looked at the 
additional value of follow up visits as an extra service to counselling.12 Again, 
the interventions compared are relevant in determining reliable cost 
effectiveness ratios. Parrott et al. (1998) compared brief advice with usual care, 
and brief advice plus a self-help kit was compared with brief advice alone. 
Nicotine replacement therapy in addition to brief physicians advice and self-help 
material was compared with brief advice and self-help material. Finally, an 
intervention using specialist smoking cessation services in addition to brief 
advice, self-help and nicotine replacement was compared with the same packet 
of care, excluding specialist smoking cessation service.7 All these comparisons 
are useful. In another study, the incremental cost-effectiveness of a mass media 
campaign in addition to a school program was subject of research.20 Two 
studies compared the smoking cessation rate at the end of the intervention with 
the estimated smoking cessation rate in the general population.1112 Only seven 
studies compared the smoking rate at the end of the program with the smoking 
rate at the start of the program.20 24 25 26 28 29 30 By using this kind of comparison, 
the authors implicitly suggest that usual care or 'doing nothing' is the best 
alternative available. Although in principle, this is often a good choice for the 
alternative comparator intervention, the authors of these articles wrongly 
assumed that there would be no quitters when the intervention under research 
were not performed. 
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In short, there are differences observed in the quality of incremental analysis 
performed. 
Discounting 
The process of discounting is strongly related to the concept of time preference. 
People prefer incurring costs in future rather than today, and they favour 
benefits today rather than in the future. This means that they prefer to spent 
money in future rather than in the short term. Drummond et al. (1997) gave 
some explanations for this phenomenon:8 it can be explained partly because the 
value of an amount of money will decrease over time, and partly because it 
provides people with more flexibility; giving them more options. 
Time preference is not restricted to monetary values. People also favour health 
benefits today rather than tomorrow. Drummond et al. (1997) provide reasons 
for this.8 One reason might be that the future is uncertain. Therefore, when the 
health benefits of a specific intervention will only be felt after 20 years of time 
people give less value to it because many other bad things can happen to them 
during that time period. Furthermore, people simply may have a short-term view 
of life. Because of the importance of time preferences - especially in preventive 
interventions - it is incorporated in the analysis via the process of discounting of 
costs and effects. 
Time preferences will only play a role when the costs or the health effects occur 
in the future. Seven of the reviewed studies in the field of cost-effectiveness of 
non-smoking interventions defined cost-effectiveness in terms of costs per 
quitter.24"30 In most cases, the costs involved are short term program costs only. 
This makes discounting unnecessary. In two studies, the intervention lasted 
more than one year and the costs were discounted.24 29 Effects expressed in 
number of quitters, does not include future health benefits. Therefore, there is 
no need for discounting either (table 3). 
The remaining studies expressed cost-effectiveness in terms of costs per yols.7 
10-15 18-23 31 33 Oost-utility is determined by Fiscella et al. (1996).23 These studies 
expanded outcome to future health benefits and should therefore have 
discounted the effects. All but one study indeed discounted effects (table 3). 
The most commonly used discount rate was 5%.11 1214"1722 Discount rates of 
1.5%,71.75%,21 3%,20 23 and 6%,101319 are used also. 
Discounting of costs was necessary only when future costs are incorporated 
(table 3). Future costs were identified in seven studies, and were included in the 
analysis in three of them.131617 In concordance with the guidelines, these three 
studies indeed discounted future costs at a rate of 5% or 6%. When future costs 
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were identified but not measured, based on literature, the assumption of a zero 
net effect was made. 
Sensitivity analysis 
Every economic evaluation contains some degree of uncertainty. Because of 
the long-term scope, this is especially true for economic evaluations of 
preventive interventions. The effect data used in the study may not accurately 
represent the actual quit rates that result from the interventions. Based on one 
or more effectiveness or even efficacy studies, assumptions are made about 
quit rates, relapse rates, compliance, and other factors that determine the effect 
of the intervention. It might be clear that elimination of uncertainty in effect data 
can never be fully achieved. This is also true for costs used in economic 
evaluation. The degree of uncertainty of the data will influence the reliability of 
the established cost-effectiveness ratio. It is important for authors and reviewers 
of cost-effectiveness studies to be aware of this. The guidelines recommend 
that researchers explore the possible variability in outcome. Sensitivity analysis 
is the most frequent used tool in investigating robustness of outcomes. Five 
studies did not perform sensitivity analysis or any other form of investigating 
variability in outcome at all.7 19 25 26 29 The remaining seventeen studies all 
performed sensitivity analysis (table 3). 
The results of sensitivity analysis have to be explored very well. Many 
researchers and policy makers consider only estimates of cost-effectiveness 
ratios that have high certainty to be of value. This may result in performing 
conservative sensitivity analysis by limiting the number of parameters varied or 
by defining unrealistic small sensitivity ranges. It is important to use realistic 
sensitivity ranges when performing sensitivity analysis and to explain explicitly 
the choice of the ranges. 
In nine studies an explanation is given for the sensitivity range chosen.11 15 16 20* 
23 27 28 confidence intervals (90% or 95%) were most often used to define a 
sensitivity range.15 16 20 21 23 27 28 Estimates of lower and higher bounds were 
based on literature in three studies.11 1622 Table 3 summarises use of sensitivity-
analysis in studies. 
Table 3: Characteristics from the cost analysis and from general aspects of economic evaluation 
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16 y y* 
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18 y y 
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n 
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n 
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n 
n 
n 
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n 
n 
y 
n 
y y 
n 
n 
y 
n 
n 
n 
n 
n 
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care 
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tra life 
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n 
n 
n 
n 
n 
n 
n 
n 
n 
n 
y 
n 
j * * 
n 
n 
n 
n 
n 
n 
y 
pro- pa- dis- dis- sensi-
duc- tient coun- coun- tivity 
tivity costs ting ting ana-
costs costs ef-
fects 
lysis 
range 
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vity 
analysis 
explai-
ned 
incre-
mental 
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lysis 
n y y n/a y n n 
n n n/a n/a n n/a n 
n n n/a n/a n n/a n 
n n n/a n/a y y n 
n y n/a n/a y y n 
n n y n/a n n/a n 
n (y) n/a n/a y n n 
n y n/a y n n/a y 
n n n/a y y n ? • 
n n n/a y y y n 
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n n y y y n n 
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* implicitly measured, ** in sensitivity analysis 
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Summary 
This article reports on a review of 22 economic evaluations in the field of 
treatment for tobacco-dependence. The articles were quite diverse in terms of 
interventions performed, alternative interventions considered and study 
populations. This indicates that cost-effectiveness ratios and cost utility ratios of 
different studies could not be compared directly. However, differences in the 
general features of studies were not problematic for the current study because 
our interest was in the quality of the economic evaluation of individual studies. 
The checklist proposed by Drummond et al (1997) was used as a guide to 
perform a quality assessment of economic evaluations in the field of treatment 
for tobacco dependence.8 
Scientific studies should start with providing a well-defined research question. In 
the case of economic evaluation, an important aspect of the research question 
is the perspective from which the analysis is performed. The perspective is 
mentioned in only 13 studies. 
In terms of the economic evaluation itself, the first condition to provide reliable 
outcome-data in economic evaluation is to make use of qualitatively good effect 
data. There were only 5 published cost-effectiveness studies that used 
effectiveness data which were obtained with a randomised controlled trial and 
which took notion of relapse when necessary. This indicates that many 
economic evaluation studies might not be based on qualitatively good 
effectiveness data. In other words, although there is evidence that stop-smoking 
interventions are effective in general, the estimates of the magnitude of the 
effect in specific studies might not be reliable. 
When reviewing cost-analysis, there was only one study that adequately 
identified cost-categories in concordance with the viewpoint taken by the study. 
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Contrary to identification of costs, measurement of the identified cost-categories 
is performed adequately by the majority of studies. 
In addition to quality of effect data and quality of cost-analysis, there are some 
general aspects that influence quality of the economic evaluation studies. 
Discounting is one of these aspects. In most of the studies reviewed, 
discounting is performed when necessary, and many studies used the same 
discount rate. 
Sensitivity analysis was performed by 17 of the 22 studies evaluated. An 
explanation for the width of sensitivity ranges is provided by only half of the 
studies. Sensitivity ranges were determined using confidence intervals and/or 
secondary literature. These methods seem to result in reasonable and 
appropriate sensitivity ranges. 
In summary it can be said that, in general the guidelines were not followed very 
well. This conclusion raises the important question of whether the quality of the 
studies in general is low, or whether there are large differences in quality of 
economic evaluation between studies. There was no study that accurately 
handled effectiveness data and faultlessly identified relevant costs in 
concordance with the perspective stated. The study of Fiscella et al. (1997),23 
performed from the perspective of the medical payer, is most performed in 
accordance to the guidelines of Drummond et al (1997).8 Fiscella et al. (1996) 
identified costs in concordance with the perspective mentioned, and discounting 
and sensitivity analysis were carried out and the choices for sensitivity ranges 
were explained.23 Effects were estimated on the basis of a review study. An 
important issue, however, is that this study was performed form the fairly narrow 
perspective of the medical payer. This perspective includes only a few cost 
categories, which means that the study is easier to perform than cost-
effectiveness analyses performed from broader points of view. In addition, 
having not performed the study according to societal perspective makes the 
study inadequate for decision-making at the macro level. This will be discussed 
in the following section. 
Conclusions and discussion 
Overall it can be concluded that economic evaluation studies in the field of 
tobacco cessation as in other fields of research do not follow guidelines for 
economic evaluation very well. Authors often falsely assume that effectiveness 
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studies are of high quality. This study indicates that more attention has to be 
paid to the quality of the sources of effectiveness data. Furthermore, it is shown 
that the first step in the economic evaluation of smoking cessation interventions, 
namely identifying costs, was performed according to guidelines only in a few 
cases. It is of great concern that the basis of the determination of costs is 
frequently subject to inaccuracies. 
The observation that sensitivity analysis often is performed in a non-scientific 
way is also of concern. Sensitivity analysis is the only part of the study in which 
the assumptions used to generate the cost-effectiveness ratio or cost utility ratio 
can be varied to test the robustness of the outcome ratio. This part of the 
evaluation has to be carried out very carefully. 
In addition to the poor scientific quality of the studies, there is another caveat 
worth mentioning. To achieve information about costs per life years saved 
resulting from preventive interventions within a limited time frame, it is 
necessary to make use of modelling. In economic evaluation of quit-smoking 
interventions a diversity of models has been used to extrapolate the number of 
quitters to the numbers of life years saved. Studies based on modelling 
techniques are subject to a number of frequently raised concerns. Some 
frequently mentioned concerns are an inappropriate use of clinical data, 
concerns about bias in observational data, concerns about the validity of 
models, and concerns about difficulties in extrapolation.34 Especially concerns 
with the validity of the models is very problematic. As a result of this, the quality 
of the models cannot be judged. 
Studies that did not make use of models present the outcome in terms of cost 
per quitter. The main problem with these studies is that cost-effectiveness ratio 
cannot be compared to health care interventions presenting outcome in costs 
per years of life saved. This does not necessarily mean that studies in which the 
costs per quitter is the only outcome measure mentioned are not useful. When 
more insight into modelling is gained, costs per quitter might be translated 
easily by economists into costs per life years saved and/or costs per qaly. 
Retaining these studies from analysis offers a broader view on costs and effects 
of smoking cessation interventions. 
Because the studies are not of high quality scientifically, and because there is 
uncertainty about the validity of models, we are left with the question as to 
whether the economic evaluation studies in the field of smoking cessation are of 
practical use. The costs per life years saved presented in the studies are low 
($220 to $19000), but because of the poor qualities of the studies, no firm 
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conclusions can be drawn about the cost-effectiveness of smoking cessation 
interventions. However, there is a very high consistency between the studies sr* 
concluding that stop smoking interventions are cost-effective, and the results 
stay favourable after having performed sensitivity analyses. Furthermore 
although there are many biases observed in most of the studies, it is highly 
unlikely that the biases observed in many of the studies all modify the results in 
favour of the non-smoking interventions. Finally, cost-effectiveness ratios 
presented in studies about smoking cessation interventions are much lower 
than other already accepted health care treatments. So, in spite of the generally 
low quality of economic evaluations in the field of smoking cessation, thm 
conclusion from other reviewers,4 6 namely that treatments to reduce the 
number of smokers are cost-effective at least in relative terms, is likely to be 
true. 
This is important information for policymakers, who thus are advised to continue 
smoking cessation interventions, at least until better insight is gained into the 
cost-effectiveness of interventions to reduce tobacco consumption. 
More robust scientific evidence can be gathered using a model that has the 
potential to modify all aspects relevant for estimating the cost-effectiveness of 
smoking cessation interventions. Developing such a model might be a 
challenge for researchers in order to solve the problem of cost-effectiveness of 
smoking cessation, and it may even be helpful in clarifying cost-effectiveness 
issues of other health care interventions, 
Such a model might also solve another issue of importance, namely that of the 
external validity of the studies. Medical technology assessment is a research 
area that builds a bridge between science and policy. It is aimed at facilitating 
decision-making about implementation of health care interventions at a macro-
level. To be able to make these decisions, studies have to be performed from 
the societal perspective, which very few of the reviewed studies used. 
Development of a meta-model in which all aspects of economic analysis can be 
simulated would increase the usefulness of the large number of economic 
evaluations performed from a non-societal perspective. 
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Abstract 
This study was performed in order to render cost-effectiveness studies on 
smoking cessation therapies performed until now more comparable and more 
useful for policy-making. For this aim, the cost-effectiveness ratios reported by 
the studies were recalculated using a societal perspective and guidelines for 
economic evaluation. It was observed that the costs of individual interventions 
generally increased as a result of the standardisation procedure, while the effect 
size decreased. This resulted in increases in the cost-effectiveness ratios for 
individual studies ranging from 120% to 5600%. This means that not following 
guidelines when calculating cost-effectiveness ratios can result in large errors. 
Despite the fact that the standardised cost-effectiveness ratios of smoking 
interventions were higher than the non-standardised cost-effectiveness ratios, 
interventions aimed at reducing the prevalence of smoking are cost-effective. 
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Introduction 
During the last two decades, major increases in medical and technical 
knowledge have resulted in a large increase in the number of effective 
interventions and treatments available for almost any disease.1 Because of fixed 
health care budgets, however, insufficient resources are available to implement 
all effective interventions. This means that choices have to be made about 
interventions to be implemented, and these are often based on cost-
effectiveness (CE) studies providing information about the costs per unit of 
health gain (e.g. years of life saved (yols)). When performed adequately and in 
a uniform way, cost-effectiveness studies within the entire field of health care 
can be compared, which greatly facilitates decision-making at the macro level. 
Meta-studies and systematic reviews can facilitate the process of decision-
making at macro-level, because they combine information from a number of 
studies in one analysis. Until recently, however, no such review had been 
produced for the field of smoking cessation therapies. Hence, the previous 
chapter of this thesis presents a review of all cost-effectiveness studies on 
smoking cessation in a systematic review. The review revealed considerable 
differences in methodology and in the way effects and costs were measured. 
First, only two studies had been performed from the societal perspective, the 
preferred method for analyses to be used at the macro level. Second, measures 
of effectiveness differed. Some studies measured the effect size in terms of 
numbers of quitters, while others defined effectiveness in terms of years of life 
saved or quality adjusted life years. Furthermore, studies differed in length of 
follow-up, relapse rates and unaided cessation rates, factors that can influence 
the effect size. Among the latter group, studies used a variety of models to 
extrapolate the effect size in term of quitters to the effect size in terms of years 
of life saved. Finally, costs had not been calculated in a uniform way and 
guidelines for cost determination had frequently been ignored. These 
differences in methodology make using their results in policy-making 
problematic. 
The studies also differed with respect to more general characteristics, such as 
intervention, comparative interventions, outcome measure, study population 
and country and year of study, which also hampers the decision-making 
process. For example, the choice within a study of an intervention and a 
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comparative intervention often represents an implicit choice between an 
incremental and an average cost-effectiveness analysis. For the purpose of 
policy making, incremental analyses are much more informative.23 Furthermore, 
recruitment of the study population might influence the cost-effectiveness ratio. 
The effect size of an intervention will be much higher if only highly motivated 
persons are included than if a general sample of the smoking population under 
study is included. This might also influence the cost-effectiveness ratio. 
Because of this large diversity in methodological and general characteristics of 
studies on the cost-effectiveness of smoking cessation interventions, no firm 
conclusions can be drawn about the cost-effectiveness of such interventions, 
which means that the studies were not very informative from the point of view of 
policy making. 
The aim of the present study was to standardise the cost-effectiveness (CEA) 
ratios in order to improve their value for policy making. 
Methods 
We recalculated the cost-effectiveness ratios reported by the individual studies 
by using a societal perspective and the guidelines proposed by Drummond et 
al.,2 together with information from the individual studies. These adjusted results 
were expected to make studies more comparable and therefore more useful. 
Differences in CE ratios among studies can be caused by various factors, 
including the use of different perspectives, differences in calculating the costs of 
the interventions, differences in determining effect sizes and differences in 
extrapolating effect sizes in terms of quitters to effect sizes in terms of years of 
life saved. This section describes the methods we used to standardise these 
factors. 
First, however, a short description is provided on the exclusion and inclusion of 
studies. 
For practical reasons, some studies from our previous review were not included 
in the present analysis, viz. the studies by Croghan et al. (1997), Haycox 
(1994), Korhonen et al. (1992), Miller et al. (1996), Nelson et al. (1989), Ratcliffe 
et al. (1997) and Seeker-Walker et al. (1997).4 5 6 7 8 9 10 The main reason was 
that it was impossible to recalculate the cost-effectiveness reported in these 
studies using our standardisation procedure. Five of the excluded studies 
reported on community interventions.5 6 8 9 10 This means that the results of the 
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present study will only be applicable to non-community intervention studies 
aimed at reducing the prevalence of smoking. The remaining 14 studies did 
allow for standardization. In order to facilitate the analysis, the comparisons 
included in the studies that did allow standardization were divided into 
subgroups, as shown in table 1, Individual studies could be assigned to more 
than one category, if they involved more than one comparison. The present 
analysis thus included 14 studies, covering 26 comparisons.11 «13U151«17181»20 
21222324 | n a^ j f lQ^ s o m e studies provided data allowing analyses that had not 
been performed in the original studies.12 17 23 24 For example, some studies 
provided cost-effectiveness analyses of self-help versus usual care and 
counselling versus usual care within one study,7 12 17 24 without attempting to 
analyse the incremental cost-effectiveness ratio of counselling versus self-help. 
The present review tried to fill these gaps. 
Table 1: Intervention components relevant for the cost-calculation per subgroup 
of intervention and comparative intervention 
1 2 3 4 5 6 7 
Counsellor's counselling time X X 
Study material X X 
Room rent X X 
Counsellor's travel time X X 
Counsellor's travel costs X X 
Patient counselling time X X 
Patients' travel time X X X 
Patients' travel costs X X X 
Self-help manual X X 
Other self-help assistance X X 
Distribution X X 
Patient time X X 
Extra costs specific manual X 
Physician's time follow-up visit X 
Gum/patch/nasal spray X 
Costs of counselling 
Minus costs of self-help X 
1 coun-selling/self-help versus usual care 
2 self-help versus usual care 
3 specific self-help versus general self-help 
4 counselling versus self-help 
5 counselling versus usual care 
6 counselling + FU versus coun-selling 
7 NRT + counselling versus coun-selling 
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Eliminating cost difference 
Costs can be divided into those related to recruitment of participants, 
intervention costs, savings due to better health and costs resulting from people 
living longer.2 3 The standardisation procedure we used was restricted to the 
recruitment costs and the treatment (or intervention) costs, for two reasons. 
First there is evidence that savings due to better health are balanced out by 
future costs due to living longer.25 
Second, the studies analysed in this review provided insufficient data about 
future costs to allow the standardisation procedure to be applied: only three of 
the original studies reported savings due to better health and only one study 
reported costs incurred during the expanded lifetime.111319 
An adequate cost determination requires three steps to be taken. First, it is 
important to draw up an overview of all costs involved, so step one involves 
identifying costs. With regard to intervention costs and recruitment costs, it is 
important to include only those costs that will have to be incurred if the 
intervention is performed again. This means that development costs and costs 
incurred for research purposes should not be included. After the relevant cost 
components have been defined the volume is attached to each component in 
step 2. Finally, step three involves valuing the costs. 
First, the recruitment costs reported by the individual studies were recalculated. 
Cost components of recruitment and their volume components were derived 
from the original studies where possible. In many studies, recruitment consisted 
of 5 minutes of additional physician time for each smoker visiting a physician. 
Assuming a 25% acceptance rate, recruitment thus required 20 minutes of 
physician time per person actually participating in the study.14 1922 If we assume 
a 50% acceptance rate, recruitment required 10 minutes of physician time per 
participant.11 15 16 20 In the study by Bertera et al., recruitment consisted of four 
1-hour lectures for all smokers in a company.12 The counsellor devoted 3.5 
minutes per participant to recruitment. Recruitment costs in the studies by 
Mudde et aL and Altman et aL consisted of start-up costs and the costs of the 
telephone helpline.17 24 Their articles did not provide enough data to recalculate 
these costs. We used data provided by Mudde et al. to estimate the recruitment 
costs per participant and applied this value to both studies. Stapleton et al. 
were unclear about recruitment, so theirs is a missing value.21 Finally, some 
studies compared counselling with self-help, which means that recruitment 
costs were the same for the intervention and the comparative intervention, and 
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thus not relevant to an incremental comparison.12 17 24 There were also some 
studies in which ail smokers were counselled or given a self-help manual, which 
meant that no recruitment costs were incurred at all.3151623 
Valuation of these recruitment costs was performed in a standardised way, 
using Dutch price levels for the year 2002. Although we used Dutch price levels, 
the costs are presented in US Dollars. Table 2 shows the values attached to 
each individual service, together with the source of the prices used. Because 
Dutch values are used, the results are applicable to the Dutch situation and they 
cannot be used for other countries without concerns. We will return to this point 
in the Discussion section. 
After having recalculated recruitment costs, we then recalculated the 
intervention costs, using the subgroups defined in table 1. Because many 
studies performed incomplete cost-analysis, intervention costs were first re-
identified from the societal perspective. Relevant intervention components for 
each subgroup were defined. Table 1 shows the cost components that were 
relevant to the incremental comparison between the two interventions reported. 
Because there were minor differences between interventions belonging to the 
same subgroup, not all costs defined were relevant for all studies within a 
subgroup. For instance, travel costs made by the counsellor were included if 
counselling was part of a community intervention, but not if counselling took 
place in a hospital where the counsellor was an employee. Travel time or travel 
costs for patients were not calculated if the study subjects were hospital 
inpatients, and room rent was not incorporated in the cost analysis if the study 
had been performed at a hospital. After having thus defined cost components, 
we attached the volume components, using information from the individual 
studies if possible. If no specific information was available, assumptions had to 
be made, based on information from other articles using the same intervention 
or (in some cases) from other literature. The following assumptions were made: 
• The costs of a nicotine nasal spray are the same as those of nicotine gum; 
• When group size was unclear in interventions involving group counselling, it 
was assumed that the group had consisted of 10 persons; 
• The distance travelled was assumed to be the mean distance from a 
person's home to the nearest hospital26; 
• The time spent travelling to a hospital was assumed to be 10 minutes26 
• Travel costs were estimated at $0.10 per kilometer26. 
• Follow-up visits were assumed to take 15 minutes; 
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• Distribution of the self-help material was estimated to require 
• Five minutes of counsellor time when the self-help material was handed 
over personally; 
• Five minutes of secretary time and a $1 stamp when the self-help materia! 
was posted. 
The final step in the recalculation of the intervention costs was the valuation of 
costs, which was again performed using Dutch prices for the year 2002 (table 
2). We expressed the costs in US Dollars, because most studies reported this 
currency. 
Table 2: The valuation of the material and personnel input 
Cost component price in the year 2002 ($) source 
time Input by GP 21,60**** Dutch guidelines27 
time input by non-physician 
counsellor 56,80** financial records Heartbeat Limburg 
time input by secretary 20** financial records Heartbeat Limburg 
time input by patient 9,20** Dutch guidelines27 
travel costs 0,11*** Dutch guidelines27 
gum 2 mg 0,23* internet pharmacy 2002 
gum 4mg 0,27* internet pharmacy 2002 
patch 5 mg 2,60* internet pharmacy 2002 
patch 10 mg 2,60* internet pharmacy 2002 
patch 15 mg 2,60* internet pharmacy 2002 
self-help manual 5* mean of studies 
relaxation tape 2,5* study by Bertera et al.13 
stamps for distributing manual 1* financial records Heartbeat Limburg 
room rent financial records Heartbeat Limburg 
* per piece, ** per hour, *** per kilometre, **** per consult 
Eliminating differences in effect sizes in terms of quitters 
The earlier systematic review that is presented as chapter 2 from this thesis 
revealed that studies differed considerably in the way they calculated effect 
sizes in terms of quitters.27 The present analysis calculated the so-called 
lifetime incremental quit rates in order to standardise aspects that cause 
undesirable differences in effect sizes in terms of quitters between studies -
such as differences in values used for short term and long term relapse, annua! 
unaided cessation and comparative quit rates. We calculated the long-term 
effect-size resulting from a particular anti-smoking intervention, taking into 
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account the short-term incremental quit rate (resulting from the specific 
intervention), short-term relapse (within 1 year), long-term relapse (after 1 year) 
and annual unaided cessation. 
Uniform values for short-term relapse, long-term relapse and annual unaided 
cessation were used to eliminate differences between studies. If the study 
duration had been less than 1 year, our analysis controlled for short-term 
relapse. Based on the studies by Prathiba et al. (1998), a 50% short-term 
relapse was assumed for studies with a follow-up period of 2 months or less, 
which implies that after 1 year the success rate would be reduced from 50% to 
25%.20 When studies had a follow-up period of 3 months, 33% of the quitters 
were assumed to relapse within the first year of cessation, while a 12.5% 
relapse rate was assumed when the follow-up period was 6 months.20 We 
assumed a long-term relapse rate of 35% after 1 year of follow-up 14. Annual 
unaided cessation was assumed to be 1.5%. 21 Following Oster et al. (1988), 
we assumed annual unaided cessation to occur until the age of 72.18 
Quit rates of comparative interventions were standardised when possible, 
meaning that uniform quit rates were used for comparative interventions that 
were the same. The quit rate resulting from self-help was assumed to be 4%. 
Some exceptions had to be made. 
First, in most cases, there were differences between alternative interventions 
used in studies belonging to the same subgroup. An example is the use of 
counselling as a comparative intervention. In some studies, the comparative 
intervention consisted of one 5-minute counselling session, while others used 
more or longer sessions. The quit rate resulting from short advice was assumed 
to be 4.5%, 18 21 22 while longer counselling was assumed to result in a higher 
quit rate. The quit rate resulting from longer counselling was estimated, on the 
basis of only one study, to be 10%.11 Another example is the use of 'usual care' 
as a comparator intervention. Sometimes usual care means no intervention, 
while in other studies usual care is a brief advisory session by the physician. 
The quit rate resulting from brief physician counselling was assumed to be 
4.5%. 18 21 22 When usual care meant no intervention, the annual unaided 
cessation rate of 1.5% was used to estimate the alternative quit rate. 
The second exception is related to the study population. Most studies included 
all smokers, but some included only hospitalised patients or even only patients 
having a smoking-related disease. Therefore, standardised comparative quit 
rates were only applied to studies whose population consisted of a sample of 
smokers from the general population. If the study had been performed among a 
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highly specific population (e.g. hospitalised persons or persons recovering from 
myocardial infarction), the comparative quit rate was taken from the original 
study. Finally, our analysis also involved comparisons that were not made in the 
original study. These analyses were often also made on the basis of quit rates 
used in the original studies. 
Eliminating differences in extrapolating the incremental cessation 
rate to yols 
Effect data can be made more useful for medical decision-making by 
extrapolating the effect size in terms of quitters to an effect size in terms of yols. 
Some of the studies included in our systematic review failed to apply this 
extrapolation, leading to the calculation of CE ratios in terms of costs per 
quitter.12 17 23 24 In the other studies, this extrapolation made it possible to 
express the results in terms of costs per yols.11 13 14 1516 18 192021 The studies that 
did extrapolate effect sizes in terms of quitters to yols used different methods, 
leading to different numbers of yols per quitter. The number of yols per quitter 
ranges from 0.5 in the study by Akehurst et al. (1994) to 2 in that by Prathiba et 
al. (1998). All of the techniques used are subject to one or more objections. 
Because it cannot be judged at this moment which method of extrapolation 
results in the most realistic data about years of life saved, we standardised this 
by using the data provided by Oster et al. (1988). Arguments in favour of using 
their data are that they seem to have developed an adequate model (face 
validity), produced age- and sex-specific data, produced figures that were in the 
centre of the range referred to above (0.5 to 2 years per quitter), and last but 
not least, that their data were the most frequently used by other studies in the 
systematic review. By taking the work of Oster et al. as a standard, we 
simultaneously standardised the discount rate (5%). If the characteristics of the 
study population were known, yols were calculated using age- and sex-specific 
characteristics of the specific population. In cases where the study population 
was not clear, data for a 45-year old male were used for the present analysis. 
Results 
Changes in cost-effectiveness ratio resulting from our recalculations may have 
different causes, including changes in costs, changes in effect size, and/or 
differences in the way the effect size in terms of quitters is extrapolated to the 
effect size in terms of yols. 
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Changes in costs 
There were very large differences between the studies in the changes in costs 
resulting from standardisation. Costs might increase by up to 1000%, but there 
were even studies for which costs slightly decreased. In most cases, however, 
the standardised costs were considerably higher than those reported in the 
original articles, the mean increase being over 200%. Costs reported in the 
original articles and standardised costs are compared in table 3. 
Table 3: Costs of the original article and the standardised costs 
study sub- original standard- standard- standard- standard- change change in 
group costs ($) ised re- ised per- ised total ised total in costs costs (%) 
cruitment formance costs ($) costs <%) excl. year 
costs ($) costs ($) excl. year of study 
of study 
($) 
Bertera 1 26 3 100 103 ? 293 ? 
Mudde 1 141 48 61 109 76 -23 -46 
Altman 2 5 40 11 51 27 1009 487 
Bertera 2 17 9 23 32 ? 93 ? 
Mudde 2 6 68 11 79 55 1154 773 
Windsor 2 5 0 13 13 7 157 39 
Windsor 2 5 0 13 13 7 157 39 
Windsor 3 0 0 0 0 0 0 0 
Altman 4 78 0 146 146 72 88 -7 
Bertera 4 16 0 112 112 ? « 618 ? M 
Mudde 4 53 0 177 177 123 236 133 
Altman 5 82 40 157 197 103 139 25 
Bertera 5 32 6 135 141 ? 4 1 338 ? • 
Cummings 5 12 0 15 15 10 25 -17 
Krumholz 5 100 14 176 190 140 90 40 
Meenan 5 159 14 62 76 60 -52 -62 
Mudde 5 59 170 188 358 248 507 320 
Prathiba 5 107 14 224 238 182 123 70 
Cummings 6 30 0 28,5 28,5 19 48 -37 
Akehurst 7 154 15 234 249 184 62 19 
Fiscella 7 69 29 117 146 118 113 72 
O ster 7 16 29 48 77 45 370 174 
Plans-Rubio 7 201 29 192 221 184 10 -8 
Plans-Rubio 7 320 29 240 269 224 -16 -30 
Stapleton 7 51 ? 78 78 69 52 35 
Wasley 7 42 29 117 146 118 248 181 
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Besides the original costs, the standardised recruitment costs, the standardised 
performance costs the standardised total costs and the percentual changes 
after complete standardisation, table 3 also shows the standardised total costs 
and the changes in costs when year of performance (the year of publication was 
used as a proxy) was not controlled for. Both analyses are presented because 
they serve different goals. The analysis without a correction for the year of 
performance provides information about the magnitude of the error in the CE-
ratio's due to not following guidelines for economic evaluation. Analysing the 
results with a correction for the year of performance provides up to date CE-
ratio's. These results are thus useful for decision making in the present time. 
Changes in effect size in terms of quitters 
Just like costs, quit rates changed considerably after standardisation. The effect 
sizes reported by most studies decreased after the standardisation procedure, 
by percentages ranging from 7% to 94% (table 4). Table 4 shows the original 
effect size in terms of quitters (%), the effect size in terms of quitters (%) when 
short term relapse was controlled for, the effect size in terms of quitters when 
short term as well as long term relapse were controlled for and the percentual 
changes between the standardised effect size and the effect size mentioned in 
the original article. 
Twenty-eight cost-effectiveness ratios were calculated (table 5). In twelve non-
standardised cases, no adjustment had been made for short-term relapse.131723 
24 Lifetime relapse had not been controlled for in eighteen cases.12 15 16 17 18 20 23 
24 Sixteen studies did not correct for annual unaided quit rates when the effect 
size in terms of quitters.12 13 15 16 17 18 20 23 24 In six cases, no comparative quit rate 
had been used.121724 
Changes in extrapolation from effect size in terms of quitters to 
effect size in terms of years of life saved 
In four of the studies, the standardised extrapolation rates had the same value 
as the original extrapolation rates reported.13 14 18 22 For two studies, our 
standardisation procedure led to a higher extrapolation factor,11 14 i.e. the yols 
due to a given number of quitters is higher in the current analysis. The increase 
in the extrapolation factor is 42% and 10% respectively. The transformation 
factor decreased in five cases, 15 19 20 28 by percentages ranging from 21% to 
45%. 
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Table 4: Effect-sizes of the original article and standardised effect-sizes 
study subgroup original 
quit rate (%) 
one-year 
standardised 
quit rate(%) 
life time 
standardised 
quit rate (%)* 
change in 
quit rate* (%) 
Bertera 1 17,14 15,6 6,15 -64 
Mudde 1 15,5 13,8 5,5 -65 
Altman 2 21 17,5 4 -81 
Bertera 2 11 9,5 3,8 -65 
Mudde 2 13 9,9 4 -69 
Windsor 2 4 0,7 0,24 -94 
Windsor 2 12 7,8 2,69 -78 
Windsor 3 8 7,1 2,45 -69 
Altman 4 14 7 2,9 -79 
Bertera 4 10 10,5 3,9 -61 
Mudde 4 9 8,7 3,6 -60 
Altman 5 35 16 6,9 -80 
Bertera 5 21 19,5 7,7 -63 
Cummings 5 2,43 3 1,3 -47 
Krumholz 5 26 26 12,5 -52 
Meenan 5 4,3 4,3 1,8 -58 
Mudde 5 22 18,6 7,6 -65 
Prathiba 5 13,5 13,5 5,8 -57 
Cummings 6 1 to 12 range 1-12 0,43-5,2 -57 
Akehurst 7 16 16 6,2 -61 
Fiscella 7 1,3 3,4 1,5 15 
O ster 7 0,3 1,2 0,7 133 
Plans-Rubio 7 0,7 2 0,9 29 
Plans-Rubio 7 1.1 3,6 1,6 45 
Stapleton 7 0,6 1,3 0,56 -7 
Wasley 7 0,9 8,4 3,7 311 
* effect size in terms of quitter 
Standardised cost-effectiveness ratios 
The non-standardised cost-effectiveness ratios of the studies that presented the 
costs per yols, ranged from $220 to $5050 per yols. After complete 
standardisation, these values ranged from $490 to $15,280 per yols. When 
standardisation excluded adjustment for the year of performance, the CE-ratios 
ranged from $332 to $12750. 
Non-standardised cost-effectiveness ratios reported by studies expressing cost-
effectiveness in terms of costs per quitter ranged from $22 to $940 per quitter. 
After extrapolation of the effect size in terms of quitters to years of life saved as 
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proposed by Oster et al. (1999), the cost-effectiveness ratios for these studies 
ranged from $895 to $10031 per years of life saved, if costs were adjusted for 
the year of performance. If the CE-ratio was only adjusted for guideline aspects, 
the cost-effectiveness ratios of these studies range from $481 to $5400. 
Table 5: Original and standardised cost-effectiveness ratios 
standardised CE-ratio standardised CE-ratio 
adjusted for year of study not adjusted for year of study 
study sub-
group 
original 
effect 
para-
meter 
Original 
CE-
ratio 
costs 
per 
quitter 
costs 
per 
vols 
change (%)* costs per 
quitter 
costs 
per 
yols 
change 
(%)* 
Bertera* 1 quitter 153 1675 2233 1000 9 » 9 • ? 
Mudde 1 quitter 940 1982 2447 110 1382 1557 50 
Altman 2 quitter 22 1275 1614 5700 675 855 2510 
Bertera 2 quitter 150 842 1040 460 9 m 9 « 9 < 
Mudde 2 quitter 48 1975 2324 4020 1375 1618 2770 
Wlndsor 2 quitter 119 5417 10031 4450 2917 5402 2350 
Windsor 2 quitter 51 483 895 850 260 481 410 
Windsor 3 na na 0 0 0 0 0 0 
Altman 4 na na 5034 6538 na 2483 3228 na 
Bertera 4 na na ? • 3989 na 9 • ? na 
Mudde 4 na na 4917 6385 na 3417 4544 na 
Altman 5 quitter 235 2855 3708 1120 1493 1941 540 
Bertera 5 quitter 154 1831 2543 1090 9 9 • ? 
Cummings 5 yols 748 1154 1049 40 769 700 -6 
Krumholz 5 yols 220 1530 1520 590 1120 1120 400 
Meenan 5 yols 3680 4222 5556 50 4333 20 
Mudde 5 quitter 328 4710 6118 340 3263 5503 900 
Prathiba 5 yols 652 4103 3730 470 3137 2856 340 
Cummings 6 yols 241- 548- 498- 110 365- 332- 60 
5051 6628 6025 4419 4017 
Akehurst 7 yols 2188 4016 5657 160 2968 4155 90 
Fiscella 7 qaly 4671 9733 8849 na 7867 7159 na 
Oster 7 qaly 4113 11000 10000 240 6429 5850 1330 
Plans-Rubio qaly 2877 9 » 9391 * 9 • 9 • 9 • 
Plans-Rubio 7 qaly 3297 16812 15282 360 14000 12740 290 
Stapleton 7 qaly 660 9 « 9 • 9 • 9 • ? 9 « 
Wasley 7 qaly 1796 3946 3591 100 3189 2902 60 
Note: CE = cost-effectiveness; yols = years of life saved; qaly = quality adjusted life years; na = not 
applicable. 
* percentage of change responds to the change in the standardized CE ratio compared to the CE 
ratio of the original study 
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Thus, the standardised cost-effectiveness ratios were systematically and 
considerably higher than those presented in the original articles. Increases in 
cost-effectiveness ratios after standardisation ranged from 0 to as much as 
5800%. All original and standardised cost-effectiveness ratios are presented in 
table 5. 
The table reveals a pattern in the magnitude of the cost-effectiveness ratios, 
with incremental cost-effectiveness ratios generally being lower when the 
intervention was less resource consuming. Figure 1 summarises these results 
by presenting the mean standardised incremental cost-effectiveness ratios per 
subgroup. 
Figure 1 shows that the most cost-effective intervention included in our analysis 
consisted of a self-help manual written for a specific subgroup of smokers, 
namely smoking pregnant women.23 This intervention led to an incremental cost 
effectiveness of $0. The cost of the specific self-help manual was equal to that 
of a general self-help manual, but the number of quitters increased when the 
information in the manual was more specific about the risks of smoking while 
pregnant. The second most cost-effective intervention consisted of both 
counselling and self-help, provided to a general sample of smokers ($2340). 
The smokers chose the interventions based on their own preferences. Self-help 
and counselling provided in separate intervention programmes were slightly 
less cost-effective than when participants could choose either of them, but the 
cost-effectiveness ratio was still very favourable ($3179 and $3213 
respectively). The incremental cost-effectiveness of counselling versus self-help 
was $5637. When NRT was added to a counselling programme, the 
incremental cost-effectiveness increased to $8794. One study investigated the 
value of providing a follow-up visit in addition to counselling. Because there 
were no other studies that addressed the issue of follow-up in addition to 
counselling in the same way, a broad sensitivity analysis was performed. Using 
a broad sensitivity range, the incremental cost-effectiveness of counselling plus 
follow-up compared with a counselling session alone ranged from about $500 to 
about $6000. 
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Figure 1: The incremental cost-effectiveness of various smoking cessation 
therapies 
$2340 
• counseling or self help 
$3179 $0 
usual care • self-help • 
$5637 
$3213 * $498-$6025 
• counseling • 
$8794 
• 
NRT = Nicotine replacement therapy 
Discussion and conclusions 
To increase the value of economic evaluations in the field of tobacco 
dependence treatment, we recalculated and standardised cost-effectiveness 
ratios of studies on this topic using the guidelines proposed by Drummond et al. 
(1997). The standardisation procedure is performed to the effect size, the input 
of material and personnel resources and to the monetary value of the 
resources. We would have preferred to provide results that were applicable to 
all countries in all situations. This goal could not completely be achieved: 
although the effect size is expected to be context independent and although 
both the material and personnel input are not likely to vary much between 
countries, in each country different costs apply to specific material resources 
and personnel. As a result of this, it is impossible to present CE-ratios that are 
fully applicable to all countries and situations. In spite of this 'problem', we 
provided information relevant for all countries by presenting a detailed overview 
of input that is necessary for different smoking cessation therapies. This 
information can be applied to all countries. Then, we applied the model to the 
Dutch situation. For decision makers in other countries, only a small step has to 
be taken to make the data applicable to their own situation, namely replacing 
the values used in the current study by county-specific cost values. 
pregnant specific self help 
counseling + follow up 
counseling + NRT 
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Following these steps, we did not only make CE-ratios in the field of smoking 
cessation comparable and more useful, we also developed a new method for 
reviewing CE-studies. This can be applied to other fields of medicine. 
Changes in costs 
There were a number of reasons for the increase in costs resulting from 
standardisation. 
Firstly, standardised costs were generally more complete than those reported in 
the original article, because our analysis was based on guidelines for cost 
determination, whereas the cost analyses in the original articles often failed to 
include factors like patient time, travel time, travel costs, room rent and 
recruitment costs. The effect of incomplete cost calculations can be very large, 
as was the case, for example, in the studies by Altman et al. and Mudde et al., 
comparing self-help with usual care.17 24 In both cases, recruitment costs were 
not included. The costs that have to be made to recruit one participant, 
however, often represent a considerable part of the total costs. Recruitment in 
the studies by Altman et al. (1997) and Mudde et al. (1996) included TV and 
radio commercials, posters and telephone quit lines, while the actual 
intervention was a low-cost self-help manual. Standardised recruitment costs 
per participant in the studies by Altman et al. and Mudde et al. were $40 and 
$68 respectively, while the original articles mentioned intervention costs of only 
$11 per participant (table 5). 
Secondly, some of the studies were performed many years ago. If, for example, 
the costs of a study performed 20 years ago are corrected for an annual 
inflation rate of 3%, they increase by almost 100%. Because the impact of the 
year of performance on the costs can be considerable, table 3 also presents the 
standardised costs corrected for the year the study was conducted. This allows 
for increases in costs due to differences in methodology to be distinguished 
from increases in costs due to a study characteristic like the year it was 
conducted. 
Recalculation caused a decrease in costs in three studies.161719 The article by 
Plans-Rubio et al. (1998) used a very high valuation of the nicotine patch 19, 
which seems to be the main cause of the high costs. The other two studies 
included development costs in the cost assessment, which explains a large 
proportion of the decrease in costs after our recalculation. 16 17 Furthermore, 
both studies used a very detailed cost analysis, monitoring prospectively all 
costs incurred during the study period. Our own standardised analysis was 
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somewhat less detailed, and might therefore have slightly underestimated real 
costs. 
Changes in effects 
The impact of the standardisation procedure on the effect size can be 
illustrated by the study by Altman et al. (1981),24 which compared counselling 
with usual care. Altman et al. used the 6-8 week quit rate of 35% as their final 
quit rate. Within the first year after the intervention, however, 50% of these 
quitters can be expected to relapse, based on the data by Prathiba et al..20 
Adjustment thus reduces the 1-year quit rate to 17.5%. Furthermore, their study 
used no comparative quit rate. (In essence, they did not correctly apply an 
incremental analysis). Counselling was compared with usual care (which meant 
hardly any intervention). Based on the data by Prathiba et al. (1998) it can be 
assumed that 1.5% of this group of smokers would have quit without any 
intervention. 20 Adjusting for the annual unaided quit rate further reduced the 
rate reported by Altman et al. to 16%. To calculate the standardized effect size 
(lifetime incremental quit rate), our analysis adjusted this percentage for a 35% 
lifetime relapse and annually for a 1.5% spontaneous quit rate. This resulted in 
a standardised effect size in terms of quitters of 6.9%. So, applying the entire 
standardisation procedure to the study by Altman et al. reduced the quit rate 
from 35% to 6.9%. 
As was mentioned above, there were some studies whose effect size increased 
after standardisation. This was only the case in those studies in which the 
original cost-effectiveness ratios were calculated on an intention-to-treat basis, 
14 18 19 22 s j n c e p r e s e n t analysis calculated cost-effectiveness ratios for 
persons actually making use of the intervention. Although the number of quitters 
obviously remains the same, the percentage of quitters will be higher when it is 
based only on those persons accepting the intervention, than when it is based 
on all persons to whom the intervention has been offered. These four studies 
had assessed the cost-effectiveness of nicotine replacement therapy (NRT) in 
addition to counselling. Since the acceptance rate of NRT is estimated to be 
25%, the study population is four times larger in the original articles than in our 
analysis. Accepting a given number of quitters due to the intervention thus 
means that the percentage of quitters after one year in our analysis is 4 times 
higher than that in the original articles, resulting in a higher standardised effect 
size. This, however, does not affect the CE-ratio. The reason for this is that the 
recruitment costs are four times higher when calculating CE based on persons 
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actually making use of the intervention instead of calculating the CE based on 
intention to treat. The decrease in effect after standardisation is thus balanced 
out by the increase in costs. 
In the present analysis, effect sizes in terms of quitters were adjusted for study 
duration (if this was less than 1 year), lifetime relapse and unaided annual quit 
rate. If studies had calculated average cost-effectiveness instead of incremental 
cost-effectiveness ratios, this was also corrected for. The original articles had 
often failed to apply these corrections to the observed quit rate. 
CE-ratio 
The present study revealed that the standardised cost-effectiveness ratios of 
smoking cessation interventions were systematically higher than the non-
standardised ratios. Despite this, interventions aimed at reducing the 
prevalence of smokers were still found to be cost-effective. It was also 
concluded that, in general, less intensive interventions were more cost-effective 
than more intensive interventions. Although this general trend is apparent 
among all studies, it cannot completely account for individual variations and will 
thus not be applicable to every single smoker. For example, persons who are 
less motivated are likely to benefit more from the more expensive interventions 
than from less intensive ones. The fact that less resource consuming 
interventions are in general more CE than more resource consuming 
interventions does not mean, however, that more intensive interventions should 
not be performed, as their cost-effectiveness ratio is still lower than that of many 
accepted curative interventions. Furthermore, more intensive interventions may 
have their own value by inducing specific groups of smokers (e.g., heavy 
smokers) to quit smoking, where less intensive interventions have failed. 
Although the CE ratios of all interventions remained acceptable after 
standardisation, the differences between studies in the percentage increase in 
cost-effectiveness ratio after standardisation are striking. This not only confirms 
the observation made in our previous review, that there has been no uniform 
method to calculate cost-effectiveness in the studies performed until now, but 
also shows that the use of non-standardised methodologies in cost and effect 
calculation has a considerable influence on the outcome in terms of cost-
effectiveness: even when standardisation only includes standardisation to the 
guidelines (that means that the CE-ratio is not adjusted to the year 2002), the 
CE-ratio increases up to 2800 percent. 
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The method of analysis used in the present study has several advantages. It 
makes cost-effectiveness ratios more informative: costs are complete and up to 
date and information about intermediate effects (in this case costs per quitter) 
are transformed into information about costs per years of life saved. This 
increases our knowledge. Most CE-studies performed in the past can be used 
for current decision making and even studies reporting only intermediate 
effects, without an additional economic analysis, can be made useful for 
medical decision-making at the macro level by applying the method used in the 
present article. Because evidence exists that the quality of economic 
evaluations in other fields of medicine is also a subject of concern, this method 
might be applied to other fields of medicine as well. 
Although it would be useful to apply the analysis used in this article to other 
fields of medicine, there are some disadvantages to the present methodology. 
Our primary aim was to make CE-ratios from different studies comparable. In 
doing so, we used information from the reviewed CE-studies. We did not aim at 
providing the best CE-data as possible. This led to two caveats. The most 
troublesome is that models need to be used to extrapolate intermediate effects 
(effect size in terms of quitters) to the effect size in terms of yols. The decision 
for which model to use in this study was based on the frequency with which the 
models were used in the original studies. We used the model that was most 
frequently applied in the original studies. This was also the model with the 
extrapolation rate most close to average. So, in the present study, no efforts 
were made to gain insight into these models. In other words, they were treated 
as black boxes. CE-estimates are expected to be even more reliable when 
insight is gained into the models. Future research should focus on this aspect. 
Second, we did not aim to search all the literature for the best figures about 
effects available, but we used information from the reviewed studies 
themselves. An additional search on effectiveness rates for smoking cessation 
might result in more precise estimations of the CE-ratios. 
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Abstract 
The prevalence of cardiovascular diseases (CVD) as well as the prevalence 
and clustering of (biological) risk factors for CVD is higher among persons with 
a low socio-economic status (LSES) than among persons with a high socio-
economic status (HSES). Because biological risk factors for CVD exert a 
negative exponential effect on CVD, the potential health gain from preventive 
interventions is expected to be larger among LSES groups than among groups 
with a HSES. From a medical point of view, it seem thus more efficient to focus 
on LSES groups than on HSES or the general population. In the current article, 
we used information from previous research in order to critically debate health 
promotion to LSES groups from an economic point of view. The results of this 
study suggest that focussing on LSES groups does not result in an additional 
health benefit among these groups. Furthermore, an intervention program 
among LSES groups would induce much more costs than is the case among 
HSES groups. 
We conclude than there is no evidence for community programs focussing on 
LSES groups to be more cost-effective than community programs designed to 
reach the society as a whole. Implications of this conclusion for policy and 
research are discussed. 
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Introduction 
Health among persons with a higher socioeconomic status (HSES) has 
consistently been shown to be better than that among persons with a lower 
socioeconomic status (LSES).1 2 3 Because of the high prevalence of 
cardiovascular diseases (CVD) in the Netherlands and the rest of Western 
Europe,4 this article focuses on CVD. The risk of CVD has been reported to be 
3 to 4 times higher in LSES persons than in HSES persons, and the prevalence 
of risk factors for CVD is also much higher among LSES groups.2 5 6 Since 
health improvements resulting from lifestyle interventions are often thought to 
be greatest in groups at highest risk (in this case LSES groups), interventions to 
reduce CVD are often implemented in LSES groups. In addition to the 
assumption of being more effective, health-promoting interventions among 
LSES groups provide at first glance a semblance of cost-effectiveness. 
This article investigates the assumption that preventive interventions are more 
cost-effective in LSES groups than in HSES groups. 
Potential benefits in LSES: a 'medical' perspective 
Current beliefs about the effectiveness of lifestyle interventions among LSES 
groups seem to be greatly influenced by medical knowledge about CVD, and its 
classical risk factors.6 7 It is well-known that high blood pressure, an 
unfavourable cholesterol profile and the negative biological effects of smoking 
increase the risk of CVD.89 These biological risk factors have even been proved 
to exert exponential negative effects on cardiovascular health.10 11 12 The 
lifestyle factors smoking, exercise and diet influence cardiovascular risk mainly 
through the above biological risk factors.13 This is the basic knowledge medical 
practitioners use in CVD management. 
Since CVD as well as traditional biological and behavioural risk factors are more 
prevalent among LSES groups they can be seen as a group at high risk 2 31014 
15 16 17 targeting high risk groups generally yields greater effects than 
targeting groups at low risk,1718 the cost-effectiveness ratio of CVD prevention 
programmes is also expected to be more favourable when they are 
implemented among LSES groups than among HSES groups or, for that matter, 
in the total population. 
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Actual benefits of health promotion in LSES 
The contribution of traditional risk factors for CVD to the risk on CVD in LSES 
groups was the focus of research within a number of longitudinal observational 
studies.2 3 5 6 14 15 19 20 These studies involved large adult populations followed for 
7 to 10 years. The studies recorded the prevalence of CVD (and CVD mortality) 
during the follow-up period. From all participants, risk factors for CVD (biological 
and / or lifestyle) and SES were available. The observational data were used to 
calculate CVD risks and compare the risk for the lowest SES group with that for 
the highest SES group, resulting in observed (relative risk) RR ratios for LSES 
groups compared to HSES groups. The results are summarized in table 1. 
Furthermore, the RR ratio for CVD in LSES groups compared to HSES groups 
was calculated correcting for traditional (behavioural and / or lifestyle) risk 
factors. Statistical adjustment for the traditional risk factors for LSES groups 
shows how much of the RR of LSES persons can be explained by traditional 
risk factors, compared to HSES persons. The findings are presented in table 1. 
Among studies in which only lifestyle differences between LSES and HSES 
groups were made equal, risk reductions for CVD mortality and all-cause 
mortality among LSES groups were calculated to be about 30% and 12% 
respectively.5 6 See table 1. 
Adjustment of traditional biological factors has been found to yield reductions of 
the RR of CVD (and CVD mortality) from LSES groups compared to HSES 
groups ranging from 14 to about 40 percent. 5 14 15 19 20 See table 1. However, 
the risk of CVD mortality remained higher in the LSES groups (RR 1.2 and 3.8) 
even when biological risk factors of LSES groups were made equal to HSES 
levels. 
Even when biological and behavioural risk factors among LSES persons are 
equated to those of HSES persons, the CVD risk among the LSES groups was 
reduced by only 15% to 35%. The RR for LSES persons compared to HSES 
persons is thus still 1.6 to 2.6.2315 Improving unhealthy lifestyles therefore does 
not lead to a proportional decrease in the relative CVD risk, and the medical 
exponential model of traditional medical risk factors for CVD cannot be fully 
applied to LSES groups. As was made clear in the previous section, this model 
is often used when estimating the potential effectiveness of CVD prevention 
programmes. The observation that the medical exponential model of traditional 
medical risk factors for CVD cannot be fully applied to LSES groups means that 
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the benefits of life-style improving interventions among LSES groups may thus 
not be as effective as they are often believed to be. 
Factors described in the literature, such as living conditions, social environment, 
working environment, material and financial conditions, psychosocial stress and 
coping mechanisms, also play a role in explaining the risk for CVD among 
LSES groups.21 
Table 1: The effects of biological and lifestyle risk factors for cardiovascular 
diseases on cardiovascular risk among low socio-economic status groups 
study SES indicator Classes1 observed Adjusted Reduction 
RR RR RR 
LSES2 LSES3 LSES (%) 
Biological risk factors 
Davey-smith, 1990 employment grade/ 4 2.0 1.6 20 
car owner (CVD mortality) 
Davey-smith, 1990 employment grade/ 4 6.5 3.8 42 
no car (CVD) 
Lynch, 1996 income 5 4.3 2.8 35 
(fatal AMI) 
Marmot, 1984 employment grade 4 2.7 2.1 22 
(CVD mortality) 
Pocock, 1987 employment grade 2 1.4 1.2 14 
(IHD events) 
Saionen, 1982 education 2 9 * 2.1 ? • 
Salonen, 1982 income 2 ? 1.7 ? • 
Lifestyle risk factors 
Lynch, 1996 income 5 2.7 1.8 30 
(CVD mortality) 
Lantz, 1998 income 3 3.2 2.8 14 
Biological and lifestyle risk factors 
Rose, 1981 employment grade 4 4.0 2,6 35 
(CVD mortality) 
Rosengren, 1988 employment grade 5 2.1 1.6 24 
(coronary death) 
Rosengren, 1988 employment grade 5 2.3 1.9 17 
(nonfatal Ml) 
Rosengren, 1988 employment grade 5 2.2 19 14 
(total CAD) 
1 Number of classes used to classify SES 
2 The relative risk ratio from LSES compared to HSES as is observed within the longitudinal follow-
up study 
3 The relative risk ratio from LSES compared to HSES after statistical correction of the classical 
biological and / or lifestyle risk factors. 
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The costs of preventive interventions among LSES 
groups 
In addition to the problem of the effectiveness of interventions among LSES 
groups, there is the additional problem of their costs. 
The literature provides several factors influencing the success of interventions 
among LSES persons. The summary of these factors presented below is mainly 
based on Jansen and ten Dam (2002) and on Lindenberg, et al. (2001 ).2122 
Effective preventive measures require a community partnership to be built, 
which means getting to know the needs of the target population. This should 
lead to long-term participation by various community-based institutions (health 
institutions, welfare service, local policymakers, etc.). There should also be 
enough capacity (in terms of funding and partnerships) to allow the project to 
continue for a long time. The best way to contact LSES groups is by including 
members of the target groups in the team, because they can identify with the 
clients. Personal contact is essential to recruit persons from LSES groups for 
preventive activities. In addition, it is very important that the intervention is 
tailored to the social context and the knowledge available among the target 
population. Furthermore, a multiple intervention strategy is needed when 
targeting LSES groups. 
It will be clear that such interventions require much greater resources than 
traditional community programmes. The high level of staffing and material 
resources required also results in costs that are much higher than for 
programmes targeting HSES persons. This puts a negative strain on the cost-
effectiveness ratio of preventive interventions in LSES groups. 
Discussion 
The hypothesis that prevention among LSES groups would result in a more 
efficient use of resources than prevention among HSES groups could not be 
confirmed based on the current overview of literature on this field. This has two 
reasons. 
First, the effects of CVD prevention among LSES groups are less than could be 
expected from the medical exponential model: even if all traditional biological 
and lifestyle risk factors of LSES groups were to be equated to the HSES 
groups, the risk of CVD among LSES groups would not decrease to the level 
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found in the HSES groups. Therefore, the traditional medical model should be 
adapted for LSES groups 23. Although other factors than the traditional risk 
factors are found to play a role in the LSES, we have as yet found no 
information how the adaptation of the model should be performed. The only 
conclusion that can be drawn with certainty from the information available is that 
the risk of CVD among LSES groups cannot be completely eliminated by 
changing traditional biological and lifestyle factors. It is important, however, to 
assess the quantitative impact of all variables influencing the risk of CVD 
(individually and in combination) among LSES groups, in order to select the 
most efficient combination of interventions to reduce health inequalities. 
The second reason why prevention among LSES groups may not result in a 
more efficient use of resources than among HSES groups is that the costs are 
higher than those of preventions aimed at HSES groups or at the whole 
population. 
The conclusion that targeting lifestyle interventions to LSES groups does not 
necessarily lead to a more efficient resource use than targeting HSES groups 
does not mean that LSES groups should be neglected. There are several 
political reasons to continue the prevention of CVD and poor health in general 
among LSES groups. 
First, health differences between LSES and HSES groups in Western Europe 
are large and in some countries, such as the Netherlands, they have not 
decreased over time.24 For reasons of solidarity, equity has become a major 
policy goal, for which lifestyle changes among LSES groups might be more 
important than among HSES groups. 
Second, lifestyle-promoting interventions not only affect physical health. Such 
programmes also lead to advantages in terms of welfare and social well-being. 
Third, making lifestyle interventions part of a broader intervention strategy to 
reduce socio-economic health differences will increase health effects. Next to 
lifestyle interventions, attention should also be paid to aspects like education 
and reduction of income differences between LSES and HSES.24 
Finally, it should be mentioned that the problem of health inequalities is a 
complex issue and successes will probably be gained in small steps, so long-
term investment in the various strategies to reduce this inequality will be 
necessary. 
The present study was restricted to CVD and only a selection of the relevant 
literature was used. In spite of this we think that our conclusion that lifestyle 
interventions among LSES groups are not necessarily more efficient than 
i 
i 
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lifestyle interventions among HSES, groups is not restricted to the field of CVD, 
because the underlying mechanism is the same. 
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Primary and secondary prevention of 
cardiovascular diseases: the influence 
of behavioural counselling on quality of 
life within the 'Hartslag Limburg' 
programme 
Based on: Ronckers ET, Groot, W, HQbben M, Ament A. Prevention of 
cardiovascular diseases in primary and secondary care: the influence of 
behavioural counselling on quality of life within the 'Hartslag Limburg' 
programme, (submitted for publication) 
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Abstract 
Little is known about the effects of behavioural counselling to prevent 
cardiovascular diseases on quality of life. The aim of the present study is to gain 
more insight into this relationship for both persons at risk for cardiovascular 
diseases (secondary prevention) and persons with established cardiovascular 
diseases (tertiary prevention). Within the secondary prevention study, a cluster 
randomised controlled design was used to assess the effectiveness. Within the 
tertiary prevention study a randomised controlled trial was used. Quality of Life 
was assessed with the RAND-36. To assess any effects of the intervention, 
multilevel analyses were performed after four and 18 months within the 
secondary prevention study, while multiple linear regression analyses were 
used within the tertiary prevention study. In the secondary prevention trial, 
significant differences were observed on physical functioning in the intervention 
group compared with the control group after 18 months of follow-up (p=0.006). 
No effects of behavioural counselling on quality of life were found within the 
tertiary prevention trial. It can be concluded that, in spite of the difference in 
physical functioning between the intervention and control population within the 
secondary prevention trial, the present study could not firmly prove the 
effectiveness of behavioural counselling on quality of life. 
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Introduction 
Cardiovascular diseases (CVD) are the main causes of death in today's western 
society.1 It is widely known that exercise, nutrition and smoking are major 
behavioural risk factors for CVD. In order to reduce the prevalence of CVD, a 
number of behavioural risk factor interventions have been developed. An 
example of such an intervention is behavioural counselling, in which people 
receive personal advice about behavioural risk factors and assistance in 
adopting healthy behaviour. A number of studies evaluated the effects of these 
interventions. 
Most studies performed so far have evaluated changes in behavioural or 
biological risk factors due to behavioural counselling. Evidence exists that 
behavioural counselling can be effective in both persons at risk for CVD and 
persons with established CVD in short-term2 and long-term.3 4 5 6 7 However, 
some studies did not report long term effects on these parameters8 9 while one 
study was not able to show any effects of the intervention at all.10 
For economic evaluation research, however, it is not the change in behavioural 
or biological risk factors, but the quality-adjusted life years gained which is the 
most favourable outcome measure. This outcome-measure not only takes into 
account changes in mortality, but also changes in quality of life (QoL). With this 
uniform outcome-measure, effects of different interventions within the whole 
field of medical care can be compared. 
As far as we are aware, only one study on behavioural counselling measured 
effects in terms of QoL.11 Although no changes in biological risk factors could be 
observed, there were changes reported on QoL at 12 months after counselling. 
It concerned effects on the SF-36 scales general health, role physical, vitality 
and bodily pain. This means that health education can improve QoL, even when 
effects on biological parameters cannot be shown. 
The aim of the present study is to gain more insight into the effects of individual 
behavioural counselling on quality of life of both persons with established CVD 
and persons at risk for CVD. 
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Methods 
Study population 
Two independent study populations were enrolled, namely a GP-population, 
and a cardiology population. 
Within the GP-population, the effects of secondary preventive counselling on 
QoL were investigated. The aim within the cardiology population was to gain 
more insight into the effects of tertiary prevention on QoL. 
The GP population consisted of persons with a risk of at least 20% of incurring 
a cardiovascular event within 10 years. The absolute risk was determined using 
the 'American Association, risk tables from FramingharrT. The participants were 
recruited from 19 GP-practices (including 56 GP's), settled in the southern part 
of the South of Limburg. 
GP-patients were included if they met one of the following criteria: 
• One of the following diseases: angina pectoris, myocardial infarct, 
cerebrovascular accident, transient ischaemic attack, PAV, concentric left 
ventricle hypertrophy, or heart failure 
• Diabetes mellitus 
• Very high blood pressure (>105 diastolic) measured at any time in the past 
• Very high cholesterol (>8.0 mmol/l) measured at any time in the past 
• All men younger than 60 years of age with 2 or more of the following risk 
factors: in current treatment for hypertension or hypercholesterolemia, 
smoking, cardiovascular disease in a first degree family member younger 
than 60 years of age 
• And finally all men older than 60 years of age with one or more of the 
following risk factors: in current treatment for hypertension or 
hypercholesterolemia, smoking, cardiovascular disease in a first degree 
family member younger than 60 years of age 
The cardiology population consisted of persons with established CVD. These 
participants were recruited from the outpatient cardiology ward of the Academic 
Hospital in Maastricht. 
Persons visiting the department of cardiology were included if they suffered 
from one of the following diseases: angina pectoris, myocardial infarct, 
cerebrovascular accident, transient ischaemic attack, PAV, concentric left 
ventricle hypertrophy, or heart failure. 
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For both the cardiology and the GP-participants, the following exclusion criteria 
were defined: 
• Age > 75 
• Participation in another cardiovascular intervention study 
• Existence of serious cardiac co morbidity 
• Existence of other lethal, non-cardiovascular diseases 
• Cognitive inability to participate in the study 
• Not being able to visit hospital regularly 
• Living outside the intervention area 
Intervention 
The intended intervention was twofold, namely individual health counselling in 
combination with an optimisation of the individual cardiovascular drug 
treatment. 
Nurses or dieticians, who received special education for counselling, provided 
the health counselling. The counselling focussed on quitting smoking, improving 
the dietary pattern and increasing the exercise rate. The patients and the 
counsellor decided in consultation which lifestyle factors would be counselled. 
Within the secondary prevention trial, the mean number of counselling sessions 
was 2.31, with a mean total duration of counselling 83 minutes. Within the 
tertiary trial, persons received on average 2.76 counselling sessions, with a 
mean total duration of the counselling of 91 minutes. 
Besides the health counselling, an optimisation of individual drug treatment was 
intended to be an important aspect of the intervention. Based on a 
computerized absolute cardiovascular risk factor profile, individual treatment 
should be improved by adjusting the medication to recent guidelines. This 
should have been achieved via communication with the GP. During the 
intervention period, it was the health counselling that received most attention. 
For a more detailed description of the intervention, see Harting et al. 2004.1213 
Design and procedure 
The GP intervention was performed within a cluster randomised controlled trial. 
Within the GP practices, potential participants were pre-selected, based on 
information from their medical status. They were either personally asked to join 
in into the program during a routine consultation or they received an invitation 
letter. 
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The cardiology intervention was carried out within a randomised controlled trial. 
The participants of the cardiology intervention were recruited when they visited 
the outpatients' cardiology clinic with one of the above-mentioned diseases. 
Recruitment took place from April 1999 until October 2001. After having signed 
informed consent, the participants filled out the first questionnaire. At 4 months 
and 12 months post-test, they received a similar questionnaire by post. 
At baseline, and after 4 and 18 months, quality of life was assessed 
with the RAND-36 questionnaire and the visual analogue scale of the Euroqol.14 
The current study was added to an already existing study addressing 
the effects of health counselling on health behaviour and biomedical risk factors 
for cardiovascular disease. This study had already started at the time that we 
sent out the quality of life questionnaires. As a result of this, not all the 
participants were sent a questionnaire at baseline and T4. Because our study 
started more that one year later, there were even some participants from which 
no questionnaire at all was available. This is true for the intervention groups as 
well as the control groups. 
Questionnaire 
Quality of life was assessed with the RAND-36 questionnaire and the visual 
analogue scale of the Euroqol.14 The RAND-36 covers the following scales: 
physical functioning, social functioning, role physical, role emotional, mental 
health, vitality, bodily pain, general health, changes in health. 
Statistical analysis 
T-tests were used to detect any selection bias at baseline. Because not all the 
participants were sent the questionnaires at baseline and T4, the research 
groups do not consist of the same individuals at the different moments of 
measurement. This means that the analysis should either be restricted to those 
individuals having received all the questionnaires, implicating loss of data, or 
the analysis should be performed on a group level. It was decided to perform a 
group analysis to prevent loss of data. 
T-tests were use to detect any differences between the demographical variables 
of the intervention and control groups at baseline, T4 and T18. 
To assess any effects of the intervention, multilevel analyses, using TSP 4.5 
software, were performed in the GP population (due tot the cluster randomised 
design). Within the cardiology population, multiple linear regression analyses 
were done using SPSS 11.5. 
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When investigating the relationship between the condition (intervention versus 
control) and the dependent variables the following variable were controlled for: 
age, gender, educational level, smoking, body mass index, the baseline value of 
the dependent variable and - for the GP population - GP-practice. 
Results 
Participant flow and follow-up 
GP-population 
Within the GP-research 1355 patients were included. 698 Persons were 
included into the intervention group, while the control group consisted of 657 
persons (figure 1). 292 (173+119) persons did not receive a baseline 
questionnaire; to 177 (118+59) persons no questionnaire was sent to and at T4 
and 82 (54+28) persons did not receive any of the questionnaires (figure 1). 
Figure 1: Patient flow in the secondary prevention trial 
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Furthermore, figure 1 shows that within the first 4 months, 143 (94+49) persons 
(10 percent) of the initially included persons had dropped out. Between 4 and 
18 months of follow-up another 158 (80+78) persons (12 percent) were lost to 
follow-up. This means that 78 percent of the participants completed the study 
successfully. 
Cardiology population 
The total number of included participants within the cardiology study was 1388. 
Of these, 700 persons were randomised into the intervention group, and 688 in 
the control group (figure 2), No questionnaire was sent to 647 (337+310) 
persons at baseline, whereas 417 (216+201) and 194 (89+105) persons did not 
receive a questionnaire at T4 and T18 respectively (figure 2). 
At T4, 100 persons were lost to follow-up. This represents 7 percent of the 
iL 
research population. From the follow-up measurement at 4 months until the 18 
month of follow-up, another 156 persons of the original research population (11 
percent) did not return the questionnaire. This means that the total dropout rate 
is 18 percent. This is also shown in figure 2. 
Figure 2: patient flow in the tertiary prevention trial 
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Baseline analysis 
As was mentioned before, only a subgroup of the participants received a 
questionnaire at baseline. The question rises whether the persons who started 
the study later due to organisational problems are comparable to the persons 
who received all the questionnaires. 
Table 1 shows that these groups do not differ much on baseline characteristics. 
Only the mean age of the non-participants at baseline within the GP control 
group was significantly lower (1.2 years) than the age of the participants within 
this group. Within the cardiology intervention group, the non-participants at 
baseline were significantly younger (1.8 years) than the participants at baseline. 
Although these differences do not appear to be clinically relevant, a 'per 
protocol' analysis was performed in addition to the group analysis, so as to 
obtain more reliable results. 
Table 1: Demographic characteristics of persons that received a baseline 
questionnaire and persons that did not receive a baseline questionnaire 
Intervention Control group 
TO not TO not 
TO received received p-value TO received received p-value 
GP 
age (mean) 62,4 61,2 0,174 62,9 59,9 0,002 
male (%) 63,40% 61,00% 0,596 70,80% 64,60% 0,223 
education 
low 52,20% 54,70% 0,57 47,70% 52,30% 0,706 
average 34,80% 33,60% 37,90% 29,90% 
high 13,90% 11,70% 14,70% 18,20% 
Cardiology 
age 60 61,8 0,016 61,7 60,8 0,213 
sex 71,50% 71,10% 0,922 67,60% 65,30% 0,533 
education 
low 54,30% 51,10% 0,945 52,40% 57,50% 0,188 
average 29,50% 39,40% 31,80% 29,50% 
high 16,20% 11,70% 15,80% 13% 
Furthermore, analysis showed that more males were included in the GP-
intervention group than in the GP-control group. The percentage of males in the 
intervention group, however, was the same at TO, T4 and T18. Finally, the 
analysis showed that more males were in the control group, compared with the 
intervention group at T18. 
Baseline characteristics of the RAND-36 scales are shown in table 2. In the GP-
study the control group did not differ from the intervention group on any of the 
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variables. Within the cardiology study, the control group had a higher score on 
the scale 'role physical' than the intervention group. 
Table 2: Mean values of the quality of life indicators at baseline and after 4 and 
18 months of follow-up 
TO T4 T18 
Intervention Controle 
mean (SP) mean (SD) 
Intervention Controle 
mean (SD) mean (SD) 
Intervention Controle 
mean (SD) mean (SD) 
GP 
physical 
functioning 
social 
functioning 
role physical 
role 
emotional 
mental 
health 
vitality 
bodily pain 
general 
health 
thermometer 
72.7 (23.4) 73.7 (24.7) 74.5 (23.1) 73.5 (24.1) 74.3 (23.8) 71.7 (25.0) 
81.8 (22.4) 
68.8 (39.9) 
80.9 (23.9) 
72.9 (38.6) 
82.5 (22.8 
74.0 (37.9 
79.4 (35.7) 78.6 (37.2) 77.4 (37.3 
72.6 (19.4) 
61.7 (20.5) 
77.3 (24.4) 
56.1 (18.0) 
71.8 (16.4) 
70.3 (19.6) 
59.9 (20.0) 
75.9 (24.9) 
56.1 (18.7) 
72.9 (15.4) 
72.8 (19.2 
63.0 (19.7 
77.6 (24.6 
56.7 (18.0 
70.8(16.5 
80.7 (24.7) 
72.7 (40.0) 
81.3 (22.9) 80.6 (24.3) 
71.7(39.0) 70.3(41.0) 
78.4 (37.0) 76,5 (38.1 ) 78.0 (37.6) 
70.6 (20.3) 
62.6 (20,1) 
77.1 (24.3) 
56.8 (19.6) 
73.3(15.0) 
73.1 (18.4) 
63.4 (19.1) 
76.9 (25.5) 
56.9 (18.2) 
74.1 (45,9) 
71.8 (20.3) 
61.9 (20.7) 
77.2 (24.8) 
56.2 (19.6) 
71,6 (15,8) 
Cardiology 
physical 
functioning 
social 
functioning 
role physical 
role 
emotional 
mental 
health 
vitality 
bodily pain 
general 
health 
thermometer 
68.5 (23.9) 68.1 (25.2) 68.7 (25.4 67.0 (25.8) 69.9 (24.8) 66.9 (25.8) 
72.7 (25.1) 
47.4 (43.2) 
71.9 (26.0) 
54.4 (43.5)* 
75.9 (25.0 
584 (42.4 
76.4 (25.6) 
59.8 (42.9) 
79.0 (23.6) 78.7 (24.4) 
66.7(41.0) 65.3(41.3) 
63.4 (43.8) 65,5 (42.8) 70,9 (41.0 69.1 (42.3) 76.7 (37.6) 74.2 (39.3) 
66,6 (20.5) 
54.9 (21.9) 
69.3 (25.7) 
52.6 (18.9) 
66.9 (17.4) 
66.6 (20.5) 
54.7 (21.1) 
72.3 (24.6) 
52.2 (18.5) 
67.5(16.5) 
68.3 (20.5 
57.1 (22.4 
75.0 (26.1 
54.4 (20.7 
68.1 (16.4 
69.3 (20.9) 
57.5 (21.3) 
75.8 (23.9) 
51.8 (19.1) 
67.4 (16.7) 
70.9 (19.5) 
59.1 (20.9) 
76.7 (25,4) 
53.5 (20.2) 
69.3(16,2) 
70.7 (19.5) 
59.2 (20.7) 
77.1 (24.3) 
53.1 (20.3) 
68.9 (16.3) 
P<0.05 
Effects of the intervention 
GP population 
No effects of the intervention could be shown after 4 months of the intervention 
(table 3): the QoL scores of the RAND questionnaire at T4 were almost equal to 
the QoL scores at TO in both the intervention population and the control 
population. This is shown in table 2. For most QoL scales, this was also true at 
18 months of follow-up (see tables 2 and 3). One significant difference between 
the intervention and the control population emerged however: the score on the 
QoL scale physical functioning was significantly higher in the intervention group 
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compared with the control group after 18 months of follow-up (p=0.006). As 
table 2 shows, this seems to be the result from a slight deterioration of physical 
functioning in the control population. 
Cardiology population 
Within the cardiology population the QoL of persons having experienced a 
coronary event increased over time (see table 2). This phenomenon was 
observed for almost all scales of the RAND-36. However, both at 4 months and 
18 months follow-up there were no differences observed in the change of QoL 
between persons from the intervention group and persons from the control 
population. This means that the intervention was not effective in improving the 
QoL for persons having recently experienced cardiovascular problems. 
Table 3: The effects of the individual counselling sessions after 4 months and 
18 months of follow-up 
T 4 T 1 8 
unstandardised p-value unstandardised p-value 
coefficient (SE) coefficient (SE) 
GP 
physical functioning 1.301 (1.116) 0.244 2.587 (0.949) 0.006 
social functioning 0.469 (1.328) 0.724 0.202(1.733) 0.907 
role physical 2.893 (2.709) 0.286 1.547 (3.163) 0.625 
role emotional 0.421 (1.896) 0.824 0.873(1.062) 0.251 
mental health 0.734 (0.019) 0,286 0.873 (1.062) 0.934 
bodily pain -0.651 (1.126) 0.563 -2.845 (1.386) 0.894 
general health 0.576 (0.975) 0.555 0.634 (0.238) 0.897 
thermometer 0.432 (0.968) 0.772 1.502 (1.053) 0.238 
Cardiology 
physical functioning 0.652 (0.863) 0.450 1.619(0.674) 0.106 
social functioning -0.681 (0.959) 0.478 -0.093(1.002) 0.929 
role physical 0.449 (1.586) 0.777 1.519(1.049) 0.389 
role emotional 1.257 (1.583) 0.427 1 571 (1.639) 0.338 
mental health 0.601 (0.713) 0.400 0.020 (0.806) 0.980 
vitality -0.412(0.757) 0.587 -0.297 (0.849) 0.727 
bodily pain 0.136 (0.939) 0.885 -0.093 (1.061) 0.930 
general health 1.338 0.705) 0.058 -0.110(0.846) 0.990 
thermometer 0.516(0.597) 0.388 0.244 (1.031) 0.717 
Conclusion and discussion 
The present study tried to gain more insight into the effects of individual 
behavioural counselling on QoL within two different populations, namely 
persons at risk for cardiovascular diseases (secondary prevention) and persons 
with established cardiovascular disease (tertiary prevention). 
Within the secondary prevention study, individual counselling did not show any 
effects on QoL four months after the intervention stopped. However, after 18 
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months of follow-up, significant differences on the RAND-36 scale physical 
health were observed between the intervention and control group. Persons 
having received individual counselling had higher scores on this subscale than 
persons who had not received counselling. This might indicate an effect of 
individual health counselling, but the effects should be interpreted with care for 
several reasons. 
First, no changes were observed within the intervention population. Instead, the 
control population reported a lowered physical functioning than at baseline and 
at four months after the intervention started. Although it was expected that the 
physical health increased in the intervention population this finding might imply 
that the effects of individual counselling are postponed, in that counselling will 
lead to a better lifestyle which in its turn will lead to maintained physical 
functioning in spite of growing older. However, these results are not in line with 
earlier research on health behaviour and physiological changes within the same 
study population. These studies observed slightly improved self-reported 
behaviour styles at 4 months (mainly a decrease in fat consumption) 
accompanied by slight improvements in body mass index, which vanished after 
18 months of follow-up12 (and P.van Limpt et al., in progress). 
Another reason why the results should be interpreted with care is that the 
absolute changes on the QoL scale physical functioning are small: it concerns a 
decrease of 2 points on a 100-point scale. The difference with the intervention 
group concerns only 3 points on this 100-point scale. Although statistically 
significant, the clinical relevance of this change in QoL in terms of physical 
functioning is questionable. 
Within the tertiary prevention study, neither at four nor at 18 months of follow-
up, any effects of counselling on QoL could be shown. This means that the 
intervention in its present form was not effective in improving QoL. This is in line 
with earlier research performed on the same study group, which found no 
effects of counselling on lifestyle or physiological parameters.13 (and P.van 
Limpt et al., in progress). 
Within both the intervention group and the control group, however, self-reported 
Qol increased substantially on almost all subscales of the RAND-36. This 
indicates that there is a natural recovery of QoL after having experienced a 
cardiovascular event. This recovery process was not increased or accelerated 
by the counselling sessions. 
Contrary to our findings, an earlier research of Elley et al (2003) did report 
improvements on QoL scales after behavioural counselling.11 The studies 
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differed on some points, which might at least partly explain the different 
outcomes of the studies. 
First, the present study included all persons for counselling, regardless of their 
behavioural styles. Patients' involvement in the process of determining the 
behavioural risk factor to which most attention was paid during the counselling 
sessions was high. In contrast to this, the study of Elley et al. (2003) only 
included persons with low exercise rates and the counselling was specifically 
designed to improve this exercise pattern.11 This might indicate that it is more 
effective to focus on one aspect of lifestyle that needs improvement, than to 
apply a general multiple life style approach. 
Furthermore, the interventions of both studies differed slightly. In addition to 
counselling, persons in the present study were encouraged to improve their 
lifestyle by providing them with general information about lifestyle courses in 
their neighbourhood. Elley et al (2003) used the counselling sessions to set 
concrete goals for increasing exercise, which were evaluated during telephone 
follow-up calls.11 The formulation of concrete goals might be more effective than 
providing general advice. Extending counselling with elements that facilitate 
changing the life-style, like classes on skills for adopting and maintaining 
healthy behaviour and exercise programs, was found to be favourable in other 
studies too.151617 
In addition to these aspects the intervention in the current study might have 
been more effective if several other aspects had been taken into account. 
First of all, the quality of the counselling was not optimal.18 Although the quality 
did improve over time, it used to be sub-optimal in many cases. A better 
counselling might have led to more improvements in lifestyle, possibly resulting 
in an improved biomedical cardiovascular risk profile and improved QoL. 
Second, the optimisation of the medication was not carried out as was planned 
at forehand. Computerized risk profiles could not always be implemented 
because many GP practices were not equipped with computerized patient 
registers. When computerized systems were available, GP's simply often did 
not adjust the medical therapy to the guidelines. A recent review revealed that 
counselling is more effective (at least in behavioural and biological terms) when 
provided in addition to drug treatment/ 
Finally, the effects might have been larger if the duration of the study period had 
been longer. Evidence exists that more extensive counselling during a long 
period of time reaches more effect that less extensive counselling during a short 
period of time.16 
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Besides these aspects related to the counselling intervention itself, there are 
some other points worth mentioning. 
Due to the fact that the QoL questionnaires were added to an already existing 
research, a number of participants did not receive a questionnaire at baseline. 
Some did even not receive the questionnaire of the first follow-up measurement 
at four months. In spite of this flaw, we believe that the results of the study are 
still reliable for several reasons. First, the groups that received a questionnaire 
at baseline were comparable to the group that did not receive a baseline 
questionnaire at baseline regarding demographic characteristics. Furthermore, 
a per-protoco! analysis was performed in addition to the group analysis to 
assess the robustness of the results. The results of both analyses were 
comparable, which implies that the results of the study are reliable. 
In addition, there are some important remarks concerning the implementation of 
counselling sessions within secondary and tertiary practice. It turned out to be 
very difficult to recruit GP's and cardiologists to participate in the study. This 
means that the results can only be generalizable to a selection of physicians. 
Furthermore, in the current study all patients who fulfilled the inclusion criteria 
and who were motivated to participate were included into the study. Physicians 
stated that they believe that some patients will benefit from counselling more 
than others. In a real life situation, it is thus expected that physicians will offer 
individual counselling only to a subgroup of patients instead of to all patients. 
Cardiovascular risk, life style and motivation of the patient to engage in 
counselling sessions might become important factors for inclusion in a real life 
situation. This will probably lead to changes in effectiveness. Further research is 
needed to investigate the effects of changes in referrals on the effectiveness of 
counselling within secondary and tertiary prevention. 
In short it can be concluded that the present study could not prove the 
effectiveness of individual counselling on QoL. Improvements (e.g. increasing 
the quality of counselling) to and expansions (e.g. inclusion of medication 
optimisation or life style programs, increasing duration of the intervention) of the 
intervention will possibly contribute to the effectiveness of individual counselling. 
It is still possible however that changes in QoL of a-symptomatic patients at risk 
for cardiovascular diseases, will only be visualised in far future. 
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Abstract 
Results of community-based prevention strategies have generally been 
disappointing, possibly because they are performed in an environment that 
makes it difficult for people to change their behaviour. Public-private 
partnerships could be used to change this environment, which might make it 
easier to adopt healthy behaviour. We analysed the effects of health education 
and price incentives at a butcher's shop. The health education intervention at 
the butcher's shop consisted of (1) labelling low-fat meat products (2) posters 
and leaflets and (3) education about healthy food provided to clients by the 
shop's staff. The effects of price reductions (special offers) were analysed using 
information about these price reduction periods. The analysis was based on 
information about price elasticity and the additional amounts of products sold 
during periods of price reduction. The results showed that the health education 
intervention did not result in a shift in consumption from high-fat meat to low-fat 
meat. Price elasticity values o f -4 to -28 were found. It can thus be concluded 
that the use of price incentives seems to be a particularly strong instrument to 
influence the sales of low-fat meat products. Price incentives haven proved to 
be successful in other food areas as well. 
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Introduction 
Western Europe has a high prevalence of and mortality from cardiovascular 
diseases. In the Netherlands, almost 50,000 persons a year die from such 
diseases.1 This represents 35% of the total mortality. Unhealthy behaviour like 
smoking, unhealthy nutrition and lack of exercise are known to contribute to the 
development of these diseases. In order to reduce the prevalence of 
cardiovascular diseases, efforts are made to increase healthy behaviour, using 
health education. Results of community-based prevention strategies have, 
however, generally been disappointing.2 3 A reason for this might be that it is 
difficult to change people's behaviour by education alone, in a society in which 
unhealthy behaviour is promoted at the same time by commercial parties and in 
which unhealthy behaviour is often less expensive than healthy behaviour. 
An increase in healthy behaviour among the population is most likely to occur 
when it becomes easier to adopt such behaviour. This might be achieved using 
a public-private partnership, meaning that non-profit institutions and commercial 
parties work together for the promotion of healthy behaviour. 
Commercial parties could contribute in two ways. One method is to shift the 
emphasis in advertising from unhealthy products to healthier products, while the 
second method involves the use of financial incentives. Both methods have 
been the subject of previous research. Previous researchers found that small, 
short-term effects could be gained, in terms of larger sales of low-fat food, by 
using health education in restaurants and cafeterias,4 5 6 7 but not in a grocery 
store.8 The effect of price reductions on the consumption of healthier food in 
restaurants and cafeterias was found to be more substantial.49 510 Most studies 
were performed in restaurants and cafeterias. Although it is useful to change 
behaviour in these settings, the results cannot simply be generalised to other 
settings. 
We were interested in the effects of health education and price incentives on 
the everyday purchase of food items by households. We therefore evaluated 
the effects of health education and price incentives on meat consumption. 
As far as we are aware, public-private partnerships aiming at increased 
consumption of low-fat meat products using health education and price 
incentives have never been evaluated. 
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Such a public-private partnership was established within the community part of 
a large-scale prevention programme for cardiovascular diseases, called 
Hartslag Limburg (Dutch for Hearbeat Limburg; named after the Dutch province 
of Limburg, where it took place). A butcher joined the prevention programme by 
providing education at his shop about fat and low-fat meat products. In addition 
to the health education, prices of meat products (low-fat as well as high-fat) 
were regularly reduced in price during special offers. 
The first aim of the present study was to evaluate the effect of the health 
education provided at the butcher's shop on sales patterns. The second aim 
related to price incentives and was twofold. We wanted to investigate whether it 
is possible to use price incentives to achieve a shift in consumption from high-
fat to low-fat meat. In addition, we wanted to investigate whether different 
characteristics of the price reduction periods and of the products would induce 
different outcomes in terms of sales patterns. 
Methods 
Research questions 
The following research questions were formulated: 
1 Health education 
Does providing health education at a butcher's shop result in a shift in 
consumption from high-fat to low-fat meat? 
2 Price incentives 
2a Can sales of meat be affected by price incentives? 
2b Are there other characteristics besides the level of price reduction that 
influence sales? 
Research design 
A pretest-posttest design was used, with data gathered retrospectively. During a 
period of 1 year the intervention took place. The year preceding the intervention 
year was used as a reference. This means that there is a two-year observation 
period, with year 1 representing the reference year, and year 2 representing the 
intervention year. 
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Intervention 
Health education 
At a butcher's shop in Maastricht, all products with less than 10% fat were 
labelled as 'tasty and healthy' for a period of one year. In addition, the shop staff 
provided information about low-fat meat during two periods of three months 
within the intervention year. During these periods, posters and leaflets about 
low-fat meat were also displayed in the shop. 
Price incentives 
During the two-year observation period, the butcher regularly introduced price 
reductions during special offers (referred to below as 'price reduction periods'). 
The characteristics of these price reductions periods were as follows. In the 
year preceding the intervention, meat with a low fat percentage was reduced in 
price 92 times, while meat with a higher fat percentage was reduced in price 91 
times (not significant (ns)). In the intervention year, this happened 71 and 75 
times for low-fat meat and high-fat meat, respectively (ns) (see table 1). 
There were no differences between the durations of the price reduction periods 
for low-fat meat and high-fat meat, nor in the mean number of products 
simultaneously reduced in price (table 1). 
In the year preceding the intervention, the mean percentage of price reduction 
was the same for low-fat and high-fat meat, namely about 20% (ns). In the 
intervention year, the price reduction for low-fat meat increased to 26.8% 
(p=0.01), while the price reduction for high-fat meat increased to 22.2% (ns). 
(See table 1.) This meant significantly larger price reductions for low-fat meat 
than for high-fat meat in the intervention year. 
Data collection 
The information collected from the butcher's shop consisted of the prices and 
amounts (in kg) of all products sold during the intervention year and the year 
preceding the intervention. Composing usable data files took a great deal of 
effort. The information about prices and amounts sold were provided on a four-
weekly basis. Price reduction periods differed in length (three days, six days or 
longer) as did the percentages of price reduction in the various price reduction 
periods. After a product had been reduced in price for some days, the additional 
amounts sold as a result of the price reduction had to be estimated from the 
four-week records. 
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Table 1: Characteristics of the price reduction periods 
year one year two 
low- high- P1 low- high- P2 P3 p4 
fat fat fat fat 
meat meat meat meat 
number of price 
reduction periods 92 91 71 75 
mean number of days 
that a product was 
reduced in price 4.0 4.4 0.158 5.2 5.0 0.503 0.000 0.005 
price reduction* (%) -22.3 -20.0 0.102 -21.7 -19.4 0.353 0.739 0.719 
price reduction** (%) -20.3 -19.0 0.432 -27.8 -23.6 0.040 0.000 0.020 
mean number of 
products reduced in 
price simultaneously 18.8 18.8 0.949 13.1 13.9 0.269 0.000 0.000 
mean frequency of 
price reduction per 
product 14.4 12.3 0.020 15.9 13.6 0.018 0.096 0.159 
* three-day intervention periods, ** six-days intervention period 
p1 low-fat versus high-fat year one 
p2 low-fat versus high fat year two 
p3 low-fat meat year one versus year two 
p4 high-fat meat year one versus year two 
Analysis 
Research question 1 
To answer the question whether there was an effect of labelling and additional 
information, the share of low-fat meat in the total sales of the selected products 
(in kg) during the intervention year was compared with the share of non-fat 
meat in the year preceding the intervention. A t-test for independent samples 
was used. 
Research question 2a 
The question whether it is possible to influence meat consumption patterns by 
price incentives at all was investigated using the concept of price elasticity (PE) 
and the total amount of meat sold during price reduction periods. PE values 
indicate by how much the sales of a product change (in percentages) when the 
price is changed by 1%. Mean PE values and additional amounts sold were 
calculated separately for high-fat meat low-fat meat. Because PE is a time 
dependent measure, price reduction periods were only included when the price 
reduction lasted for three or six days. This was true for 91.7 percent of all price 
reduction periods. Other periods were longer. 
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Research question 2b 
The question which characteristics of the sales period and which characteristics 
of the products themselves influenced the sales during a price reduction period, 
were investigated with a multivariate regression analysis. 
Characteristics of the sales period that were expected to potentially influence 
the effect of price reductions - in terms of the additional amounts sold - were; 
• The number of products reduced in price simultaneously; 
• The percentage of price reduction; 
• The frequency with which a product was reduced in price; 
• The duration of the price reduction period. 
Characteristics of the product that were expected to potentially influence the 
effect of price reductions were: 
• The sales volumes when a product was not reduced in price; 
• The price of a product; 
• Healthy versus less healthy products. 
Results 
Sales volumes and prices 
The overall sales at this butcher's shop amounted to 6100 kg in the first four 
weeks of the observation period and 4800 kg in the final four weeks of the 
observation period. Of the 162 products selected for the intervention, a total of 
4700 kg were sold during the first four weeks of the observation period, while 
3550 kg were sold during the last four weeks of the observation period. 
Although sales in kg of all products were thus about 20% lower in the last four 
weeks of the observation period than in the first four weeks of the observation 
period, the share of the selected products in the shops total sales was constant 
at a mean of 75%. 
Of the 162 products selected for the intervention, 58 (40%) had a fat percentage 
of less than 10 and were thus labelled as 'tasty and healthy', while 74 products 
(15%) had a fat percentage of more than 10 and received no label. A further 30 
products (15%) had a fat percentage of less than 10, but were incorrectly not 
labelled as 'tasty and healthy'. In the analysis, these products were treated as 
not labelled. Sales of the products labelled as 'tasty and healthy' accounted for 
almost 50% of the sales of the products selected for the intervention (figure 1). 
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Figure 1: The share of the products used for Hartsiag Limburg in the total sales 
of the butcher. 
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The top 10 products in terms of sales volumes are shown in table 2. Seven of 
these products have a fat percentage of less than 10. 
Table 2: Overview of the ten most frequently sold products 
product kg sold percentage cumulative 
per month of total sales percentage 
minced meat 376 8.9 8.9 
ham* 192 4.6 13.5 
chicken breasts* 160 3.9 17.4 
round steak* 159 3.9 21.3 
ham (grilled)* 132 3.2 24.5 
beef 127 3.1 27.6 
lean pork chops* 127 3.1 30.7 
streaky pork chops 103 2.5 33.2 
steak tartare 101 2.4 35.6 
smoke-dried beef* 77 1.9 37.5 
* low-fat meat product 
Overall, sales of low-fat meat exceeded those of high-fat meat (p<0.01). The 
mean share of low-fat meat in the sales over the entire two-year period was 
61% (table 3). At the start of the observation period, about 3000 kg of low-fat 
meat were sold, against 700 kg of high-fat meat. At the end of the observation 
period 1700 kg of low-fat meat were sold, against 500 kg of high-fat meat (table 
3). The mean amount of meat sold by the butcher per week decreased by about 
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the same percentage for both groups of products, namely 29 and 27 percent for 
low-fat and high-fat products, respectively (table 3). 
Price developments can only be reported in relative terms here, since we were 
not allowed to publish absolute prices. Prices of non-labelled products at the 
start of the observation period were taken as a reference. At that time, the 
prices of the products labelled as 'tasty and healthy' were on average 56% 
higher than those of high-fat products (table 3). At the end of the intervention 
period, the labelled products were 47% more expensive than the non-labelled 
products. Prices of the labelled products increased by 10%, while those of the 
non-labelled products increased by 16% (table 3). 
Table 3: Prices and amounts of meat sold of the products used in the analysis 
of Hartslag Limburg 
share relative relative increase kg sold kg sold decrease 
in price at price at in price at start at end in sales 
sales start of end of (%) of study* of study* (%) 
(%) study (%) study (%) 
products labelled 
'tasty and healthy' 47 156 170 10 2243 1680 29 
non-labelled pro-
ducts (>10% fat) 39 100 116 16 1844 1414 27 
non-labelled pro-
ducts (<10% fat) 15 132 153 16 693 483 30 
* the mean value of five periods was used to obtain a more reliable value 
Research question 1 
The share of low-fat meat sold in the intervention year did not differ from that in 
the year preceding the intervention: 60% of the sales of the selected products. 
As mentioned above, there was a decrease in overall sales (figure 1). 
Research question 2a 
Price incentives turned out to have a strong influence on sales: the mean PE 
varied from -4.3 (for six-day intervention periods, high-fat meat, year 2) to -27.7 
(for three-day intervention periods, low-fat meat, year 1), as shown in table 4. 
This table also shows that PE values were generally higher when the products 
were sold at reduced price for only three days than when they were reduced in 
price for six days. 
There were generally no significant differences between the mean PE values for 
low-fat meat and high-fat meat (table 4). The only significant difference between 
PE values for low-fat and high-fat meat were found in the intervention year, and 
only for six-day price reduction periods (p=0.006). Nor were there generally 
I 
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large differences in PE values between the two years. The only significant 
decrease in PE was found for low-fat meat products reduced in price for three 
days (p=0.001). 
Table 4: Price elasticity of low-fat and high-fat meat products and additional 
amount of meat products sold during the price reduction periods. 
year one year two 
low- high- P1 low- high- p2 P3 p4 
fat fat fat fat 
meat meat meat meat 
price elasticity* -27.7 -22.1 0.206 -12.3 -22.7 0.069 0.001 0.904 
price elasticity** -9.4 -6.8 0.109 -8.1 -4.3 0.006 0.475 0.390 
p5 0.000 0.000 ns 0.000 
Kilograms* 38.8 31.7 0.190 30.3 21.5 0.139 0.148 0.070 
Kilograms** 36.9 22.1 0.004 41.4 30.0 0.111 0.498 0.207 
P5 ns ns ns ns 
* three days intervention period, ** six days intervention period 
p1 p-value of low-fat meat versus high-fat meat in year 1 
p2 p-value of low-fat meat versus high-fat meat in year 2 
p3 p-value of low-fat meat in year 1 versus low-fat meat in year 2 
p4 p-value of high-fat meat in year 1 versus high-fat meat in year 2 
p5 p-value of 3-days versus 6-days intervention period 
Calculation of PE on the basis of the increases in price and decreases in sales 
that occurred during the complete study period (see table 3) yields PE values 
for the labelled low-fat meat products and the non-labelled high-fat products of 
2.9 and 1.7, respectively. 
To a butcher, it is not so much the PE value that matters, but the additional 
amounts sold relative to the periods when the products are not reduced in price. 
Unlike PE values, the amounts sold did not differ significantly between three- or 
six-day price reduction periods (p=0.714; p=0.094; p=0.070; p=0.195). This was 
true for low-fat meat as well as high-fat meat, and for the intervention year as 
well as the year preceding the intervention. 
Furthermore, the large decrease over time in the PE of healthy meat products 
reduced in price for three days (p=0.001) did not result in a significant decrease 
in the extra amounts sold during the price reduction periods (p=0.148), as is 
shown in table 4. This implies that it is not only the price reduction that makes 
people decide what meat products to buy. The observation confirms our 
hypothesis that certain characteristics of the sales periods or of the product are 
important elements in the prediction of the amounts sold. 
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Research question 2b 
The results of the multivariate regression analysis (Table 5) show that the 
amount of a product sold in periods without price reduction had the greatest 
influence on the additional amount sold during price reduction periods (R=0.535; 
p<0.01). The percentage of price reduction was the second most important 
characteristic influencing the additional amount sold during price reduction 
periods ((S=-0.401; p<0.01) as shown in table 5. The higher the percentage of 
price reduction, the larger the additional amount of a product sold. A third factor 
was that the additional amounts sold during price reduction periods were larger 
for low-fat products than for high-fat products ((1=1.39; p<0.01). The final 
characteristic that influenced the additional amounts sold during price reduction 
periods was the frequency with which a product was reduced in price (&=0.106; 
p<0.05). The more often a product was reduced in price, the larger the 
additional amounts sold during price reduction periods. 
Table 5: The influence of independent variables on the additional amount sold 
during price reduction periods 
standardised coefficient (beta) ievel of significance 
basic sales -.115 .000 
price reduction (%) -.268 .000 
healthy (=2) versus less healthy (=1) -.519 .000 
number of products reduced in price simultaneously -.026 .641 
period (year 1 versus year 2) .663 .000 
basic price -.009 .871 
frequency of price reduction .309 .000 
Discussion 
The present study found no shift in consumption from high-fat meat to low-fat 
meat as a result of the intervention. This does not necessarily mean, however, 
that health education in a butcher's shop is not effective. Some external factors 
have probably influenced the results. The most important of these is the 
economic recession which started during the research period, which meant that 
people had less money to spend. In such a situation, they can be expected to 
consume less meat in general and/or to shift their consumption from more 
expensive (low-fat) to less expensive (high-fat) meat products. In the present 
study, the total sales of the butcher did indeed decrease, but the share of the 
more expensive low-fat meat products sold remained the same. If the trend in 
the Netherlands as a whole for this period, contrary to the butcher's shop we 
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investigated, had been a shift from the consumption of the more expensive low-
fat meat to the less expensive high-fat meat, then the health education 
intervention might be said to have been successful in preventing this decrease 
at this particular butcher's shop. In fact, however, the consumption of pork, 
beef, and poultry in this period remained constant in the Netherlands: no shift in 
meat consumption categories was observed.11 Furthermore, Dutch meat 
consumption figures for the year 2001 and 2002, calculated by the Statistics 
Netherlands (CBS), allow the conclusion that the overall meat consumption in 
the Netherlands did not decrease.11 
The observation that the 30% decrease in total sales at this butcher's shop did 
not reflect a general trend rises the question what could explain this decrease. 
The reason for this decrease is probably the increase of meat being bought at 
supermarkets instead of at butcher's shops in the Netherlands.12 In 2002, 80 to 
90 percent of all meat was bought at supermarkets. Furthermore, during the 
research period, a new supermarket was opened right across the street from 
the butcher's shop we studied. Because meat in supermarkets is generally less 
expensive, it seems likely that clients kept buying the same low-fat meat 
products, but bought them from less expensive shops (supermarkets). This 
might be true for the clientele of the butcher's shop under study as well as for 
the Dutch population in general. 
It can be concluded, nevertheless, that we were not able to show the 
effectiveness of health education in a butcher's shop. 
The study further confirmed the findings of earlier research, that price 
reductions can be used to guide sales.459 13 The observed mean PE values o f -
11 and -16.6 for high-fat and low fat-meat, respectively, are high, indicating that 
price reduction is an effective tool to influence sales patterns. Because high-fat 
meat was reduced in price just as often as low-fat meat, the desired health 
effects of price reductions for low-fat meat might have vanished. The calculated 
PE value is much higher than those reported in other studies, which have 
reported values of 0.3 to 0.6.1415 This large difference probably results from a 
different starting point in calculating PE values. In the present study, PE values 
were calculated based on temporary price reductions, while other studies 
calculated PE values based on permanent price reductions or increases. Sales 
volumes during regular price reduction periods might show additional increases 
because of anticipatory buying behaviour In other words, the meat sold during 
price reduction periods does not necessarily have to be consumed in the short 
term. It is likely that customers buy more meat and store most of it for 
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consumption at a later moment. Furthermore, it is possible that customers who 
usually patronise another butcher may have bought their meat at the butcher's 
shop participating in our study only during price reduction periods. Meat that is 
bought by persons visiting the butcher's shop only once causes an increase in 
the sales, but does not reflect an increase in low-fat meat consumption among 
regular customers. Purchase acceleration and store switching are indeed 
common phenomena when price incentives are used.13 In our study, the fact 
that the PE values for three-day price reduction periods were higher than those 
for six-day periods confirms that these mechanisms did indeed play a role. 
Further evidence of purchase acceleration is that the PE values in the present 
study were considerably lower when calculated on the basis of price increases 
and decreases in sales for the entire study period rather than for the short-term, 
recurrent price reductions. 
In spite of these phenomena, the current study confirms the finding of previous 
research that price incentives have a greater influence on consumption 
behaviour than health education.4 5 9 10 This is in agreement with the study by 
Lannernas (1997), in which a representative sample of European citizens rated 
price and taste above health when asked what determined their food choices.16 
Some evidence even exists that health messages might reduce the effect of 
price incentives when provided at the same time.5 The authors' conclusion from 
this observation was that healthy food is not always associated with being tasty, 
whereas the taste and the price of a product are generally more important than 
health aspects.16 As far as meat is concerned, however, it is our impression that 
low-fat meat products are generally preferred over high-fat meat products in 
terms of taste. 
In addition to the effect of price reduction and health education, we tried to 
evaluate other characteristics that influenced the butcher's sales. The finding 
that the basic sales (sales in non-price reduction periods) and the type of 
product (low-fat versus high-fat) influenced the sales, while the basic price does 
not, suggests that the customers of this particular butcher's shop either based 
their product choices primarily on whether they liked the taste, or were already 
consciously making healthy choices. This is confirmed by the fact that seven of 
the ten most frequently sold products were the more expensive low-fat meat 
products. 
Our results should be interpreted with care. The study used a rather weak 
design. First, no control group was available. Second, price reductions for high-
fat meat were the same as those for low-fat meat in terms of numbers and 
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percentages. Further, a number of circumstances made it difficult to analyse the 
data properly. During the two years of observation, the price of most products 
increased, total sales decreased by 33 percent, the euro was introduced, there 
was an epidemic of foot and mouth disease and an economic recession started. 
In addition to this, the butcher's shop changed its sales policy on price 
reductions. When the observation period started, price reduction percentages 
were relatively small, and a rather large number of products were reduced in 
price simultaneously. At some time during the second year of observation, the 
shop decided to decrease the number of products that were reduced in price 
simultaneously, but to increase the percentage of price reduction. Finally, the 
butcher's shop that participated in our study was located in a high social class 
neighbourhood. Results might have been rather different if we had done the 
same study at a butcher's shop with a clientele from a lower social class. In the 
general discussion of this thesis, we will go into the improvements for the study 
design. 
Further research is needed allow firmer conclusions. Before starting a study of 
public-private partnership, some precautions need to be taken. First, it is of 
great importance to pay attention to the design of the study. Furthermore, clear 
agreements should be made with the private partners, to prevent confounding 
due to decisions made by them during the intervention period. This could be 
done, for example, through contracts. 
In our study, a butcher was chosen as our private partner from the food 
industry. However, since (1) more and more people buy their meat at 
supermarkets instead of at the butcher's and (2) there is a rising consumption of 
fast-food and microwave meals, working together with a traditional butcher's 
shop does not seem the most logical option when trying to influence community 
health. Greater effects could probably be achieved by asking supermarkets or 
firms producing microwave meals to collaborate. 
Even with better agreements with the private partners and using partners like 
supermarkets, however, a major problem remains when trying to implement 
long-term public-private partnerships. This problem follows directly from the 
goals of the public and private partners. The public sector consists of non-profit 
organisations and aims to increase public health, whereas the main goal of the 
private sector is profit maximisation. It is probably very difficult to merge the 
goals of the two sectors. 
It might be better to coordinate the use of price incentives at the political level, 
by introducing measures like special taxes on food with a high fat or a high 
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sugar percentage. Such a regulatory measure has already been successfully 
applied in the Netherlands for many years with regard to cigarette smoking. In 
17 states of the United States of America, special taxes on snacks and soft 
drinks have already been implemented.17 
Implementing special taxes in more countries around the world might stop the 
rise in the percentage of overweight people, which might substantially reduce 
the morbidity and mortality connected with cardiovascular diseases. 
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Abstract 
Little is known about the costs of community programmes to prevent 
cardiovascular diseases. The present study calculated the economic costs of all 
interventions within a Dutch community programme called Hartslag Limburg, in 
such a way as to facilitate generalisation to other countries. Costs were 
calculated using the guidelines for economic evaluation in health care. An 
overview of the material and staffing input involved was drawn up for every 
single intervention, and volume components were attached to each intervention 
component. These data were gathered during to the implementation of the 
intervention. Finally, the input was valued, using Dutch price levels for 2004. 
The economic costs of the interventions that were implemented within the five-
year community programme (n=180,000) were calculated to be about €900,000. 
€555,000 was spent on interventions to change people's exercise patterns, 
6250,000 on improving nutrition, G50,000 on smoking cessation, and 645,000 
on lifestyle in general. The current cost-calculation allowed the costs to be 
easily adapted to other countries and regions. The study further showed that the 
difference between economic costs and the costs incurred by the coordinating 
agency can be very large. Cost sharing was facilitated by the unique approach 
used in the Hartslag Limburg programme. 
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Background 
Many western countries have a very high prevalence of cardiovascular diseases 
(CVD).1 In the Netherlands, more than a million persons suffer from CVD,2 
corresponding to 8% of the adult population. Because of their high prevalence, 
CVD lead to high costs. The 2003 medical costs for cardiovascular diseases in 
the Netherlands, were G5.2 billion,3 corresponding to almost 10% of the total 
Dutch health care costs. 
Reducing risk factors for CVD might reduce the burden that they impose on 
public health and on the health care budget. There are many ways in which this 
can be achieved. A promising method to reduce the prevalence of CVD is the 
implementation of community programmes. 
While there is a considerable body of evidence on the effectiveness of 
community programmes to prevent CVD,4 5 6 little is known about the costs of 
these complex interventions. There have been some attempts to calculate the 
costs of community interventions,7 8 9 10 11 12 13 14 15 16 but the studies performed 
so far have lacked two essential elements, namely (1) costs are not calculated 
according to guidelines for economic evaluation research and (2) costs are 
presented at an aggregated level. 
It is important that the costs are calculated according to guidelines because 
previous research, which is amongst others presented in chapter three of this 
thesis, has shown that considerable bias may occur in the costs when 
guidelines are ignored.17 18 19 Only if the costs are calculated according to 
r 
economic guidelines and in a uniform way can they be combined with data on 
the effectiveness of a programme and used for policy making.2021 
The value of presenting costs of community programmes in a detailed overview 
instead of presenting the costs at an aggregated level is twofold. First, providing 
insight into the costs of all individual interventions in a community programme 
facilitates budgeting for anyone who might want to implement such a 
programme. The combinations of interventions to change lifestyle that are used 
in community programmes are different for each programme and it is thus 
important to know which specific interventions are used, how they are 
implemented and what their individual costs are. The second advantage of 
presenting detailed costs instead of only final costs is that the latter may give 
rise to problems when generalising the costs to other regions and countries, 
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because local factors are likely to affect the costs of a programme. Presenting 
detailed costs avoids these disadvantages of aggregated presentation. The 
present article reports on the costs of the community programme included in the 
Hartslag Limburg campaign, which aimed at preventing cardiovascular 
diseases. 
The aim of the study was to provide detailed information about costs of 
interventions within a community programme, calculated in accordance with 
guidelines for economic evaluation and in such a way as to facilitate 
generalisation to other countries. 
Methods 
Target population 
The intervention region consisted of the town of Maastricht (120,000 
inhabitants) and four adjacent municipalities (60,000 inhabitants). The majority 
of the people thus lived in urban areas. 62% of the inhabitants of the 
intervention region had paid jobs, while 17% of the inhabitants were older than 
65 years. 
In the intervention region, cardiovascular diseases accounted for 32% of all 
deaths. The prevalence of the acute heart infarction in the intervention region 
was 3.7%, which is almost 2% higher than the average prevalence in the 
Netherlands. 
As regards lifestyle, 32% of the inhabitants smoked and almost 50% of the 
inhabitants in the intervention region did not meet national recommendations for 
exercise (30 minutes a day for at least 5 days a week). 
Development of the community programme 
The community programme in the Hartslag Limburg campaign aims at health 
promotion among all inhabitants of the intervention region, that is, the town of 
Maastricht and four adjacent municipalities (n=180,000). Special attention was 
paid to inhabitants of four low socio-economic status (LSES) neighbourhoods 
(n=20,000), in which 50% of the interventions took place. 
The programme is based on a unique design. Before interventions were 
implemented, a network was formed consisting of large number of participating 
organisations. Amongst these organisations were the campaigns coordinating 
agency, which is the Regional Public Health Institute of Maastricht, as well as 
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other health promotion agencies, the local hospital, general practitioners, 
welfare services and local authorities. This network can be described as the 
cornerstone of the campaign. Each of the agencies implemented a number of 
CVD prevention interventions, and also contributed financially. In this way, the 
network served as the starting point for the implementation of interventions. The 
network made it possible to implement a multiple intervention strategy and to 
reach inhabitants of the region in a variety of ways. Both would have been very 
difficult to achieve if a network had not been created first. 
The community-based health promotion within the campaign was implemented 
through nine local health committees: one in each of the five municipalities and 
one in each of the four LSES areas. Each committee consisted of employees of 
the Regional Public Health Institute and of welfare services, civil servants and 
individuals from the target population themselves. The committees approached 
individuals and groups within the target populations by means of health 
promotion projects and activities. 
The participation of community members in the local health committees was 
essential to facilitate the recruitment and participation of inhabitants. This was 
especially true for the LSES regions, because their residents are difficult to 
reach with general health promotion activities. 
The participation of civil servants was important as they could effect policy 
changes, and because health promotion activities are partially financed by city 
councils. 
The choices about which interventions to implement came about in a variety of 
ways. The most occurring were the following: (1) The coordinating agency or 
one of the other partners proposed an intervention, which was preferably 
evidence based. Together with one of the local health committees its value was 
discussed and the best way to implement the intervention was determined. 
When necessary partners or 'external' institutions were approached to 
collaborate in the implementation (2) The health committees explored the needs 
and wishes of the target-population. Based on this information, existing 
interventions were implemented or new ones were developed. When 
cooperation of institutions or organisations was needed, these were approached 
(3) Agencies outside the network contacted the coordinating agency of Hartslag 
Limburg with a suggested intervention. Together with the coordinating agency 
or a local health committee, the suggested intervention was evaluated on its 
merit for Hartslag Limburg and its attainability. In case of a positive attitude 
towards the intervention, implementation followed. 
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The similarity between these ways is that they were based on the observed 
needs within the community and on the expertise of the various implementers 
about the methods to reach the inhabitants in the region. 
Cost calculation 
An adequate cost calculation requires three steps to be taken, namely 
identification, quantification and valuation. 21 
In the identification phase, decisions were made about the aspects of the 
complex Hartslag Limburg programme that were to be included in the cost 
analysis and those that were to be excluded. 
Starting from this framework, the quantification step addressed the methods 
used to obtain an overview of the material and personnel resources necessary 
for the campaign interventions to be successfully implemented. 
Finally, the valuation phase applied the pricing methods. 
Identification 
Since the present study focused on the costs of the actual interventions, costs 
related to creating and maintaining the network were excluded from the 
analysis. The reason for doing so was that the latter costs were dependent on 
local organisational aspects, which means that no context-independent estimate 
was possible. Furthermore, the network was not solely used for the CVD 
prevention programme, but might serve many purposes. Hence, we were 
unable to estimate which part of the network costs had to be attributed to the 
community program of Hartslag Limburg. 
We focused on calculating the costs of the interventions. Because of the large 
diversity of interventions, the aim was to calculate the costs of every single 
intervention separately. Within Hartslag Limburg, about 1000 interventions were 
implemented. About 800 of these were large-scale or frequently recurring 
interventions. In addition, there were about 200 small-scale, nonrecurring 
events. For practical reasons, only a random sample of the small-scale 
interventions was used to calculate costs according to the guidelines, and the 
resulting costs were then extrapolated to all other small-scale and non-recurring 
interventions. We think this is justified, because of the relatively small 
contribution of these smaller interventions to the total costs of the programme. 
Not all the costs related to the interventions were relevant to the present cost 
calculation. Costs incurred for the development of new interventions were 
irrelevant because they do not have to be incurred again when the intervention 
is applied elsewhere, nor would future implementers have to pay indirectly for 
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the development costs. Hence, they were excluded from the analysis. Because 
future programmes might involve developing new interventions, we provide an 
indication of the development costs within Hartslag Limburg, which are reported 
separately. 
Finally, a cost calculation according to the guidelines implies that all inputs 
should be included to obtain a reliable overview of the actual costs of a 
programme. This also means that all input should be given a monetary value. 
For the present cost calculation this meant that (1) monetary input or input in 
kind that was received from other institutions (subsidies, sponsors) was 
included in the cost analysis, and (2) input from volunteers was also included. 
Although the guidelines recommend to include input from participants in the 
cost analysis as well, the current analysis did not include time input by 
participants, due to lack of data. 
Quantification 
In the quantification phase, an overview of all the material and staffing input 
involved (both in kind and in quantity) was drawn up for every single 
intervention. The overview was based on documentation, like budget 
statements, registrations of hours worked by staff, plans of action, evaluation 
reports and accounts. After an intervention had been implemented, we verified 
whether the actual input was in agreement with the anticipated input. This was 
done in regular meetings (once every two months) with health education 
specialists involved in implementing the interventions. This information was 
used for an accurate estimation of the resources that were necessary for the 
intervention to be successfully implemented. 
Valuation 
In the third and final step, the staff and material inputs were valued, using Dutch 
price levels for 2004. Interventions were mainly valued using prices. 
Staff input 
In order to obtain reliable estimates of the costs of staff input, and in 
accordance with guidelines for cost research,20 21 22 staff input was valued using 
salaries based on national mean wage levels for each task level, instead of 
taking staffing costs in terms of hourly wages directly from the programme's 
records. This made the cost estimation less dependent on the local context and 
made it more likely that the estimated costs will correspond to thé actual costs 
of future programmes implemented elsewhere. 
In valuing staff input, we assumed an efficient use of input. This meant that 
adjustments had to be made for inefficient use of staff input by the programme 
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due to start-up problems. When identifying staff input, we used the task level 
necessary to implement an intervention successfully to define the type of staff 
input and thus the price attached to it. 
Material input 
The prices of the material input were derived from the Hartslag Limburg 
records. 
Results 
From 1999 until 2003, a total of 790 interventions were implemented. These 
included 21 different types of large-scale or frequently repeated interventions, 
accounting for 590 interventions over the five-year intervention period. Table 1 
presents an overview of these interventions. Of the 590 major interventions, 193 
were aimed at dietary change, 361 were related to physical activity and 9 aimed 
to make people give up smoking (table 1). There were an additional 27 
interventions that aimed at a healthier lifestyle in general. In addition to these 
interventions, 200 small-scale and non-recurring interventions were 
implemented. Almost 50% of the interventions took place in disadvantaged 
areas. 
The costs of the individual major interventions and the resulting total costs of 
the Hartslag Limburg community programme are shown in table 2. Tables 3 and 
4 present the monetary value of the material and staff input. 
As table 2 shows, the total expenditures over the five-year period were 
estimated to be about 6900,000. Of this amount, about 686,000 took the form 
of so-called start-up costs. These are expenditures that are incurred only once 
to allow an intervention to be implemented. Examples of such costs in the 
Hartslag Limburg programme are the training costs of various professionals and 
of the staff of the butcher's shop involved in one of the interventions. 
Furthermore, 680,000 of these start-up costs was spent on a single 
intervention, namely the intervention called Tasty and Healthy'. There were 
large differences in the investments made to influence the various behavioural 
risk factors. The greatest investments were made to improve exercise habits 
(about 6555,000). The smallest amount was spent on interventions to make 
people give up smoking (650,000). On improving the dietary pattern 6250,000 
was spent. Another 645,000 was spent on improving lifestyle in general. 
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Table 1: Description of the interventions performed within the Hartslag Limburg 
community program 
Intervention Description 
Nutrition 
Nutrition party Discussion meeting about healthy food. 
Orientation in supermarket Education about healthy food in a supermarket. 
Lifestyle seminar Seminar about healthy living, focusing on nutrition. 
Personal dietary advice Based on a questionnaire about dietary habits, 
people receive written personal advice about dietary changes. 
Cookery course A course about healthy cooking. 
Debt assistance Persons with debts are taught to cook a healthy meal on a small 
budget 
Tasty and Healthy Health education programme carried out at a butcher's chain, 
consisting of several components: 
1) Labelling meat with less than 10% fat 
2) Posters and postcards with healthy recipes 
3) Education about healthy meat provided by the butcher's staff. 
Exercise 
Walking guide Guide showing 10 walking routes. Distribution via health centres, 
media etc. 
Walking schedule Guide showing 70 dates of guided walks. 
Walking guide + schedule Guide showing 10 walking routes and 70 guided walks. 
Cycling guide Guide showing cycling routes. 
Exercise TV Daily TV-guided aerobics programme, including information about 
the health advantages of exercising. 
Walks/cycle tours Organised walks and cycle tours. 
Sports clubs Weekly group sports activities. 
Focus on Heart and Sports Exercise education at schools, combined with introduction course 
at a sports club. 
Smoking 
'Congratulations' campaign Campaign consisting of five components: 
1) 80 commercials, each lasting 34 seconds, on a local radio station; 
2) 80 billboards; 
3) Posters and postcards in health centres. 
500 posters and 7500 leaflets were placed in 250 health centres; 
4) Information packages about quitting smoking containing 8 leaflets 
and an application form for free nicotine patches (300 requests). 
5) Free nicotine patches (50 requests). 
Theatre show on smoking Intervention consisting of 2 components: 
1) A lesson at school about quitting smoking ; 
2) A theatre show. 
Stop smoking around kids 1) An information package containing 9 leaflets and a poster was 
sent to all nursery schools and all health centres in the region; 
2) Personal consultation by welfare worker with parents of 
small children; 
3) Four seminars; 
4) Distribution of 10 billboards; 
5) Distribution of 100 t-shirts with the text: 'no smoking around kids'. 
Quit smoking campaign Anti-smoking campaign using billboards, posters and leaflets. 
Lifestyle in general 
Lifestyle course Six 3-hour sessions in which health aspects were discussed with 
teenagers. 
Promotion stand A display stand with health promotion materials. 
Regular one-page advertisement in local newspaper with information 
Newspaper advertisement about nutrition, smoking or exercise. 
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There were also large differences between the costs of individual interventions. 
Some interventions were very cheap (e.g. lifestyle seminars, the 'nutrition party' 
and cycle tours), whereas others involved very high costs, such as the 
interventions called 'Exercise TV', 'Tasty and Healthy' and 'Focus on Heart and 
Sports'. These three interventions accounted for 45% of the total costs. 
Of the total of G900,000 that was spent on the interventions, the coordinating 
agency, the Regional Public Health Institute, supplied only about 10 percent, 
illustrating that only a fraction of the costs of the interventions have to be borne 
directly by the organising agency. 
Table 2: Costs of the community program Hartslag Limburg 
Intervention Costs per Number of Total Start-up Development 
intervention (€) interventions costs (€) costs (€) costs 
Nutrition 
Nutrition party 399 59 23.541 
Orientation in supermarket 224 63 14.143 
Lifestyle seminar 234 43 10.083 
Personal dietary advice 8.906 1 8.906 4.000 
Cookery course 1.937 16 30.992 
Debt assistance 534 8 500 4.500 
Tasty and Healthy 50.000 1 50.000 80.000 2.700 
Small non-recurring events 200 116 23.200 
Total costs/subsidy 
relating to nutrition 165.138 84.500 7.200 
Exercise 
Walking guide 3.212 2 6.425 
Walking schedule 7.510 2 15.020 
Walking guide + schedule 15.910 1 15.910 
Cycling guide 7910 1 7.910 
Exercise TV 2.000 120 240.000 
Walks/cycle tours 255 191 48.705 
Sports clubs 4.179 41 171.339 
Focus on Heart and Sports 39.909 1 39.909 
Small non-recurring events 200 51 10.200 
Total costs relating to exercise 555.148 
Smoking 
'Congratulations' campaign 11.162 2 22.325 1.500 5.000 
Theatre show about smoking 575 3 1.725 
'Stop smoking around kids' 6.955 1 6.955 
Quit smoking campaign 8.727 1 8.727 
Small non-recurring events 200 23 4.600 
Total costs relating to smoking 44.332 1.500 5.000 
Lifestyle in general 
Lifestyle course 1557 16 24.912 
Promotion stand 300 10 3.000 
Newspaper advertisement 2.160 7 15.120 
Small non-recurring events 200 10 2.000 
Total costs relating to lifestyle 45.032 
Total costs of programme 809.650 86.000 13.200 
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Table 3: Overview of the monetary value of the material input 
Resource value (G/unit) source 
room rent 25* Unit price within Hartslag 
travelling expenses 0.15** Dutch manual of cost research 
printing costs Unit price within Hartslag 
- posters 0,6 
- leaflet/postcard 0,1 
- covering letter 0,1 
- billboard 4 
- nutritional advice 
questionnaire 0.25 
- book with recipes 7 
(dept assistance) 
- walking/cycling guide 0.8 
- walking guide+schedule 1.5 
- walking schedule 1.5 
- book with introductory 
- courses by sports clubs 3 
envelope (A4) 0.15 Unit price within Hartslag 
envelope (A5) 0.15 Unit price within Hartslag 
stamped envelope (A5) 0.55 Unit price within Hartslag 
postage (walking schedule, 
walking/cycling guide) 1.5 National rate 
postage 0.4 National rate 
distribution of billboard 20 Unit price within Hartslag 
distribution of nicotine patches Unit price within Hartslag 
designing newspaper ad 500*** quotation by printer's 
publication of newspaper ad 1300*** quotation by printer's 
tv production and broadcast 160**** quotation by TV station 
radio broadcast #| * * * * quotation by radio station 
nicotine patches 2 Q***** Unit price within Hartslag 
food for cookery course 100 Unit price within Hartslag 
t-shirt 10 Unit price within Hartslag 
billboard 100 Unit price within Hartslag 
* e / hour, ** e I km, *** G I unit, **** G I minute tv or radio, ***** G / box 
Table 4: Overview of the monetary value of the staff input 
resource value (G/hour) source 
dietician 40 national salary scale* 
expert on walks 20 national salary scale* 
health expert 45 national salary scale* 
secretary 20 national salary scale* 
welfare worker 70 national salary scale* 
sports teacher 40 national salary scale* 
* based on average salary 
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Discussion 
As far as we are aware, this is the first study to present detailed costs of a 
large-scale community intervention programme, using the necessary material 
and staff input for every single intervention as a starting point and applying 
guidelines for economic evaluation. 
The costs of the total programme were about 6900,000. The 800 large-scale 
and recurring interventions accounted for 95% of the costs, while the 200 small-
scale and non-recurrent interventions accounted for the remaining 5%. 
The three most expensive interventions - 'Exercise TV', Tasty and Healthy' and 
'Focus on Heart and Sports' - accounted for 45% of the costs. Because of the 
high costs incurred, it would be of great interest to assess the effectiveness of 
these interventions. However, the large number of interventions performed 
simultaneously within the Hartslag Limburg campaign makes it impossible to 
measure the effects of individual interventions. 
The present methodology has some major advantages over those used in 
previous studies in this field, in terms of validity, reliability, generalisability and 
health promotion practice. 
Validity: The costs were calculated according the societal perspective presented 
in chapter three of this thesis when possible. The accuracy with which the costs 
were calculated by using a bottom-up procedure based on necessary 
resources, instead of the specific resources used in Hartslag Limburg, improved 
the validity compared to previous studies. Previous attempts to calculate costs 
of community programmes were based on retrospectively analysing a 
programme's financial records. This can lead to considerable bias, because 
community programmes are often endowed with large contributions (monetary 
or in kind) by other agencies or organisations, which are often not incorporated 
in the coordinating agency's financial records and as a result are easily 
overlooked. Input from volunteers, which was included in the present study, is 
usually not shown in financial records either. 
Reliability: The bottom-up procedure we used ensured that all relevant costs 
were included in the analysis, making the cost-calculation more reliable than 
previous studies. Unlike previous studies, which used a retrospective design, 
the present cost calculation was made during the implementation of the 
Hartslag Limburg interventions, decreasing the degree of bias. Another aspect 
that contributed to the reproducibility of our results is that efforts were made to 
detach the costs from the local context, for example by using average salaries 
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large-scale community intervention programme, using the necessary material 
and staff input for every single intervention as a starting point and applying 
guidelines for economic evaluation. 
The costs of the total programme were about 6900,000. The 800 large-scale 
and recurring interventions accounted for 95% of the costs, while the 200 small-
scale and non-recurrent interventions accounted for the remaining 5%. 
The three most expensive interventions - 'Exercise TV1, 'Tasty and Healthy' and 
'Focus on Heart and Sports' - accounted for 45% of the costs. Because of the 
high costs incurred, it would be of great interest to assess the effectiveness of 
these interventions. However, the large number of interventions performed 
simultaneously within the Hartslag Limburg campaign makes it impossible to 
measure the effects of individual interventions. 
The present methodology has some major advantages over those used in 
previous studies in this field, in terms of validity, reliability, generalisability and 
health promotion practice. 
Validity: The costs were calculated according the societal perspective presented 
in chapter three of this thesis when possible. The accuracy with which the costs 
were calculated by using a bottom-up procedure based on necessary 
resources, instead of the specific resources used in Hartslag Limburg, improved 
the validity compared to previous studies. Previous attempts to calculate costs 
of community programmes were based on retrospectively analysing a 
programme's financial records. This can lead to considerable bias, because 
community programmes are often endowed with large contributions (monetary 
or in kind) by other agencies or organisations, which are often not incorporated 
in the coordinating agency's financial records and as a result are easily 
overlooked. Input from volunteers, which was included in the present study, is 
usually not shown in financial records either. 
Reliability: The bottom-up procedure we used ensured that all relevant costs 
were included in the analysis, making the cost-calculation more reliable than 
previous studies. Unlike previous studies, which used a retrospective design, 
the present cost calculation was made during the implementation of the 
Hartslag Limburg interventions, decreasing the degree of bias. Another aspect 
that contributed to the reproducibility of our results is that efforts were made to 
detach the costs from the local context, for example by using average salaries 
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for particular task levels instead of using the actual salaries paid within the 
campaign we studied. 
Generalisabilitv: Using average price levels instead of the actual price levels 
used within the Hartslag Limburg campaign makes the costs applicable to all 
parts of the Netherlands, and even to other countries with a price level 
comparable to that in the Netherlands. 
Generalisation to other countries is facilitated by the fact that we have provided 
a detailed overview of the necessary material and staff input. Generalisation is 
thus a matter of linking local prices to the necessary material and personnel 
resources (which are not expected to differ much between regions or even 
between developed countries). 
Added value for health promotion practice: The insights our study has provided 
into the resources necessary to perform lifestyle interventions facilitate 
budgeting, allowing costs to be anticipated. 
The main shortcoming of our study is that the bottom-up procedure was not 
consistently used for the 200 small-scale and non-recurring interventions, but 
that their costs were estimated from the average costs of similar interventions. 
However, since these 200 small-scale interventions accounted for only 5% of 
the total costs, the bias resulting from this adjusted cost calculation method is 
not large. 
A practical disadvantage of the present study was that applying a bottom-up 
methodology to such a complex programme is very time-consuming. 
In spite of the fact that the present study paid more attention to the external 
validity than previous studies, it must be realized that the costs of community 
programs will never be completely independent of time and place. 
As was shown in the Results section, it is possible to share the costs of such 
interventions among various parties. If such a cost-sharing approach is to be 
used in future programmes, it is important to form a network of participating 
organisations. These partners should be well informed about the goals of the 
project and the advantages for their own organisation, in order to improve 
cooperation. Effective collaboration can be promoted by the use of written 
agreements, especially when private organisations are included. The 
involvement of the partners can be enhanced by informing them about the 
progress of the programme. Furthermore, the programme should be brought to 
the attention of the public, to increase the likelihood of attracting external 
funding. This public attention can for example be achieved by using the media. 
Within Hartslag Limburg, it was the task of the project leader to create, maintain 
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and expand the network of partners. It is highly recommendable for future 
programmes to also appoint a person who can execute this task on a full-time 
basis. To give an indication of the staffing involved: the Hartslag Limburg 
coordinating agency invested an annual staff input of at least 1.5 full time 
equivalents (including a project coordinator, a health educator and a public 
relations coordinator). 
The main question that remains is whether spending money on programmes 
like Hartslag Limburg is useful. This question can only be answered by relating 
the costs of the programme to its effects. Schuit et al. (in press) have already 
analysed the overall effects of the Hartslag Limburg campaign, and their 
findings are promising: the community part of the campaign seems to have 
succeeded in reducing the age- and time-related increase in body weight and 
blood pressure among the community.23 
Whether the effects of a community intervention like Hartslag Limburg will 
outweigh its costs will be addressed in the following chapter of the thesis. 
Conclusions 
The costs of the interventions of the community programme of the Hartslag 
Limburg campaign were calculated to be €900,000. Because the costs of all 
interventions were calculated separately, using a bottom-up procedure, our 
results should provide valuable information to health promotion specialists and 
policy makers. Furthermore, the methodology used improves the validity and 
reliability compared to previous studies in this field and it makes it easy to 
generalise the costs to other settings and countries. 
This study further shows that the costs do not have to be borne by one agency. 
Cost sharing can be achieved by means of funding, subsidies and sponsoring. 
These can be regarded as valuable potential sources of funding. A network is 
required, however, to successfully implement a large-scale set of interventions 
like Hartslag Limburg. 
Finally, contrary to previous studies, the present study calculated the costs 
according to guidelines for economic evaluation. This means that costs can 
easily be related to the effects of the intervention to calculate a cost-
effectiveness ratio, which can be used for decision-making at macro-level. 
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Abstract 
Up to now little is known about the cost-effectiveness of community programs to 
prevent cardiovascular diseases. The objective of the present study is to 
calculate the cost-effectiveness ratio of the 'Hartslag Limburg' Community Heart 
Health Program. The costs were calculated following economic guidelines. The 
intermediate effects (cholesterol level, blood pressure and the prevalence of 
smoking) were assessed at baseline and after five years of the intervention in a 
cohort of persons living in the intervention area and in a cohort of persons living 
in a comparable non-intervention area. To extrapolate the intermediate results 
into the number of years of life saved over a period of 5 years, a Markov-type 
multi-state transition model was used. Both costs and effects were discounted 
at a 4% rate in the baseline analysis. A sensitivity analysis was performed to 
assess the robustness of the results. In the base case analysis, Hartslag 
Limburg led to 108 yols. The costs of the intervention were estimated to be 
€1.350.000. The saved health care costs within the 5 years following the 
intervention are estimated to be €950.000. A conservative base-case scenario 
was chosen, resulting in a cost-effectiveness ratio (excluding saved health care 
costs) of €12,500, ranging from €950 to about €16,500 in the sensitivity 
analysis. Based on these results, it can be concluded that a program such as 
'Hartslag Limburg' seems to be a cost-effective tool to decrease the prevalence 
of cardiovascular diseases, even under conservative assumptions. 
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Background 
Many countries, who have adapted the Western life style, have a very high 
prevalence of cardiovascular diseases (CVD)s.1 In the Netherlands, more that a 
million persons suffer from CVD,2 corresponding to 8% of the adult population. 
Like in most other West-European countries - CVDs are the most important 
cause of death in the Netherlands: 35% of all deaths can be attributed to CVD 
each year.1 3 Therefore reducing the prevalence of CVD would imply a great 
improvement to public health. 
Because of this high prevalence, CVDs lead to high costs. In the Netherlands, 
the 2003 medical expensed for CVD were G5.3 billion,4 corresponding to almost 
10% of the total Dutch health care costs. 
Improving risk factors for cardiovascular diseases may reduce the burden that 
CVDs impose on public health and on the health care budget. There is evidence 
that community programs to prevent CVDs may improve cardiovascular health.5 
6 7 The limited health care budget, however, means that choices have to be 
made about the interventions to be implemented. Such choices can be 
facilitated by cost-effectiveness analyses. 
Although cost-effectiveness information is available about curative interventions 
in the field of cardiovascular diseases, little is known about the cost-
effectiveness of community-wide health education programs to prevent CVDs. 
Several reasons for this lack of knowledge can be identified. 
First, only a limited number of studies have been performed in this area.89101112 
1314 is 16 r e a s o n f o r this may well be that it is rather difficult to perform 
economic evaluations of community programs to improve healthy behavior: (1) 
material and staffing input have to be monitored carefully during the whole study 
period, (2) effects are difficult to assess because no experimental design can be 
applied and because the process of change may require a long time, and (3) 
intermediate effects have to be extrapolated to years of life saved (yols) - which 
requires detailed knowledge about relative risks and modeling. 
Second, the studies of the cost-effectiveness of interventions to prevent CVDs 
that have been performed so far did not calculate the cost-effectiveness 
according to economic guidelines, which limits the interpretability of the results. 
In chapter two of this thesis we highlighted the imperfections encountered in the 
cost-calculation of, for instance, community programs for the prevention of 
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CVDs.17 18 The most important shortcomings were that (1) cost calculations 
were performed from the viewpoint of the coordinating agency, rather than from 
a societal point of view;8 910111215 (2) the inclusion of irrelevant cost categories 
or the exclusion of relevant ones (e.g. the input of volunteers);9111215 and (3) 
the use of non-transparent methodologies.8121416 
Furthermore, most of the studies failed to include a control population when 
measuring effects. In some cases, effects were presented in intermediate end 
points instead of in terms of years of life saved (yols) or quality adjusted life 
w ^ ™ / „ „ i , 9 13 14 15 
years (qaly). 
The current study calculated the cost-effectiveness ratio for the 'Hartslag 
Limburg' Community Heart Health Program, in accordance with guidelines for 
economic evaluation wherever possible. 
A previous study, presented in chapter seven of this thesis, already presented 
the economic costs of the community programme of Hartslag Limburg.19 
Although insight into the costs of a community programme is important for 
budgeting purposes, it does not provide information on whether the costs of a 
community programme like Hartslag Limburg outweigh its effects. 
The current study constitutes an advance over the previous study, because it 
provides insight into the efficiency of a community programme like Hartslag 
Limburg and can thus be used for decision-making at macro level. 
Methods 
Intervention 
The Hartslag Limburg community program aims at health promotion among all 
inhabitants of the intervention region, consisting of the city of Maastricht and 4 
adjacent municipalities (n=l80,000). Special attention was paid to inhabitants of 
4 low socio-economic status (LSES) neighborhoods (n=20,000) situated in the 
town of Maastricht. For the implementation of the program a unique design was 
used, through a network of organizations. The Regional Public Health Institute 
(GGD) of Maastricht coordinated the program. It was joined by a large number 
of other agencies, including health promotion agencies, the local hospital, 
general practitioners, welfare services, and local authorities. The large number 
of participating organizations made it possible to implement a multiple 
intervention strategy and to reach inhabitants of the region in a variety of ways. 
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About 800 interventions were implemented over a 5-year period, (e.g. a TV-
program providing aerobic lessons; guides containing walking routes; regular 
sports activities; small scale guides through supermarkets to teach persons 
about healthy food; healthy cooking lessons; discussion evenings about healthy 
food; radio commercials; food labeling in a butchers shop etc). 
For a more detailed description of the Hartslag Limburg program, see Ruland et 
al. (1999) and Ronckers et al. (2006).19 20 
Estimation of the costs 
The costs were calculated by following the guidelines for economic evaluation 
as closely as possible. Contrary to the guidelines of Gold et al. (1996) and 
Drummond et al. (1997) who advise a 3% discount-rate,2122 we used a discount 
rate of 4% according to Dutch guidelines.23 The analysis included the costs of 
the program itself and the costs of building and maintaining a network. In the 
sensitivity analysis also the health care costs saved by improved health were 
included. 
Costs of the program 
The cost calculation of the program has been described in the previous chapter, 
but we present a brief description of the procedure here. 
The aim was to calculate the costs according to guidelines for economic 
evaluation, in such a way that the costs could easily be generalized to other 
regions. The costs of the program were estimated using a bottom-up procedure, 
taking necessary input to perform the individual interventions as a starting point 
instead of the actual expenditures incurred by the coordinating agency. From an 
economic point of view, the time input by participants should also be included. 
However, because we lacked the necessary data to do this, the current analysis 
does not include this. 
First, for every single intervention, a list was drawn up of all the material and 
staffing input necessary to perform the intervention. Input that was not directly 
paid for (e.g. the input by volunteers) was also included. We then attached 
volume components to each intervention component. To ensure generalizability, 
an efficient use of material and staffing input was assumed, instead of using the 
exact input within the Hartslag Limburg program. In the third and final step, 
intervention costs were valued, based on Dutch costs for the year 2003.23 
Not all of the costs incurred for the programme were relevant to the current cost 
calculation. For example, a number of interventions were developed during the 
programme, leading to so-called development costs. Development costs 
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incurred within the programme will not have to be paid again when the 
intervention is applied elsewhere, nor will future implementers have to pay 
indirectly for the development costs. These costs were therefore excluded from 
the analysis. In a previous article, an indication of the development costs was 
provided.19 
Costs of building and maintaining the network 
One of the characteristics of Hartslag Limburg is the use of a large network of 
contributing parties. Since the costs of creating, maintaining and expanding the 
network depend very much on the existing regional cooperation between 
agencies, they are expected to differ between regions. For the current cost-
analysis, the investments by the coordinating agency were used in the baseline 
analysis as an estimate of the network costs. 
Health care costs saved 
The chronic disease model (explained below) is able to predict the number and 
types of cardiovascular cases that will be prevented. The diseases incorporated 
in the model for the present calculation were acute myocardial infarction, 
coronary heart disease, heart failure, cerebrovascular accident and diabetes 
mellitus. The health care costs saved were estimated using the available 
information about the number of cases of these diseases that were prevented, 
in combination with the costs related to these diseases. The disease costs were 
derived from a Dutch }cos\s of diseases' study.4 
Calculation of the benefits of the campaign 
Reliable estimates of the effects of the campaign were obtained by measuring 
biomedical parameters (body mass index, cholesterol, and blood pressure), at 
baseline and after 5 years of intervention, in a cohort of inhabitants of both the 
intervention region (N = 3000) and a control region (N = 1000). The control 
region was carefully selected so as to be comparable to the intervention region 
in terms of the prevalence of CVDs, the degree of urbanization and the age 
structure of the population. 
Both groups were selected from an existing cohort of people participating in a 
monitoring project for CVDs. 
The long-term benefits in terms of yols were calculated using the chronic 
disease model (CDM). With this model, the public health gain over a period of 5 
years (resulting from the intervention) was calculated. 
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The CDM is a dynamic multistate lifetabie model and it describes the life course 
of parallel Dutch population cohorts. The model is described in detail by 
Hoogenveen et al.. (1998).24 
The CDM consists of a demographic module that is linked to several disease 
specific modules. The population is distributed over a number of risk factor 
classes and diseases states, specified for gender and age. Risk factor classes 
used in our study are blood pressure and cholesterol level (low - normal - high -
very high), and BMI (low - normal - high). 
The demographic module describes the annual changes of total population 
numbers due to birth, mortality, migration and aging and changes of risk factor 
class prevalence numbers in the form of transitions between the classes. The 
disease specific modules are epidemiological models that describe the annual 
changes of disease prevalence numbers due to disease incidence and mortality 
of several chronic diseases. Risk factor class specifies disease incidence risks. 
The disease modules thus describe the morbidity and mortality numbers over 
time for specific disease categories. Disease states used in our study are acute 
myocardial infarction, coronary heart failure, cerebrovascular accident, other 
coronary heart disease and diabetes mellitus (all: with - without disease). 
All transition rates between risk factor classes and disease incidence and 
mortality rates are based on epidemiological data, which are described in 
(Hoogenveen et al. 2000).25 
When estimating mortality, the model takes account of competing death risks by 
distinguishing cause-specific mortality risks. 
The model has the Markov-property, which means that the risk factor classes 
and health states one year ahead are only dependent on the current distribution 
of persons over risk factor classes and states: the model does not take into 
account past risk factor classes or health states. This implies for example that 
persons grouped into the same risk factor level (e.g. high blood pressure) have 
the same probability on a CVD, independent of their past risk factor profile. 
Furthermore, the model is based on the assumption of conditional 
independence. That means, that conditional on age, sex and risk factors 
disease incidence rates are assumed conditionally independent. E.g., COPD 
and lung cancer rates are assumed independent for given smoking status. In 
case of so-called intermediate diseases such as diabetes the conditional 
independence structure is built hierarchically. Intermediate diseases are both 
dependent on risk factors such as obesity, and independent risk factors for 
other diseases such as CHD. 
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In the current calculation concerning the long-term effects of Hartslag Limburg 
in terms of yols, empirical findings about the risk factor prevalence in the 
intervention region and the control region were used as input into the model. 
The input into the risk factor classes of the CDM was thus adjusted to the real-
life situation at the end of the Hartslag Limburg program. Two scenarios were 
simulated, one representing the situation with Hartslag Limburg, the other 
representing the situation without a program like Hartslag Limburg. Concretely 
this means that within the intervention scenario, fewer persons were grouped 
into the classes 'high' or Very high' blood pressure, cholesterol and BMI than 
was the case within the control scenario. Transition probabilities between all risk 
factor classes were assumed to be the same for persons from the intervention 
region and persons from the control region. 
Using this information, the CDM calculated the incidence and prevalence of 
CVDs and provided disease specific mortality figures during a period of 5 years 
within the two scenarios. Based on these data, the numbers of yols gained and 
the saved health care costs were calculated. Obviously, the difference in 
outcome between these scenarios represents an estimation of the long-term 
effects of Hartslag Limburg. 
An important assumption made within the calculation of the CE-ratios, is that 
only the changes in yols and saved health care costs within the 5-year follow-up 
period were taken into account. This means that a death prevented can lead to 
maximum 5 yols, and the health care costs saved only reflect those costs that 
are prevented within these 5 years. The absence of a life-time horizon implies 
that the calculated CE-ratios are very conservative estimates. 
In the base case scenario, the yols were discounted by 4% from the year the 
savings took place, in accordance with Dutch guidelines for economic 
evaluation.23 
Obviously, the difference in outcome between these scenarios represents an 
estimation of the long-term effects of Hartslag Limburg. 
Sensitivity analysis 
The base case scenario included the intervention costs and network costs. Both 
costs and effects were discounted with four percent. Contrary to most previous 
studies and with the aim to present very conservative CE estimates, the base 
case scenario excluded saved cardiovascular health care costs. For the same 
reason of conservativeness, only the effects that occurred during the five-year 
period following the intervention were included into the analysis. 
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Keeping all other variables constant, the input variables were manipulated one 
by one. 
First, we examined the effects of different discount rates: in addition to the 4% 
baseline discount rate, we applied a 0% and a 6% discount rate. 
Next, the effects on the cost-effectiveness ratio of a 10% decrease in the 
effectiveness of the intervention were calculated. 
Since the costs of creating and maintaining a network are likely to differ in other 
regions, we examined the effects of doubling these costs on the cost-
effectiveness ratio. 
Another manipulation undertaken in the sensitivity analysis involved calculating 
the cost-effectiveness after including the health care costs saved. 
The base case scenario assumed that the effects of the campaign would last for 
a period of 5 years. Because little is known about the duration of the effects of a 
community program like Hartslag Limburg, we also calculated the CE-ratio 
under the condition of 10 and 20 years duration of the effect. Because it might 
be unrealistic to assume the effects to be constant over a period of 10 to 20 
years without additional input during this time period, we also calculated the CE 
under the assumption that the intervention would have to be continued during 
the respectively 10 and 20 years in order to maintain its effects. 
Results 
Costs 
The baseline cost-effectiveness ratio will be based on the costs of executing the 
program and the costs of building and maintaining the network. For 
completeness, the health care costs that might be saved in the future due to the 
decreased prevalence of CVD are also presented in this section. 
Costs of the program 
The total economic costs of the interventions performed within the 5-year lasting 
community program on CVD 'Hartslag Limburg1 were estimated to be €0.9 
million. A detailed description of the costs has been presented elsewhere.19  
Costs of building and maintaining the network 
The coordinating agency invested an annual staffing input of 1.5 FTEs 
(including a project coordinator, a health educator and a public relations 
coordinator). This meant that a total amount of at least G90,000 each year 
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(6450,000 over 5 years) was spent by the coordinating agency to maintain the 
program's network. 
Health care costs saved 
The health care costs saved as a result of a decrease in the incidence of acute 
myocardial infarction, coronary heart disease, coronary heart failure, 
cerebrovascular accident and diabetes mellitus - discounted at 4% - were 
about £636.000 for men and £316.000 for women within the 5 years following 
the intervention. Thus, the total health care savings, discounted at 4%, were 
about G950.000 during the 5-year time period following Hartslag Limburg. 
Benefits of the campaign 
The intermediate effects in terms of reductions in cholesterol level, blood 
pressure, body mass index, and smoking were assessed by means of a 
regression analysis. The major effects are described in detail elsewhere.26 
In general, hartslag Limburg succeeded in reducing and in some cases even 
preventing the age and time related increases in body mass index, waist 
circumference, and blood pressure. The change in risk factors in the control 
group was according to our anticipation, except the increase in blood pressure, 
which was much higher than measured in earlier cohort groups (from which 
data happened to be available). Therefore we believe that the reference group 
may not be fully representative with respect to this parameter. 
Furthermore, for the purpose of extrapolating the intermediate results into yols, 
large research groups and representative results are of crucial importance. The 
originally selected control population was too small for reliable estimations 
regarding yols. Since we had information about change in risk factors over 5 
years in previous cohort groups (1997-2002 and 1996-2001) we decided to 
enlarge the reference group with subjects from these previous cohort years, 
making the results more representative. 
Using three cohort-years as a control group led to the following results: The 
difference between the intervention and control group in body mass index, 
blood pressure and cholesterol levels was -0,32 kg/m2, -0,03 mmHg and -0,10 
mmol/l in favour of the intervention group. 
This led to 108 years of life saved during 5 years following the intervention, 
discounted at a 4% rate. 
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Cost-effectiveness 
The baseline cost-effectiveness ratio (5-year horizon, 4% discount rate, and the 
costs of 5-year campaign) was €12,500 per yols. 
Again we stress the conservativeness of the estimation, following from the fact 
that only the yols within the 5 years following Hartslag Limburg were taken into 
account and the saved health care costs were excluded. 
Keeping all other variables constant, we varied the input in several ways. Table 
1 provides an overview of the scenarios, together with the corresponding CE 
ratios. Due to our conservative point of view, the saved health care costs in 
future due to decreased CVD is only included into the cost-effectiveness ratio 
that represents best case scenario. In all other cases, these costs are excluded. 
Without discounting, the CE ratio was estimated to be €10,800 per yols, while a 
6% discount rate resulted in a CE ratio of €13,366 per yols. 
If the effects of the intervention had been 10% smaller than was observed in the 
present study, the CE-ratio would be €13,917. 
Table 1: Cost-effectiveness ratios in relation to different assumptions about 
costs, effects and discount-rates. 
scenario discount rate discount interven- costs for saved health yols CE-ratio 
costs ( ;%) rate tion costs network care costs (€per 
effects (%) (€) (€) (€) yols) 
baseline 4 4 900.000 450.000 0 108 12.500 
no discounting 0 0 900.000 450.000 0 125 10.800 
discounting 6% 6 6 900.000 450.000 0 101 13.366 
effects 10% smaller 4 4 900.000 450.000 0 97 13.917 
inclusion saved costs 4 4 900.000 450.000 952.475 108 3.681 
double network costs 4 4 900.000 900.000 0 108 16.666 
horizon 10 years 4 4 900.000 450.000 0 418 3.230 
horizon 10 years, 
plus 10 year 
extension of costs 4 4 2.418.360 1.209.180 0 418 8.678 
horizon 20 years 4 4 900.000 450.000 0 1421 950 
horizon 20 years, 
plus 20 years 
extension of costs 4 4 3.444.109 1.722,055 0 1421 3,635 
If the costs of creating and maintaining the network were twice as high as in the 
baseline estimation, the cost-effectiveness ratio would be €16,666 per yols. 
The Hartslag Limburg community intervention became highly cost-effective if 
the health care costs saved were included, namely €3,681 per yols. 
Using the more positive assumptions that the intervention would be effective for 
10 or 20 years, the CE-ratios decreased to €3,320 and €950 respectively. Even 
if the program would have to be continued to the same extent (and thus against 
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the same costs) for the 10- or 20-year follow-up period to maintain its effects, 
the cost-effectiveness would be more favorable than the base case scenario, 
namely €8,678 for a 10 year extension of the program and €3,635 for a 20-year 
extension of the program. 
Discussion 
The cost-effectiveness of a large-scale, multifactor community program for 
CVDs was estimated. The evaluated program differed from earlier community 
programs in that a network of participating organizations, thus approaching the 
inhabitants of the intervention region in different ways, implemented it. 
Furthermore, a great deal of effort was put into stimulating healthy behavior 
among persons with a low socio-economic status. 
When estimating the CE-ratio of Hartslag Limburg, conservative starting points 
were chosen. First, it was assumed that the effects of Hartslag Limburg would 
be completely absent after 5 years of follow-up. Furthermore, only those costs 
and effects that occurred during the follow-up period were taken into account. 
This means for example that the prevention of a cardiovascular event in a 40-
year-old male in the fourth year of follow-up only leads to one yols in the base 
case scenario. This is certainly an underestimation of the actual effect. In a real 
life situation the prevention of a death of a 40-year old male in the fourth year of 
follow-up would lead more yols. Assuming males have a life expectancy of 75 
years, the total number of yols could be as high as 35. Finally, saved health 
care costs are excluded from the analysis. Their effects on the CE-ratio is only 
examined in one scenario. Including saved health care costs drastically 
decreases the CE-ratio, making a program like Hartslag Limburg far more 
favorable to implement. 
Even under the conservative assumptions used, the cost-effectiveness ratio of 
the program was €12,500, ranging from €3,230 to €16,666 in the sensitivity 
analysis. This is below the acceptable CE ratio of €18,000 that is often used in 
the Netherlands. The CE-ratios of all but one scenario are also below the 
tentative international ceiling for CE ratios (€15,000 - €75,000).27 28 A 
community program for CVDs like Hartslag Limburg thus seems to be cost-
effective, even under very conservative assumptions. 
A more detailed look at the results reveals that continued investment to prevent 
relapse for a long period of time (e.g. 10 or 20 years) after a community 
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program like Hartslag Limburg had stopped might be more favorable to do, than 
to provide a program once for a fixed period of time and then stop all 
investments. This can be concluded from the CE-ratios calculated within the 
different scenarios, which show that the CE-ratio when providing Hartslag 
Limburg once, assuming the effects to maintain for 5 years, is far less favorable 
than the CE-ratio when it is assumed that investments would be made to 
prevent relapse for an additional 10 years or 20 years. The CE-ratio drops from 
€12,500 in the base case scenario to €8,678 or even €3,635 under the 
assumption that the same yearly costs have continued to be made for relapse 
prevention during the 10 or 20 years following Hartslag Limburg to maintain its 
effects. This can be explained by the preventative nature of Hartslag Limburg. 
The deaths prevented are not evenly distributed among the years following the 
intervention: only few deaths will prevented in the first years after the 
intervention, while a relatively large number of diseases and thus deaths can be 
prevented if behavioral change is still present in far future. The same yearly 
financial investments will thus lead to an increasing number of yols per year 
when time passes. Investments to prevent relapse may thus be highly favorable 
due to this phenomenon. This is of course especially true when early relapse 
would occur. In the current analysis, we assumed that relapse prevention would 
be as expensive as performing a community program. This also seems to be a 
conservative premise. It is thus not unrealistic to expect even more favourable 
CE-ratios under the assumptions of longer follow-up periods combined with 
continued financial investments. 
An additional advantage of investing in relapse prevention is that the effects 
might not be limited to the original cohort (the target population at the start of 
the intervention period), but that other persons entering the region or target 
population also benefit from the intervention, increasing the campaign's impact 
However, even when a program like Hartslag Limburg would be completely 
discontinued, its effects would be gone after 5 years, only those yols that can 
actually be observed during the 5-year follow-up period are included, and saved 
health care costs are excluded, Hartslag Limburg turned out to be cost-
effective. 
The present study had a number of advantages over previous studies. First, 
contrary to most previous studies, the cost-effectiveness was calculated from 
the societal perspective where possible, producing CE-ratio's that are 
applicable to macro-level decision making. In addition, the resulting cost 
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estimation can be generalized to other settings and countries. Finally, there was 
a control group available, allowing the effects of the program to be estimated. 
Despite these advantages, the study had some limitations too. One of the 
imperfections was that the effects of the intervention were assessed using 
groups composed of persons from an existing cohort. This means that we may 
have measured the effectiveness of the intervention in a specific group of 
persons instead of a random sample of the population. The persons included in 
the study were motivated to participate in scientific research and might be more 
concerned with their health than a random sample of the population. 
Consequently, the effects might not be generalizable in that sense. 
Almost 50% of the Hartslag Limburg interventions were performed in the 4 
LSES areas, which comprise 20,000 inhabitants. It is not known whether our 
study population included persons from these areas. If this was not the case, 
this might have caused an underestimation of the effects of Hartslag Limburg. 
Results of an earlier study on the effects of Hartslag Limburg indicate, however, 
that there were no differences in effects between persons with a low SES and 
persons with a high SES.26 However, there is no information available whether 
the LSES persons included into the research groups were also living in the 
LSES neighborhoods prioritized by Hartslag Limburg. 
Besides the above uncertainties regarding the research group, which might 
affect the final effects and thus the cost-effectiveness ratio, the assumptions 
used in the chronic disease model - which was used to extrapolate the 
intermediate effects to yols - may have influenced the calculated CE ratio. For 
example, we assumed a cumulative effect of CVD risk factors on cardiovascular 
health and death. It is well known, however, that CVD risk factors have an 
exponential effect on CVD health. This also means that the effects - and thus 
the cost-effectiveness - of Hartslag Limburg may have been underestimated. 
As was discussed earlier in this section, constricting the time horizon to the 
follow-up time, also leads to conservative estimates of CE-ratios. 
Conclusions 
From the present study it can be concluded that the community program of 
'Hartslag Limburg' is cost-effective, even under conservative assumptions. 
Implementation of the program seems thus to be favorable, at least from an 
economic point of view. 
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Introduction 
The subject of this thesis is the economic evaluation of preventive interventions 
for cardiovascular diseases (CVD)s. The thesis (1) provides insight into 
methodological issues related to cost-effectiveness analysis of preventive 
interventions, (2) reports on the costs, effects, and cost-effectiveness of the 
CVD prevention programmes of Hartslag Limburg, and (3) critically examines 
one of the assumptions often made, namely that targeting LSES groups is most 
efficient because of the high potential health gain among these groups. 
This chapter summarizes the main findings of the individual studies and draws 
general conclusions. Then we take a critical look at the methods used for the 
calculation of the costs, the effects, and the cost-effectiveness because the 
methodology used influences the internal and external validity of the results. 
The role of reviews in the collection of evidence of cost-effectiveness is also 
discussed. 
Besides the methodology, the characteristics of the intervention and the specific 
choices made in the carrying out of the Hartslag Limburg programmes are 
expected to have influenced the outcome of the economic evaluation. This is 
especially true for the Hartslag Limburg community programme because of its 
complex and innovative design. The fourth section of this chapter describes 
some important choices made during the Hartslag Limburg programme and 
considers the effects that these choices are expected to have on the resulting 
cost-effectiveness ratio. 
* 
We conclude the chapter by elaborating on the expected influence of the study 
outcomes on policy-making. This is a relevant question because economic 
evaluation research attempts to facilitate decision-making, but is not 
independent within the decision-making process. 
Summary of the main findings 
Although guidelines for economic evaluation research are important for drawing 
firm conclusions from economic evaluation studies, it can be concluded from the 
present thesis that those studying cost-effectiveness in the field of prevention 
(Chapter 2) often do not adhere to the guidelines. It was also concluded that 
neglecting these guidelines could result in a large bias in the cost-effectiveness 
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ratio (Chapter 3). The bias gives a systematic increase of the cost-
effectiveness. In order to prevent bias resulting from not applying the methods 
correctly, the present study adhered to the guidelines for economic evaluation 
research whenever possible. In Chapter 7, the costs of the Hartslag Limburg 
community programme are calculated according to the guidelines for cost 
calculation. The recommended bottom-up procedure is used to calculate the 
costs of the interventions within the community programme, which are about 
€0.9 million. In Chapter 8, the cost-effectiveness ratio was calculated to be in 
the range of €950 to €12,500 per yols. Thus it was concluded that community 
programmes like Hartslag Limburg's are quite favourable, even in the light of 
conservative assumptions. The result is positive in spite of the fact that the 
Hartslag Limburg community programme focussed on neighbourhoods with low 
socio-economic status, which might not have been the most preferred option 
from an economic point of view, as Chapter 4 shows. 
We tried to evaluate the effects of one of the most expensive interventions 
within the Hartslag Limburg community programme separately, namely the 
Tasty and Healthy' intervention, which took place in a butcher shop. The 
effectiveness of the intervention, which consisted of labelling low-fat meat 
products and providing health education in the shops, could not be proven 
(chapter 6). 
The Hartslag Limburg high-risk programmes do not receive as much attention in 
this thesis as the community programme does because previous studies do not 
find effects on behavioural or biomedical parameters. Calculating the cost-
effectiveness ratio of the high-risk programmes only seemed important if the 
programmes were effective in terms of improving the quality of life. We 
evaluated the effects of the high-risk programmes on the quality of life in 
chapter 5, but as they could not be proven definitely, we did not consider an 
economic evaluation informative. 
Methodological considerations 
A variety of research methods were used for this thesis. The strengths and 
weaknesses of these methods are discussed here. The main points of the 
discussion of the methods are their influences on the internal and external 
validity of the study outcomes. We consider the methods used to establish the 
effectiveness, the methods used to calculate the costs, the methodology of 
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extrapolating intermediate effectiveness to years of lives saved (yols), and the 
innovative approach for reviewing cost-effectiveness studies of interventions to 
decrease the prevalence of smoking. 
Validity aspects of the methods used to establish effectiveness 
The use of a randomized, controlled trial to establish effectiveness in the 
Hartslag Limburo's secondary prevention trial 
We evaluated the effects within the secondary prevention trial with the 
randomised controlled trial (RCT), which is the 'gold standard' in medicine 
because of its high internal validity.12 3 Only one condition for the RCT was not 
met: blinding of patients was impossible because the intervention took place in 
the behavioural sphere and a good placebo intervention could not be provided. 
The awareness of patients about their own condition (intervention or control) 
threatens the internal validity in two ways. First, it might lead to greater 
compliance in the intervention group than in the control group. In the present 
study, however, dropout was equal in both study groups. Second, patient 
awareness in combination with an often-occurring preference for being 
assigned to the intervention group instead of the control group might have 
influenced the outcome measure (in our case: self-rated quality of life). It is not 
very likely that this occurred in the present study because no significant 
differences between the intervention group and the control group were 
observed. 
For the aim of the current thesis, which is to facilitate decision-making for a 
large population, a high degree of generalizability of the results is required.1234 
The drawback of the unquestionable internal validity of RCT designs, however, 
is that their external validity is often doubtful. In order to obtain unquestionably 
valid internal results, RCT designs are very experimental and do not represent 
the real-world situation very well.15 
Within the Hartslag Limburg secondary prevention trial, the blinding of the 
cardiologists prevented them from encouraging the patients to change their 
behaviour, something which they would probably do in a real-world situation, 
and which would increase the effectiveness of the intervention. 
As in most RCTs, a selected group of cardiologists performed the intervention, 
which took place within a patient population that did not fully represent the 
target population.15 
The small number of cardiologists who participated in the study was probably 
due to the degree of belief and interest in the study as well as time 
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constraints.1"5 The low degree of representation of the patient population in 
RCTs is generally due to (1) the strict inclusion and exclusion criteria, (2) the 
fact that not all eligible patients give informed consent for participation, and (3) 
dropouts, selective or not.15 
Within Hartslag Limburg, the use of strict inclusion criteria is probably the most 
important reason for the doubtful external validity of the study results. The 
intervention was available to all the patients who had recently suffered a 
cardiovascular event, in spite of the fact that most physicians (who refer the 
patients to the intervention) were of the opinion that the intervention would 
benefit only a subgroup of these patients. In a real-world situation, only this 
subgroup is expected to receive the intervention, and the results of the present 
study can only be generalized with caution. 
As in almost all studies, not all the eligible patients gave informed consent. The 
percentage of patients that did not enter the study is not known, but the 
physicians who asked people to join the study reported a high rate of inclusion. 
About 20 percent of the participants dropped out during the study, but this was 
not selective. 
The external validity of the primary and secondary prevention trial designs is 
especially problematic because the intervention is not in the biomedical sphere, 
but the behavioural. Outcomes of behavioural interventions depend to a much 
greater extent than those of biomedical interventions on characteristics of the 
patients and caregivers, such as the attitude towards the intervention and 
capacities.126 
Those who participate to studies that aim at changing behaviour are likely to be 
more receptive to the intervention than persons who do not because they are 
likely to have a more positive attitude towards the intervention. The same is true 
for caregivers: those with a more positive attitude will participate in the study 
and promote the intervention enthusiastically. Furthermore, the quality of 
behavioural interventions, and thus their effectiveness, depends on the capacity 
of the person who is giving the care. 
The use of a cluster randomized controlled trial to establish effectiveness in the 
primary prevention trial. 
The primary prevention trial was in most aspects identical to the secondary 
prevention trial, and the remarks also apply to the primary prevention trial. 
There were two differences between the designs. The effects of the primary 
prevention trial were assessed within a cluster RCT, and the physicians were 
not blinded in the primary prevention trial. 
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The cluster RCT was used in order to prevent contamination between patients 
with the same general practitioner (GP). Not blinding the GPs approximates the 
real-world situation better because GPs can provide additional support for 
healthy behaviour to patients who receive health counselling. 
The use of a cohort study to establish effectiveness of the Hartslag Limburg 
community programme 
The Hartslag Limburg community programme was evaluated in a 
nonexperimental, real-world setting and can thus be described as a pragmatic 
trial.7 Within this community programme, a cohort study with a comparison 
group was used to study the effectiveness of the programme. An RCT design 
was not used because this design cannot accommodate the flexibility and the 
large scale of community programmes.8 9Randomization cannot be achieved 
because not everybody has the same chance of receiving the intervention. 
Cohort studies that use an adequate comparison group are the preferred option 
for evaluating the effectiveness of health promotion programmes because the 
groups are then comparable with respect to most baseline characteristics and 
the known confounding variables. 1 2 6 Blinding cannot be achieved in the 
evaluation of large-scale community programmes either. 
In spite of the use of an adequate control group, the design has its drawbacks. 
Problems with the internal validity are the most prominent in pragmatic trials. 
The nonexperimental design makes the study vulnerable to bias, which 
threatens the internal validity of the study. In spite of the fact that we used a 
comparison group that was comparable to the intervention group for prevalence 
of CVD and its risk factors, demographic variables, and the degree of 
urbanization, other unknown confounding factors might not be distributed evenly 
among the regions and may have negatively affected the internal validity. 
However, a recent study shows that the quality of well-designed observational 
studies is not necessarily worse than that of RCT-designed studies.10 
Contrary to the internal validity, the external validity of pragmatic trials is 
generally unquestionable because the evaluation takes place in a real-world 
setting. A marginal comment about the external validity of the Hartslag Limburg 
community programme must be made. The cohort that was used might not be 
representative for the general population because the participants were 
recruited from a former monitoring study. Although this might have affected the 
external validity, the comparison group also consisted of participants of a similar 
monitoring project, which means that this did not affect the internal validity of 
the study. 
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A consequence of community programmes is that the results are not completely 
independent of time and place. 6 This means that evidence of community 
programmes for preventing CVD will always be in motion. 
The use of an observational design to establish the effects of the 'Tasty and 
Healthy' intervention 
Observational designs provide weaker empirical evidence than experimental 
studies do because of the potential for large confounding biases. This is 
especially true if an adequate control group is lacking, which is the case in the 
evaluation of the Tasty and Healthy' intervention. 
The evaluation of the Tasty and Healthy' study was subject to a number of 
factors that threatened the internal and external validity of the study. They 
include the emergence of foot and mouth disease, the opening of a 
supermarket in front of the butcher shop, the owner's change of the sales policy 
during the intervention, and the nonadherence of the owner to agreements 
about the carrying out of the intervention. Furthermore, phenomena like store 
switching and purchase acceleration might have biased the results. The results 
of this study must therefore be interpreted with great caution because the 
design was far from optimal. 
There were reasons for the use of this observational design. The first is related 
to the method of working in the Hartslag Limburg project. Health promotion 
specialists implemented the programmes, and the scientific staff evaluated 
them. In spite of the fact that the health promotion specialists who implemented 
the programme interventions were encouraged to appeal to the expertise of the 
scientific staff, this did not always happen. In the case of the intervention Tasty 
and Healthy', the scientific staff only became involved in the evaluation of the 
intervention after it had already been implemented. Obviously, this prevented us 
from achieving a better study design. The preferred option would have been to 
focus on the consumption pattern of the clientele instead of on the sales of the 
butcher shop. The second reason is that, although a control population was 
available, there had been no investigation about preconditions for performing a 
sound evaluation of the effectiveness. It turned out to be practically infeasible 
for the control butchers to provide us with the necessary information for the 
evaluation, namely, the amounts of meat products sold during the last 2 years. 
Finally, firmer agreements with the owner of the butcher shop might have 
prevented a further decline in the quality of the study. 
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Validity aspects of the cost calculation of the community 
programme 
Internal validity 
Although we strove for a societal view, costs related to productivity losses and 
participant costs were not included into the costs calculation. This means that 
the internal validity is not optimal. 
Including productivity losses is useful if the research consists of a working 
population. Because of the age of both those with established CVD and those at 
risk of CVDs (i.e. Chapter 5, mean age >60), excluding productivity costs does 
not seem to affect the internal validity of the study much. 
Participant costs were not included because of lack of data. For many 
interventions, such as those for the national TV programme and radio 
commercials, it is extremely difficult to estimate the time input of the 
participants, and it is thus difficult to estimate its impact on the internal validity. 
Furthermore, we decided to exclude costs for the development of new 
interventions because costs would not have to be made if the particular 
intervention were implemented elsewhere. Looking back at Hartslag Limburg, it 
might have been more accurate to include these costs, as the choices for the 
interventions to be done cannot be determined beforehand, but depend on the 
region-specific pre-conditions to a large extent. Specific circumstances would 
thus ask for specific interventions to be developed, and for this reason, 
including development costs would have been more accurate. The development 
costs within 5 years of Hartslag Limburg accounted for only €13,000, which is 
less than 1 percent of the total costs. This means that the bias caused by not 
incorporating the development costs is small. 
In spite of these imperfections, the internal validity remains acceptable in our 
opinion. 
External validity 
It is important to have insight into the generalizability of the costs to other 
regions and countries. Because the cost calculation of the interventions was 
based on the resources necessary for successfully implementing a programme 
like that of Hartslag Limburg, the intervention costs that are calculated within 
Hartslag Limburg can be generalized to comparable regions with the same price 
level. Generalization of the intervention costs to other regions in the 
Netherlands is thus permissible. 
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When price levels differ from those in the Netherlands, generalization is slightly 
more complicated. Recent research shows that cost-effectiveness results vary 
from country to country.11 This variation is due to different price levels; resource 
use is shown to be comparable in different countries.11 The best way to 
guarantee the generalizability of the intervention costs is to give a detailed 
overview of the resource use.11 Assuming that the necessary resources and the 
effects of the intervention do not vary between countries,11 the costs can be 
generalized by linking local prices to the resource used. In this thesis, we 
applied this method to calculate the intervention costs. 
This method could not be applied to the calculation of the network costs 
because these are very dependent on the existing degree of cooperation 
between institutions in a region. The specific input within Hartslag Limburg was 
used, and although this is internally valid, the external validity is doubtful. 
Sensitivity analysis shows that variation in the network costs does not greatly 
affect the cost-effectiveness ratio. 
Healthcare costs saved because of better cardiovascular health were also 
calculated differently. For the cost savings that take place in the future, 
modelling techniques are used. These are sensitive to bias, because 
assumptions have to be made. The modelling technique used in this thesis is 
considered in the following section. 
The healthcare savings are not included in the base case analysis because the 
non-CVD healthcare costs due to living longer have been shown to undo the 
CVD healthcare savings. 
Modelling considerations 
The cost-effectiveness calculation for preventative interventions requires the 
use of modelling techniques because long-term follow up is usually not 
feasible.51213 
Recently, properties for good modelling were formulated in a consensus 
statement.14 The chronic disease model (CDM) that was used in the current 
thesis is fairly well in line with this statement.14 15 16 First, the CDM is 
transparent; Hoogenveen et al. outline it in detail.1516 Second, the model meets 
the criteria of consistency: all parameter values are consistent within the logic of 
the model, and both the structures used in the model and the data used to build 
the model are consistent with recent information.15 16 Third, an independent 
competent analyst is expected to be able to reproduce the results, which means 
that the model leads to reproducible results. Fourth, the results are expressed in 
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terms of CVD cases prevented, which can thus be used for calculating the 
years of life saved (yols) and can be interpreted easily. Fifth, the causal 
relationships included in the model are explained and substantiated by recent 
evidence. Sixth, the model is kept as simple as possible. Seventh, parameter 
uncertainty is explored. 
The CDM has some specific advantages, e.g. it combines several risk factors 
and diseases in one model.1516 Complex calculations, such as the effects on 
CVDs of changes in several risk factors occurring simultaneously, are possible. 
Another advantage of the model is the explicit modelling of 'competing risks'.15 
This means that the model takes into account that people can die of the same 
disease in a later stage or of other diseases, due to an extension of the life 
span.15 This prevents an overestimation of the effects. 
Obviously, the use of the CDM also has its disadvantages. First, as is the case 
with almost all models, historical validation is impossible17 18 because time 
series of empirical data are not available. Therefore, 'true' validity cannot be 
achieved.1718 Second, the CDM is as strong as its weakest link. Continuous 
input of high quality is thus required. To maintain and improve the quality of the 
results, the CDM is regularly updated with the latest information. Third, models 
are unable to fully represent the reality, which means that the external validity is 
not optimal.121319 Fourth, the CDM has Markov properties, which means that 
the risk of CVD is determined by the current value of the risk factor and not by 
the value of the risk factor in the past. This leads to an overestimation of the 
effect.15 For example, a decrease in body mass index in the CDM leads to a 
direct decrease in the risk of CVD. Fifth, a probabilistic sensitivity analysis is not 
possible because of the complexity of the CDM, although this is highly valued in 
the field of medical technology assessment.14 
In spite of these imperfections, the model simplifications are not expected to 
lead to a large bias. 
Reviews 
The present thesis contains two reviews: a traditional review and a more 
reflective review. The traditional review was aimed at gaining insight into the 
quality of cost-effectiveness studies. The conclusions are in line with previous 
results, namely, that guideline adherence was low. 2021 22 The disadvantage of a 
traditional review is that it does not provide insight into the magnitude of the 
bias caused by nonadherence to the guidelines. Therefore we cannot judge 
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whether guideline nonadherence is problematic. In that sense, the traditional 
review is not very informative. 
The observation from the traditional review that guidelines are often not 
adhered to means that the reviewed studies are not internally valid. If the bias is 
large, then meta-analyses for gaining insight into the effectiveness of 
interventions for larger populations 8 are not informative. Reviews that 
incorporate standardization of the results of the individual studies are then more 
useful to obtain insight into the cost-effectiveness studies of interventions for 
larger populations. This is especially true if the interventions are behavioural in 
nature. These interventions are often heterogeneous, which does not allow the 
results of the studies to be directly compared. 
Chapter 3 this thesis presents an example of a review that standardizes cost-
effectiveness ratios by recalculating the cost-effectiveness according to the 
guidelines. The outcome shows that guideline nonadherence can cause a large 
bias. We hope that showing the magnitude of the bias due to guideline 
nonadherence will contribute to improving guideline adherence for economic 
evaluation. 
Because standardization adds value to traditional reviews, it is recommended to 
perform standardization within reviews whenever possible. However, some 
conditions must be fulfilled in order to successfully apply this method. First, 
such reviews can only apply standardization if the intervention is rather simple. 
A reconstruction of the resources used for complex interventions (for example, 
community programmes) is hardly possible because detailed information about 
the intervention is necessary. 
Second, standardization can only be achieved if the intermediate effect 
parameter has clear end points and the course of the effects in the future is 
known. In our example, we used the quitting rate of smokers. Because detailed 
information is available about relapse, the long-term effects of the studies that 
have only followed up participants for a short period of time can be estimated 
accurately. This is not possible for changes in diet or exercise pattern, because 
too little is known about relapse. 
Third, a simple model should be available to extrapolate the intermediate effects 
to the yols. This was available for the case of smoking. A condition for a simple 
model to be available seems to be the dichotomy of the intermediate outcome 
measure. Dietary changes and changes in exercise cannot be captured in a 
dichotomy, and a simple model cannot be applied. 
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Fourthly, standardization is only possible if there is a single intermediate effect 
parameter: a simple model requires the existence of only one intermediate 
effect measure. If the study contains more than one intermediate effect 
measure, as is the case for Hartslag Limburg, complex models are required to 
calculate the yols. 
Performing a standardized review is thus certainly relevant and useful, but, 
before starting such an exercise, it is important to ascertain that the 
preconditions for successfully completing such a review are fulfilled. 
The influence of characteristics of the community 
programme on the study outcome 
Hartslag Limburg is a complex programme that contains both favourable and 
unfavourable elements for the study outcome. These are discussed in the next 
sections. 
Characteristics that have a positive influence on the study's effects 
A number of characteristics of the Hartslag Limburg community programme 
contributed to the success of the programme, and they therefore contributed to 
the effectiveness and to the favourable cost-effectiveness ratio. These 
characteristics included the formation of a network, the use of media to bring 
the programme to the attention of the public, the formation of local committees 
to implement the interventions, and the cooperation between health education 
specialists and scientific staff. 
Network 
As discussed in Chapter 1, one of the major innovative aspects behind the 
success of Hartslag Limburg is the creation and maintenance of a network of 
participating agencies: without such a network it would be impossible to 
implement such a variety of interventions for such a long period of time. This 
network certainly contributed to the favourable cost-effectiveness ratio. 
Media attention 
Another valuable aspect of the implementation that influences the cost-
effectiveness ratio is that the programme's initiatives and successes were 
brought to the attention of the public via newspaper, radio, local TV, and a 
conference. This increased the likelihood that inhabitants of the region would 
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participate, and it facilitated the expansion of the Hartslag Limburg network by 
attracting sponsors and commercial partners to join. 
Local committees 
The formation of local committees through which the interventions were 
implemented certainly increased the reach of the interventions. The support 
given to these committees by social workers and civil servants has been critical 
for the success of these committees. This is especially true for the committees 
situated in the low socioeconomic status (LSES) areas where social workers 
were able to engage local inhabitants because people from the disadvantaged 
areas are more likely to participate in an intervention when someone in their 
own neighbourhood invites them to do so. Having local committees guaranteed 
that the neighbourhood had some say in the interventions that were 
implemented. 
Cooperation between health education soecialists and scientific staff 
Cooperation within Hartslag Limburg between health education specialists and 
scientific staff was good, and meant that health education specialists could 
consult scientific staff whenever necessary and that the scientific staff scientific 
staff was given the information that was needed in practice. Furthermore, it 
could contribute with scientific data to illustrate what progress was being made; 
this data was used to give feed back to financers, politicians and media, in order 
to sustain support. 
Characteristics that have a negative influence on the study 
outcome 
The Hartslag Limburg community programme also had some imperfections. 
Most of the Hartslag Limburg characteristics mentioned that were necessary for 
the success the community programme have their drawbacks, but there are 
also other disadvantages of the community programme. 
Network 
The drawback of needing a network is that the coordinating agency of Hartslag 
Limburg is dependent on its participating agencies. This implies that the 
coordinating agency had to make concessions to the wishes of the participating 
agencies when implementing interventions. As a result, the wishes of the 
participating agencies often took precedence over the evidence base of the 
interventions. As a consequence, the cost-effectiveness might be negatively 
affected. 
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Media attention 
The fact that Hartslag Limburg can only be operational if it succeeds in getting 
the long-term attention of the public means that its interventions should be 
implemented without interruption. For this reason, Hartslag Limburg often put 
more emphasis on the number and reach of the interventions than on the 
quality. The cost-effectiveness ratio might have been higher if more attention 
had been paid to the quality of the interventions. 
Local committees 
Local committees are essential for the implementation of interventions, 
especially within the LSES neighbourhoods. Within these committees 
concessions had to be made as to what people wanted and would regard as 
feasible. Again, this led to the execution of interventions for which the 
effectiveness was not properly established. Moreover, the principle to respect 
people's choices caused that many interventions to increase dietary pattern and 
exercise were carried out, paying only little attention to smoking cessation (for 
which there was no support although effective interventions were available). 
Focus on low socio-economic status 
Many of the interventions were implemented in the LSES neighbourhoods. As 
Chapter 4 shows, this might not be the preferred option from an economic point 
of view because effects are more difficult to achieve and the costs for reaching 
people with LSES are much higher. This also implies that the external validity is 
limited because the results can only be generalized to comparable regions. 
Public private partnership 
The intervention carried out within a public private partnership was expensive 
and chapter 6 of this thesis shows that its effectiveness could not be proven. 
Including this intervention into Hartslag Limburg put thus a negative strain on 
the cost-effectiveness ratio. 
All of these aspects might influence the cost-effectiveness ratio. However, it 
should be realized that, while improvement of these points should be attempted, 
these characteristics are to some extent inherent to a community programme 
like that of Hartslag Limburg and the negative side effects cannot be completely 
eliminated. 
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The influence of the study outcomes on policy-
making 
Chapter 8 shows that the Hartslag Limburg community programme seems to be 
cost-effective even when conservative assumptions are made. Remarkably, the 
community programme was not continued after the 5-year evaluation period 
despite its favourable outcome, while the individual health-counselling 
intervention, which showed no effects on biomedical risk factors, was 
implemented at Maastricht University Hospital. This is incomprehensible from 
an economic point of view. In spite of this, the observation confirms the results 
of previous research, which shows that economic evaluation studies have a 
rather limited impact on public health policy-making at both the national and the 
local level.23 24 25 26 27 Fortunately, most policy-makers regard economic 
considerations as important.24 28 Lack of interest for economic evaluation 
studies does not seem to be the main reason for their small impact. The most 
plausible explanation for the limited use of economic evaluation research in 
policy-making is that policy-making is not a rational process and its outcome 
depends on many aspects, such as social, economic, cultural, practical, ethical, 
personal, and political ones.23 29 30 We now explore the specific reasons for the 
policy decisions concerning the Hartslag Limburg project. 
Hartslag Limburg 
Hartslag Limburg fulfilled some preconditions that increased the likelihood that 
its scientific results will be used in the decision-making process. First, the 
research topic corresponds with the beliefs and existing focus of the policy-
maker:23 29 31 national and local politicians were already aware of the necessity 
of lifestyle changes. Second, a collaborative team of professionals carried out 
the research.29 
The Hartslag Limburg community programme 
In spite of these preconditions, the economic evaluation study of the community 
programme was not influential in the decision-making process. Obviously, other 
considerations were more important. 
One of the reasons why the economic evaluation study of the community 
programme was not influential is that generating the scientific results took more 
time than the policy-making.24 As no judgements could be made about the cost-
effectiveness of the community programme at the time that the contributing 
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agencies reconsidered their budgets, many decision-makers decided not to 
continue the contribution to the community programme. 
Furthermore, there was a tightening of the contributing agencies' budgets 
available for health promotion activities as a result of the recession in the 
Netherlands. This was also unfavourable for the continuation of Hartslag 
Limburg, especially because decision-makers experience considerable difficulty 
in moving resources from one sector to another, as research has shown.2426 
However, even if the results of the economic evaluation study had been 
available at the time the decisions were being made, the Hartslag Limburg 
community programme would probably still not have been implemented. There 
are some specific characteristics of community programmes that make it 
extremely difficult to realise a translation of scientific findings into policy. 
First, the complex nature of Hartslag Limburg requires support from local 
decision-makers instead of from central decision-makers. Local policy-making is 
- more than central policy-making - marked by negotiation and uncertainty, 
which makes economic evaluation research less influential in local policy.23 
A second complicating factor is that a community programme like that of 
Hartslag Limburg only succeeds if many decision-makers support it. All these 
decision-makers are exposed to their specific myriad of competing pressures, 
including social, financial, electoral, strategic development, terms and 
conditions of employees, and colleagues' opinions.23 For this reason, it is rather 
difficult to change policy in many agencies at the same time. 
Third, decision-makers are often unconvinced of the study outcomes.23 24 
Because of its complexity and preventive nature, the Hartslag Limburg 
community programme is especially vulnerable to this: its effects and costs 
cannot be estimated with standard designs and guidelines, and many 
assumptions are made in the calculation of the cost-effectiveness ratio. 
Fourth - and this is also true for similar complex preventive interventions -
economic evaluation studies do not always fulfil the expectations of the policy-
makers. For example, policy-makers have a short time horizon and are 
interested in the allocation of resources. In contrast, health economists use a 
lifetime horizon and usually do not go into the allocation of resources 26 Within 
the economic evaluation of Hartslag Limburg, the base case cost-effectiveness 
did not include costs saved in the future (Chapter 8). Furthermore, the study 
tried to meet the wishes of the policy-makers in the allocation of resources by 
listing the kinds and quantities of resources used for every intervention 
implemented within Hartslag Limburg (Chapter 7). However, this was on an 
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overall level, and we were not able to specify this allocation for the contributing 
organisations separately. 
Many other factors besides efficiency considerations influence the decision-
making, so that actively promoting the Hartslag Limburg community programme 
is crucial. The need to inform decision-makers personally is great because they 
are often unconvinced of the outcomes of economic evaluation research and 
their interests in the issues are not always described in economic evaluation 
reports. Unfortunately, within Hartslag Limburg, the coordinating agency 
withdrew at the time when many contributing agencies were about to make 
decisions, and active lobbying diminished. 
The Hartslag Limburg high-risk programme 
Secondary prevention trial 
Contrary to the community programme, the secondary prevention counselling 
intervention was implemented at the Maastricht University Hospital. A number 
of aspects contributed to this. 
To start with, cardiologists believed that the intervention would be more 
effective and cost-effective if only a subgroup of patients who had had recent 
CVD events were referred to the counselling sessions. Second, only one 
decision-maker was involved: the Chairman of the Board of Directors of the 
hospital. Furthermore, implementing the intervention had only a small but clear 
effect on the budget. The intervention is straightforward and implementation is 
easy: the only resources necessary are a counsellor and a room in which the 
specialist can carry out the counselling sessions. Ethical aspects, in the sense 
of feeling obliged to offer patients preventive care, might also have contributed 
to the decision to implement the counselling interventions in the hospital. 
Primary prevention trial 
Even though the behavioural counselling in the general practices was identical 
to the behavioural counselling in the hospital setting, the intervention was not 
implemented in the general practices. This was probably due to a combination 
of unfavourable factors. 
First, although it was shown not to be decisive in the decision-making process, 
there was no scientific evidence that the intervention was effective. Second, 
many decision-makers were involved, so that making decisions was difficult. 
There were also some practical implementation problems, like the housing of 
the counsellor. Furthermore, in order to refer patients to the counsellor, GPs 
need to have an overview of high-risk patients. As we experienced within 
Hartslag Limburg, GPs are not willing to put any effort into selecting high-risk 
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patients. A time constraint on GPs is another factor why the intervention was 
not implemented. In contrast to the cardiologists in the secondary prevention 
trial, GPs are expected to spend additional time in a consultation on the CVD 
risk factors of the patient, which would not be the usual subject of the 
consultation. 
The Hartslag Limburg experience thus confirms previous research that 
concludes that economic evaluation studies are not likely to have a direct 
impact on policy-making. 
Economic evaluation research can be more influential if researchers change 
their attitude by broadening their view and by learning to understand the policy-
making process better.23 Furthermore, researchers need greater access to 
information about the priorities and needs of policy-makers.23 To influence 
policy-making more, researchers should broaden their work to include these 
priorities and needs. Providing information about the cost-effectiveness in 
reports of results is not enough, especially if interventions are as complex as 
those of Hartslag Limburg. All other information that might influence the results 
should be reported, as well as the promises and pitfalls of the intervention and 
recommendations for future research. Policy-makers can contribute by 
communicating their needs more clearly to the researchers.23 It is important that 
policy-makers learn more about economic evaluation research in order to be 
able to judge its value.31 
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Summary 
The focus of this thesis is the economic evaluation of the prevention of 
cardiovascular diseases (CVDs). In the Netherlands, more than a million people 
suffer from CVDs, and 35% of all deaths each year can be attributed to CVD. 
The high prevalence and the chronic condition of many CVDs induce high 
costs: about 10 percent of the total Dutch healthcare budget is spent on 
preventing and curing CVD. 
The continuous rise of the healthcare costs during the last decades has led to 
an increasing interest in economic evaluation research. However, most 
economic evaluation studies have focussed on curative and medical 
interventions. Relatively few in the preventive and behavioural sphere have 
been economically evaluated. Obviously, this has led to an imbalance of 
evidence, the evidence favouring the latter. Very little knowledge is available 
about the cost-effectiveness of large-scale community programmes. 
This thesis is particularly useful because of the growing need of economic 
evaluation research into preventive and behavioural interventions. We aim at 
providing insight into the methodology of economic evaluation research and 
present a cost-effectiveness analysis of a large-scale prevention project. 
Chapter 1 provides background information about CVD and about economic 
evaluation research. It gives an overview about the different types of CVD and 
CVD risk factors. It describes the available methods for achieving behavioural 
change. Trends in prevalence, incidence, and mortality are also mentioned, and 
the difficulties that emerge in cost-effectiveness studies in the field of prevention 
are explained. Finally, a description of the Hartslag Limburg (the Limburg 
Heartbeat) project is given. 
Chapter 2 aims at providing insight into the quality of cost-effectiveness studies 
related to the prevention of CVD. We used guidelines for economic evaluation 
research to review studies that reported on the cost-effectiveness of 
interventions to reduce tobacco dependence. It was concluded that the quality 
of the studies leaves much to be desired. 
Chapter 3 was designed to gain more insight into the direction and degree of 
bias resulting from nonadherence to the guidelines for economic evaluation. 
The cost-effectiveness ratios from the studies reviewed in Chapter 2, were 
recalculated, using the guidelines for economic evaluation research in 
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healthcare. This standardization procedure caused increases of cost-
effectiveness ratios in all cases. However, the degree of increase varies 
considerably: increases ranged from 120 percent to 5600 percent. This shows 
that nonadherence to the guidelines can lead to considerable bias in the cost-
effectiveness ratio. 
Chapter 4 reports a literature search to investigate one of the premises of 
Hartslag Limburg, namely, that focussing the community programme on people 
with low socio-economic status (LSES) is more efficient than focussing on the 
general population. This assumption is based on the observation that the 
prevalence of both CVD and its risk factors are greater among those with LSES 
than among those with a higher socio-economic status. The present study does 
not support the hypothesis that focussing on LSES groups is more efficient. 
This is partly due to the fact that people with LSES are also exposed to risk 
factors other than the classical risk factors for CVD, which causes the effected 
reduction of the classical risk factors of CVD to be smaller than expected. 
Further, the costs of reaching LSES groups with preventive measurements are 
much greater than the costs of reaching people with a higher socio-economic 
status. From an economical perspective, focussing on LSES groups is not 
advantageous. 
Chapter 5 reports the effects in terms of quality of life, of individual counselling 
sessions carried for by people with an increased risk of CVD and by people with 
established CVD. We evaluated two studies with a randomized design; one 
was a cluster study. The RAND 36-ltem Short Form Health Survey and the 
EuroQol visual analogue scale were used to assess the quality of life. Although 
the study showed a statistically significant difference for physical functioning 
between the intervention group at risk of CVD and the control group, the study 
does not clearly prove the effectiveness of behavioural counselling for quality of 
life. 
Chapter 6 describes the evaluation of a health-promoting intervention that was 
established with a public-private partnership. In a butcher shop, low-fat meat 
products were labelled and the personnel of the shop provided information to 
the customers about low-fat meat. The effectiveness of the intervention could 
not be shown. In the same study, the effect of regular price reductions was 
evaluated. Although the price elasticity was high, no shift from the sales of high-
fat meat to low-fat meat was observed. Because of potential confounding 
factors, some of which are related to the partnership with a private organisation, 
the results of this study must be interpreted with care. 
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Chapter 7 provides a detailed calculation of the economic costs of the Hartslag 
Limburg community programme. We calculated the costs in a bottom-up 
procedure and followed the steps for cost-calculation recommended by 
Drummond et al. (1997), namely, identification, quantification, and valuation. 
This study is the first to give an overview of all the resources necessary to 
implement a large-scale intervention like that Hartslag Limburg's. This facilitates 
budgeting. The bottom-up procedure contributes to the generalizability of the 
results. 
Chapter 8 presents the cost-effectiveness analysis of the Hartslag Limburg 
community programme. We analysed the cost-effectiveness according to the 
guidelines for economic evaluation research wherever possible. The 
intermediate effects were determined by measuring the biomedical risk factors 
for CVD before and after the intervention in the intervention region as well as in 
a comparable control region. A Markov multistate transition model was used to 
extrapolate the intermediate effects to the years of lives saved. To test the 
robustness of the results, a sensitivity analysis was used. The base case cost-
effectiveness was based on conservative estimates and was calculated to be 
€12,500, ranging from €950 to about €16,500. Thus, it was concluded that 
programmes like Hartslag Limburg are cost-effective, even with negative 
assumptions. 
Chapter 9 starts with an overview of the conclusions that can be drawn from 
this thesis. Then it reviews the methodologies used within the thesis, focussing 
on the internal and external validity of the studies. The Hartslag Limburg 
community programme has a unique design, and its characteristics influence 
the outcome. Chapter 9 considers these aspects and the way in which they 
influence the cost-effectiveness ratio. We conclude the chapter by discussing 
the effects of the favourable outcome of the economic evaluation of the 
community programme on policy-making. Although the Hartslag Limburg 
community programme is cost-effective and methodologically well evaluated, it 
is not likely that it will be implemented because of factors that are explained in 
Chapter 9. 
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Samenvatting 
Centraal in dit proefschrift staat de economische evaluatie van preventie van 
hart- en vaatziekten. Meer dan een miljoen Nederlanders leidt aan een 
hartvaatziekte en 35 procent van de totale sterfte is eraan te wijten. Door de 
hoge prevalentie en de chronische aard van veel hart- en vaatziekten brengen 
ze hoge kosten met zich mee: ongeveer 10 procent van de totale 
gezondheidszorgkosten wordt besteed aan het voorkomen, maar vooral aan het 
genezen van hart- en vaatziekten. 
De aanhoudende stijging van de kosten binnen de gezondheidszorg heeft de 
afgelopen jaren geleid tot een toenemende belangstelling voor economisch 
evaluatie onderzoek. Tot nu toe waren de meeste economische evaluatie 
onderzoeken gericht op curatieve en medische interventies. Hierdoor is er een 
scheefgroei ontstaan in de bewijskracht in het voordeel van dit soort 
interventies ten opzichte van preventieve en gedragsmatige interventies. Vooral 
over de kosten-effectiviteit (KE) van complexe preventieve programma's die 
gericht zijn op een grote bevolkingsgroep is nog weinig bekend. 
Het huidige proefschrift sluit aan bij de steeds groter wordende behoefte aan 
economisch evaluatieonderzoek van preventieve en gedragsmatige 
interventies. Het beoogt inzicht te verschaffen in zowel de methodologie van 
economisch evaluatieonderzoek binnen dit gebied als in de uiteindelijke 
uitkomsten in termen van KE ratio's. 
Hoofdstuk 1 geeft achtergrondinformatie over hart- en vaatziekten en over 
economische evaluatie onderzoek. In dit hoofdstuk wordt een overzicht 
gegeven van de verschillende verschijningsvormen van hart- en vaatziekten, 
van de risicofactoren voor hart- en vaatziekten en van methoden om 
gedragsverandering te bewerkstelligen. Ook de trends in prevalentie, incidentie 
en sterfte van hart- en vaatziekten worden besproken. Vervolgens wordt er 
ingegaan op de specifieke problemen die zich voordoen bij het uitvoeren van 
economisch evaluatieonderzoek bij preventieve interventies. Het hoofdstuk sluit 
af met uitleg over het Hartslag Limburg project. 
Hoofdstuk 2 had als doel inzicht te verkrijgen in de kwaliteit van KE studies 
binnen het gebied van preventie van hart- en vaatziekten. Als voorbeeld is de 
kwaliteit van KE studies van 'stoppen met roken' interventies geëvalueerd aan 
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de hand van richtlijnen voor economische evaluatie. De conclusie van de studie 
was dat de kwaliteit van de studies veel te wensen over laat. 
Hoofdstuk 3 is opgezet om meer inzicht te krijgen in de richting en mate van 
bias die het niet naleven van de van richtlijnen met zich meebrengt. De KE 
ratio's van de studies die gebruikt zijn bij de review van hoofdstuk twee zijn -
gebruikmakend van de richtlijnen voor economische evaluatie - opnieuw 
berekend. Deze standaardisatieprocedure zorgde bij alle studies voor een 
verhoging van de KE ratio. Echter de mate van toename verschillende zeer 
sterk: van 120 procent tot 5600 procent. Dit geeft aan dat het niet opvolgen van 
richtlijnen kan leiden tot enorme bias in de KE ratio. 
Hoofdstuk 4 onderzoekt middels een literatuuronderzoek één van de 
aannamen die ten grondslag ligt aan Hartslag Limburg, namelijk dat het richten 
van een community programma op personen met een lage sociaal 
economische status (LSES) efficiënter is dan het richten van een community 
programma op de algehele bevolking. Deze veronderstelling is gebaseerd op 
de waarneming dat cardiovasculaire ziekten en ook de gedragsmatige en 
biomedische risicofactoren het meest voorkomen bij personen met een LSES. 
De huidige studie vindt geen bewijs dat het efficiënter is om te focussen op 
LSES groepen dan op de algehele bevolking. Dit komt omdat er bij LSES 
groepen meerdere risicofactoren een rol spelen, waardoor de effecten van een 
afname in risicofactoren onder LSES groepen lager is dan verwacht kan worden 
op basis van het medisch exponentieel model. Daarbij zijn de kosten die 
gemaakt moeten worden om LSES groepen te bereiken met preventieve 
maatregelen veel hoger dan de kosten om personen met een hoge sociaal 
economische status bereiken. Vanuit een economisch perspectief heeft het dus 
niet de voorkeur om te focussen op LSES groepen. 
Hoofdstuk 5 beschrijft een voorbeeld van een samenwerkingsverband tussen 
de publieke en private sector. Een slager droeg via het labellen van 
vleesproducten met een laag vetpercentage en voorlichting door het personeel 
bij aan de preventieve activiteiten van Hartslag Limburg. Er is geen bewijs 
gevonden voor effecten van deze voorlichtingsinterventie. Verder was het effect 
van prijsreducties geëvalueerd. Er is geen verschuiving waargenomen in de 
verkoop van vlees met een hoog, naar vlees met een laag vetpercentage. De 
resultaten van deze moeten met voorzichtig geïnterpreteerd worden vanwege 
het feit dat er tijdens de studie gebeurtenissen plaatsvonden die de resultaten 
van de studie kunnen vertekenen. Een belangrijke boodschap van dit hoofdstuk 
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is dat de samenwerking met een private partner in de gezondheidsvoorlichting 
specifieke moeilijkheden met zich meebrengt, die onderkend moeten worden 
voordat een samenwerkingsverband aangegaan wordt. 
Hoofdstuk 6 evalueert de effecten van individuele counseling bij personen met 
een verhoogd risico op hart- en vaatziekte en personen die recent een 
hartvaatziekte hebben meegemaakt in termen van kwaliteit van leven. De 
studies waren opgezet volgens een (geclusterd) gerandomiseerd design. 
Kwaliteit van leven is gemeten met behulp van de RAND-36 vragenlijst en de 
thermometer van de euroqol. Ondanks de bevinding dat interventiepersonen 
met een verhoogd risico op hart- en vaatziekten een hoger lichamelijk 
functioneren dan controle personen met een verhoogd risico, kon deze studie 
niet duidelijk de effectiviteit van individuele counseling op kwaliteit van leven 
aantonen. 
Hoofdstuk 7 geeft een gedetailleerde beschrijving van zowel de methodologie 
van de kostenbepaling als de economische kosten van het community 
programma van Hartslag Limburg. De kosten zijn via een bottom-up procedure 
berekend en volgde de stappen van Drummond et al (1997), namelijk 
identificatie, volumebepaling en waardering van de kosten. De meerwaarde van 
deze studie is dat de opbouw van de kosten voor het eerst zichtbaar is 
gemaakt. Dit vergemakkelijkt budgettering. Daarbij is de bottom-up methode 
nauwkeurig en draagt ze bij aan generaliseerbaarheid van de gegevens. 
Hoofdstuk 8 presenteert de kosten-effectiviteitsanalyse van het community 
programma van Hartslag Limburg. Zoals uitvoerig besproken in hoofdstuk 7 zijn 
de kosten berekend volgens richtlijnen voor economische evaluatie. De 
intermediaire effecten zijn bepaald door de biomedische risicofactoren voor 
hart- en vaatziekten (bloeddruk, cholesterol en BMI) zowel voor aanvang als na 
afloop van de interventie te meten en dit te vergelijken met cohort uit een 
vergelijkbare controle regio. 
Een zogenaamd Markov-type multi state transitiemodel is gebruikt om de 
intermediaire resultaten te extrapoleren naar het aantal gewonnen levensjaren 
en een gevoeligheidsanalyse is uitgevoerd om de robuustheid van de resultaten 
te testen. De op conservatieve aannamen gebaseerde KE ratio kwam uit op 
€12,500, met een range van €950 tot ongeveer €16,500 in de 
gevoeligheidsanalyse. De conclusie is dat programma's zoals Hartslag Limburg 
zelfs onder negatieve aannamen KE lijken. 
Hoofdstuk 9 blikt terug op het uitgevoerde onderzoek. Na een kort overzicht 
betreffende de conclusies van het proefschrift, worden de methoden die 
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gebruikt zijn in het proefschrift geëvalueerd. De invloed van de gebruikte 
methoden op de interne en externe validiteit staat hierbij centraal. Vervolgens 
wordt bediscussieerd welke gevolgen de keuzen die gemaakt zijn binnen 
Hartslag Limburg hebben gehad op de uitkomst van het economisch evaluatie 
onderzoek. Omdat economisch evaluatie onderzoek als doel heeft 
beleidsbeslissingen te vergemakkelijken, sluit het hoofdstuk met een 
beschouwing over de te verwachten invloed van Hartslag Limburg en 
soortgelijke programma's op beleid. 
Ondanks dat Hartslag Limburg een kosten-effectief programma is gebleken dat 
methodologisch goed geëvalueerd is, is de kans dat het programma 
daadwerkelijk geïmplementeerd gaat worden niet groot. Een aantal factoren 
die in Hoofdstuk 9 besproken worden zijn hiervoor verantwoordelijk. 
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